var title_f32_16_33024="Ketotifen: Drug information";
var content_f32_16_33024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketotifen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F13246139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F13246141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44453?source=see_link\">",
"       Ketotifen (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/29/39379?source=see_link\">",
"       Ketotifen (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16764 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-F9B63D4400-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33024=[""].join("\n");
var outline_f32_16_33024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44453?source=related_link\">",
"      Ketotifen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/29/39379?source=related_link\">",
"      Ketotifen (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33025="Microscopy cord hematoma";
var content_f32_16_33025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Microscopic section through localized umbilical cord hematoma revealing extravasated blood surrounding the umbilical vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33025=[""].join("\n");
var outline_f32_16_33025=null;
var title_f32_16_33026="Patient information: Do I need imaging for low back pain? (The Basics)";
var content_f32_16_33026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/84037\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"         Anatomy of the back",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/62/41954\">",
"         Patient information: Herniated disc (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40642\">",
"         Patient information: Spinal stenosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/63/27635\">",
"         Patient information: Vertebral compression fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Do I need imaging for low back pain? (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/do-i-need-imaging-for-low-back-pain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H180117585\">",
"      <span class=\"h1\">",
"       What do imaging tests do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Imaging tests create pictures of the inside of the body. Some do this in more detail than others. In the case of low back pain, doctors do imaging tests to try to see the structures inside the back (",
"      <a class=\"graphic graphic_figure graphicRef56246 \" href=\"UTD.htm?4/51/4917\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The most commonly used imaging tests are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        X-rays &ndash; X-rays are good at showing bones and large internal structures. But they are not good at showing problems with &ldquo;soft tissues.&rdquo; (Soft tissues include muscles and the rubbery discs found between each of the bones in the spine.) An X-ray can show if you have bones that are broken or out of place, or certain types of tumors or infections. X-rays are usually done if back pain is caused by a serious injury, such as a bad fall.",
"       </li>",
"       <li>",
"        CT scans &ndash; CT scans are a special kind of X-ray. They show more detail than X-rays, but also expose you to more radiation and cost more. CT scans can show all the problems that X-rays show, plus some problems with soft tissues.",
"       </li>",
"       <li>",
"        MRIs &ndash; MRIs are created using powerful magnets. They show more detail about soft tissues than CT scans, and they do not involve radiation. Experts think these tests are often better than CT scans when low back pain is not improving and a test is needed. But some people can&rsquo;t have MRIs because they have devices implanted in their body that would be affected by the magnet. Plus, MRIs are expensive and people often have to wait to get them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180117617\">",
"      <span class=\"h1\">",
"       Do I need imaging if I have low back pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not.",
"     </p>",
"     <p>",
"      When people have severe back pain, they often jump to conclusions and assume something is terribly wrong with their back. The truth is, most cases of back pain&mdash;even severe pain&mdash;are not caused by anything serious. Low back pain usually goes away on its own or with simple treatment.",
"     </p>",
"     <p>",
"      If you see the doctor or nurse because of low back pain, do not ask for or expect to get an imaging test right away, unless you have 1 of the &ldquo;red flags&rdquo; described below. Most people do not need an imaging test in the first 4 to 6 weeks of low back pain. In most cases, it does not make sense to order the test sooner, because the treatment for most causes of low back pain during those first few weeks is the same no matter what an imaging test might show. Even without an imaging test, your doctor or nurse can learn a lot about your pain by talking with you and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180117634\">",
"      <span class=\"h1\">",
"       How can the doctor or nurse tell what is wrong without an imaging test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have low back pain, your doctor or nurse will do an exam and ask questions, such as:",
"      <br/>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do you have pain in just your back, or does it spread to your buttocks or down your leg?",
"       </li>",
"       <li>",
"        Is the pain the same on both sides, or does it affect 1 side more than the other?",
"       </li>",
"       <li>",
"        Do you have numbness, tingling, or weakness anywhere?",
"       </li>",
"       <li>",
"        Does the pain get better when you lean forward?",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The results of the exam and your answer to these and other questions will give your doctor or nurse a good idea of what is going on with your back. If you have certain &ldquo;red flag&rdquo; warning symptoms (discussed below), the doctor or nurse will know that there might be something serious going on and order an imaging test.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180117649\">",
"      <span class=\"h1\">",
"       Who should have imaging tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have had pain for 4 to 6 weeks or longer often should have imaging tests to search for the cause. People with certain warning symptoms or traits called &ldquo;",
"      <strong>",
"       red flags",
"      </strong>",
"      &rdquo; should have imaging tests done right away. This includes people who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Had a serious accident or injury recently (such as a car crash or a bad fall)",
"       </li>",
"       <li>",
"        Had a less serious accident and are older than 50",
"       </li>",
"       <li>",
"        Have back pain along with unexplained fever or weight loss",
"       </li>",
"       <li>",
"        Take medicines called &ldquo;immune suppressants&rdquo; or medicines called &ldquo;steroids&rdquo;",
"       </li>",
"       <li>",
"        Have a history of cancer (except for skin cancer that isn&rsquo;t melanoma)",
"       </li>",
"       <li>",
"        Use drugs that you inject, such as heroin",
"       </li>",
"       <li>",
"        Have osteoporosis, a condition that weakens bones",
"       </li>",
"       <li>",
"        Are older than 70",
"       </li>",
"       <li>",
"        Have leg weakness or problems controlling their bowels or bladder",
"       </li>",
"       <li>",
"        Have a problem called &ldquo;foot drop,&rdquo; which is when you cannot seem to hold your foot up, for example, while walking",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180117664\">",
"      <span class=\"h1\">",
"       Why not have an imaging test just to check?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People tend to think of imaging tests as harmless, but they are not harmless. The X-rays doctors use to try to diagnose back pain give as much radiation to your pelvic organs (ovaries or testicles) as you would get from having a chest X-ray every day for more than a year. CT scans expose you to even more radiation. Radiation is dangerous, especially for young women who might want to have children, because it can damage their eggs.",
"     </p>",
"     <p>",
"      MRIs do not expose you to radiation but they still have risks. People who have MRIs (or other imaging tests) are much more likely to have surgery and other invasive treatments than people who do not have imaging tests. That&rsquo;s true even for people who do not need surgery. That&rsquo;s because &ldquo;abnormal&rdquo; findings on imaging tests of the back are very common, even in people without back pain. Abnormal findings don&rsquo;t always mean that treatment is needed.",
"     </p>",
"     <p>",
"      If your doctor or nurse does not think you need an imaging test for low back pain, trust him or her, or ask why. Back pain can be scary but doctors and nurses see many people with symptoms like yours who improve with time and do not need an imaging test.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180117679\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=see_link\">",
"       Patient information: Herniated disc (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"       Patient information: Vertebral compression fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=see_link\">",
"       Patient information: Spinal stenosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/16/33026?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 84037 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33026=[""].join("\n");
var outline_f32_16_33026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180117585\">",
"      What do imaging tests do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180117617\">",
"      Do I need imaging if I have low back pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180117634\">",
"      How can the doctor or nurse tell what is wrong without an imaging test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180117649\">",
"      Who should have imaging tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180117664\">",
"      Why not have an imaging test just to check?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180117679\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/84037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"      Anatomy of the back",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=related_link\">",
"      Patient information: Herniated disc (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=related_link\">",
"      Patient information: Spinal stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=related_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33027="Fetal femur length";
var content_f32_16_33027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal femur length",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 434px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGyAacDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFrpfD/h+6uLb7W1u5VuYsjGQOp+lVPCug3Gv6g0MACxRL5ksjKxVV9CR0z07V7rpesafYaVFp3iHS4haooWOW042L9BQB5OiQpEouo3Ujp83ao4ZFimlmsdqxA4YMPm/CvWtT8C22uWzXWhXImiOGEbD519sV55rekXum3bb7Z4mX5ChXG73FAEej+NbnTJyJ40u4yMbJ16emK7DQ/EtlJDKsU7WF47D5SuYz7ZrhtIktJbqS11O2WJccsy5I98ir194fubePzLOaO6snyykcEe1AHrVv4ueO1Ed3HHfQ5w7LhlBHTryayNQ8OeCfEFyFexggusF3e3k8nJPqOAea8kjvtQ00vFa+YhGDjrWhY+K5lgMd9ZJcBjt3SLjB7UAdBefBy2uA8mja6u1VwYriPLb+43DA/SuX1H4UeLLRsRWMd4M4LW0oYD88fpWrp/jIpLLFua2K5xkkjBx/Lmuv0bxLcWPkbp7e5MoAUE7WHpzn/OaAPGLvwvrtnK0dxo9+rKcEiBmH5gYNZU8MkErRzxvHIvVXUgj6g19Otr2p2l0FaSAxFOIxLlsn61MuqXL20k1xp0UkITZyF3CgD5Ypa+pZ9X02L7OLvT1Mk2Gwka4H/wBap11vR4m/daWskgY4UouMnsTQB8qRo0jqkalnY4VVGST6CtODw9rNw6rFpV8xYhQfIYDJ6ZOMCvo5vF8Btma20heB5aZ2LkZ57cmph4gv7tFZLaGGM4DGSTGT/CBigDwzT/hh4qu5Nr6eLZDkb55FAz6cZP6V1em/BeRZbcazq6QeYhZo4oiSDjpuPv7V3c+tzLemK+v7CFgAWXfnPvz361i6j4vsjqTre6nOyKSMxt1X2x/WgATwj4M8OthrQahcrhP9JkDAnjJKdPyFbk+uJYhGhs/JCgtuRQq59ATya4LWPG1kbiOTRrI7to5uFyW71i3t7rmpJPNdSpbwMwcDIxj29qAOn8W+IWExmvXSQ3PISE52EdM+9cbf+JNUIRrLZFAgJwhywz6/lVV9Qs4INywG5kU9+FBz+tUtRaW7jQ/IgK79icDHvigClc3l3dSNJcu0pbnc2efeoBCssUp3kSKeh5BH1rRtrS5u1jjmcJbBiSxHy4781bMVhZsTAJZwQQQeme1AGRfWUj26yxROxjTMhC9vWsqvRrRLzU7T7JDABAB83y4DH0JrjNe0uXTLvbIoEb5KFckdemfUUAZdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABT40aSRUjUu7EBVUZJPoBTK9N+C+gyy6uuvSgiGzb9yNrfO+OoPTA/GgD174ZeGX8IeD1huRFdrqPz3aLkfMRwuD0IHHQVR1fw1arE40u5mCElRDN1j9q7GG+huYv9QxfcDh8hSfXNal7BDqLQuYljYLiTYQfxoA8Ut01XwtqcUsW+QE5Cq5Fdlda7ofieyA1czwXAOzceFDHtnFdRcaMJ2UeVb3UKj5nJbgetQ6h4P0XU4ylnIgZ1y0MrkbmH92gDzLxJ4FubS3e5hWN7V+VdDng+pFYHhq1uodQW2klRFwWIlPyNzXbXdl4g8OssUUUkln5m0Rk5XFQX8EWrnbOkdqW6D+En69qAM2S9tINT33lpaMcE7VbC4HrV6R/BmvtElzG9jAqfvRDyc+tZ9z8P8AU7qZ5oolcKuRHHJk/r1rkJtC1XTb6bEIjQDDKTtIoANV8K6da3050zU47m2Dblzw2305rKhtbz7SJo2WREyAp+9irscTD93fD7PLztYj+RpzxS+SWkeOVjyBnG36EUAMudQ2x5KbmZQSHyCp9qgi1jUZoxFbT3bxLwVWXiklsdQnGy1SVw4yFK7j1HOapXOmalauYBBKrt1LLjmgC7BqhguZHaa6ikjXABOe9I2stb3TyxXVyVfqQR1xzmsmPSL4vmeNmRB97OetX4fC+ovCJxGiovzHcev4UAVrrxJf3DANIY5VPDxnbmpDqmomAQS3UypneFB3fnUP2FEvFE7xjLYHXGPYiujD29oHH2dBbzArlhnH40AcslySmBDJNLtyXyW/Sn2kTyOfMjbc5OI/ugH3PpXoek6rHpj7bSzt5t+BynqP50ybR9b1xrx4rGJJAQTxtxQBx9tZTXLsIQYxCgBIGST61FfSGOIII3YKcb88HBziuqh8MatFYtLb3SrGJCCu/lT3FX9B8Jw3Nx5l9ckW2MlBkkydgRQB520893dMIY2ELLyhTGPfirNnp0gAjc8EcgL8wA/nXv3h3wto+m2yyx2b3V7Mu0xyvtBPY4qvp/hGOSf7Str5soYhoYW4Xn1oA8hg0i5vhb2MMcjL1VW45zXZ+Gvh5fT6hGs9qjIgJ2M2Bn1r2PTNM021tWeGELOzbVgx0buxJq/b2arAXnA8krgRp8pY9yT1oA5HSfB1paN508rYTJeNBwD2welZHj7w/pviPQLrT7PTxaTpiSK5zlVkH94A85yQeuM5wcYr0HzrKK2+z5UE8uoOc+wrPkaGW2niswY7cnn7oP1+lAHxdcQyW08kE6NHLGxR0YEFSOoIPSoq9T+NPhySHUn1mOYzCTakwKnIwMK2RxjAA7duua8soAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopaALmk2L6hfxW6KxDHLlQTtXueAa910a5tNMsoYLOPbHGuwBmO7H9a5bwTop0zRzOYN91Kw88+ZkKvYcen413Gl6NHcAS7hGGB2hhkMPegDobTVX8mCO3lBhXkI4wwP1ro7OaGW9jkf8AdTFcMVOcEe1ebS339lgq0CTRKcHy+cH8a2dG1x7aBHmUSRSdDIvzKB6YoA9LS7+1mOW2jeGbOG3HbketLc6Xa3Mqy6jExkU8PGwz9R71iaNq1pPEs0ryh/4I3OM/Srn9oTo4dirW46Kx+7nt70AN1TQb5okFrP5sKE7TcHaQD2PrXF614cvWWQYwCAFQN5m0568V6Y8kVwqQpdqrsuTEykHHqKz0tJbLfJbui4baxDc5oA870+XUdLdBNOjQ52squQeOnWtldS0i/wBMlTUUWFXcBt67zn0re1e1ivpD9piWV9o3N5YA/Ej+dOh8LaMIHeSU2ocfMQ25W/HrQBxHiDwbpWoWe+xuRDARj7uQvsB15qhYfD7U9JWCaOa1niRQY0nTKkfT1rq7nwRbF0k0XXpxDENyrjchOehPrTv7D1mzzL54uMfdEZOScdRk0Ac5P4d1PdJqENxbWM/H7qLhQfQA9KH8Najqv7zWdUOdvyoQufocV10n2yHTIpb+zvGiZiGZgrYPqO/4U6zvBsQTRXIUjABhyffPegDk9O8D2tugkuL1UU4VFBBLN688YqPUPhrC4ZvtV1I75cHzBs+prtbjU4rYrHE0rjYF/fREFPaiHxDaGLZBDOJQhyWGcntgdqAPFr74f6hDcqlrbx3IdisbbsrkdsVd0b4V6jPBKNUuIIIt2TjLMAOwHavTV1ULcRRR2M4lfAG6MDn2atLTNWlUFbrTLiSPcd/mYB46fWgDgtJ8BXMVytvZtvGA6uzYPB4+hrcHg46Tme+vlneT5jbRucsff1rrLJNR1FpZtO0026Odod2xz9ByKr2uk3NjeSST3NiXjBO6VzuU5zwaAOVh8O6ZGsj2775XJOxEJCH3J/Kug0PQLGxmhmeFyrcs0aEk+/XgVYWW0F5HPdyyzWDrlxgoS5Oe3UVbkvWk33NlBIucImSFCr6Y6/jQBNNYW93O0qyyQWw4Xf8AfZh6VHNbWukw+eLnyLYkeYA3zSc9zTIv9IumM7N5MfTYGzntjHWobvSIHuEe+ZVuFG9YjlgQT396AF1HxBBBEpsbPexXKSSN8oX1NZii81EbnYPGW+Zg2I1/xxWncTWoZILuGJVj5wq8EDGP1qjcahD5sii4iUAfdjGSQR/OgCG686zkX7XLCIlHlxpEuc59TUOtLHDaviWBmkXHlqDlQe5Peq1xE1/fL9jhcjG1VcYPHU81Zl0yKOZZNTmjOB/x7Kefxx1oA4640q71UvbxwPNBKmyQ5wCmMEZ7V4T408PXHhnxBcafcIwUfPEx53IeQc4GfQ47g19Oya1PFI9tCYrW3ThQEDD9OtcZ8T9FPirTUhst11f2xLwuXCjJxuXHTsPxA5HNAHzvRSkEEg9RwaSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK6TwXorajefaJIi9vEccNjL9vy61j6RYS6pqVvZW/+slbGfQdSfwAJr2rT7UWOh28MSI0NuPLbyiAT/tMPU9aAK8cNxbv9n/0geYPTIP8AjWrpepDTmhVzIjRt97OAfYipIbtvLQhMxxY4zkkVLJIs8JIMYhz91o/moAvCeDVncz7Eds7Joume2QaqXFk4gQStJ5qtg/LtXPrxUWktAl2q4K25yMv0zWnqLXkMDh2URdE2NuJ+vY0AQJezPEiJIu5TgknlfbNaVpqkyFre7j/dN84Yvz9R2rlLiJXlilt3w/8AGBxz9KZqN9cYAfa6MNh+UEqfwoA9MTxDZQCNYL9ZmkAAJTDp+NakerXETxC0t3vY5G3Y2YYHvXlumXkrLDAtumc5JxgmulttcuLJY5reSWLDYUuAwB7jFAHdapqVqsaGW1lhlY8eWTjPowqpfap5VmontTGh+WMBOc9qyz4um1ZEgvLWMtnBcAj8T6U9tSsIo3i1FJp40HDK2dv0IoArXAu1iZbeQQO4ywdeG/Csyae9skU+e0MifewDtPvitaS00ueaAW88+zghZJuT3rOeyvoLt1ja4McsmQg+fePagCtP4l1m4KQtfZt0UMxdQQzVEvjfUoW8lrmFQpJ3BNuRntnvVuztrKKW4j1PSFSSRThmYqfripLjTrCa2hey0dAjnISVt/I649KAIF8WX7SKI/3jfeiaWMsOB1b06mltPEt9JfBrn7EjEZ86FM5b0x2rAuZ5fPmRrbyYZXx8gK4HAxnpxiul0ZdKj05/+JoqvH/qVkX5h9eOaAFuvEt9d6iUu4t7xD7yxFSvp+dR2/jC8uEZLgTxiJ9qFYvuntnPes+31W80u6M1vcySyXTES74flQDgbfap7e9uMzzTRGVJCC0giBb2oA3NJ1HVbhC9tdzW8Epw0rDG4+uMdafNo0ohlnu91zs4Mk0u0N+A6msDU7TWLqzkltra7OVAVkJAHPBA7nmptN8P6zPp6/a5prdUOWmuCc++BQBbsrTUbu2aa1UNDAuN0km0Lz2B6+vNbemNIJkF5qEd1MoztiAP5n0rHXRGvrQKb6C3hBxNIrNmWiOO30qE3AeV4gdqYTr6E57UAdjdXCLdxvLdxOCQGEbbRGvPXFVPEFvDKqNazrJGGBkEhPr3PeuUur+zt3VrxdkTMSrkgljj0Hasu/1QSX0i2WTCFCsQucn0PYUAdPql1ZaXDLNcLA08jbVwO30rDt/EVrZ7XkjkWTBZtgG5vT6fSuQ1uaWZyJnd1Y5HBzkY79KiUSECRpsrtyM8FvxoA7m+8XrK5AfyS2Nirwc+57VmS3lrCxkuC947gnaWyqk+lcQ07m4ZZxIYm+6e4p73q2t4kcjvkjKEHoPcUAdUt5Alvu2r5ytny2GcVYiulMZunRFUcNldo/TrXCtf/Z3zxcsxJc9v1pG1Gcyxx25lmhYcRFufr9KAOV+J+kwRak2qaeki29wxM29s/vSSSQPQ/j36Vw1euSNFcxzRX5fynQqysOQT6D1HrXl2rWTaffy2zEkIflY45B6Hj2oAp0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV1PgTw5NrWofaHhc2NsQ0j7QVZhghOfXv14+tAHYfDjRJdL0+a+uIGW4uFx8wAZE9B356n8OOK6Vp5IYZUj8tt/DbhwR/jV68jQL5ccLhyQRHzgfTFQXg3XNs0H7t1YBwy80ARxWVz9l3Wm6TAzsY4I+nrTbdJ2PkytJEepBGVJ9PrWjqhlKI0UPmun8S8HFNheYwxyTxK4yM4PzD3xQBQiguftnkhWdWOCGyCPertzCqqywTuhRvmic8Go5ruFNQVo42nk6b9xBH/wBehp3kumjlgMidd6kbhQBBPDLlVEKL/Fwev40RQwSbiJFhY/8APQY5q7FbzTK32VxI6nhX4IHvTriyWLYbqDMzHjbJwaAKTRvChdZkZsAZVs49xT0uZVBWKeWe3zuPQEGp7TTBGHkEEkiMCNpbofQetaVjaxxQGR7ceY3RWBUKcUAZkGrmO5Hkbo2Y4YyLyamtWuYJGuGlchiT5Z6PnsRT7m1imWSaM7ZlHKHp+dR29zdfZA5RjApyysc7vYUASJrtxI+ZvJBgyqxuANwrU0vXru1NrcBxFvJGS+QPoKzBPo81q80gkVyMAJgbT9KyLiaIhAvmG3c/ebigDq/EGt3RuA100lwk52+aqAYHvWtpWswW0LfZGfyFXBMQ3uCfUHpXIWdrPc6f5e6YMvKB5OMdutXk0otGrCZIJWwp8vqffFAHTQ3iXVqq31lJdTu2TGECkAdz7VbvdX0xoyg00rKFC+WQMHHt6VhxadeIIw18XZxkNI2xsf4e1OjhSGdIrlZTGoJ3oQq59D3oAVdehj2E2Rf5dxCKAAv901oaF4t062Z5LbTkQknZmM5P58VzU9ndAB0RCnO1ixyB/jTI7zyrKTyLKSck/fJzjI6YoA7SXxZd7BcJAEErBS4A4+gHpWTrmtXVyI2S6WSME5R4zn8PSsWw1uCS33XWmBJgT90/dI4yVqSO5a8tVktLEu0jcPIMIPpQBLJfTSqT5S/vE+QEgbT6kVj3s0phc3NxugUgCJG469CKbq4uPPLzI0coAVCASKz1BjcRbpMbWBA6896AJlKTqZTJHM/VYNh4HvUc2oP9nWGNfLJOSEXGD9KuaHFmCSNQwmYcysBkDHIqheNGkr28KThh9927/U0AQXmoXE8UAkuQqRfwtjrmk85L64SIxA5+7IvXGPSkliib/SJBvgI+VUBwPT6mmWMptLkkxFVb5VR/T60ARXPnQ3bpbPHITxgjJH+FUruOOHBlhMb9DznOa1Y52FxPdTReUEBA29D+Fc/ezy3kpkWOQHJIAGcCgCvqISOIbVwg5yeDVKO9kB3jcCv930qe6VigC5ZiPmLCqU8Dqv8AqyzDlsHigC+0zXUmIyQhG5iwrL8Raeb+zR4xm4jHyBF3M49D/SpIZ0+Vfu7uGAOKvwzNCqrFIiID87GgDzUgg4IwR2pK6HxFo7xyTXtnGz2ZbLMqgBCevA7dO3eueoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCaztpry5jt7WJpZpDhUUZJr3/wnaR6FpNva2ScDBndP+WjEck88Vwvw30OW0tTrR2faSp8hWTJRehbnuR6du/NegaMBdlpNzK5+8qjg0Ab99d3VvtHlbBjKtt3cem4VlanJHJcCYy4ZgNw/+vWrJffZGFooaRZAPmkHQ+1OWW3mUNb3cP2sH95HKmC/tQBRWxmjnRhIzQOAV/iB9s1UvYlhuADHsC9HYED6cV0N7bwtFEyy7I25aI/wn1FZ4shPvDXKkA5WRjzj3FAFGxs7SZ32yMJWIIiB+8fUUXOlrBdibLxE9HJ4zRbxmLUGhliaQAfI0ZH546ird7PcW8KxzypJG33QRlhQBPZySSySpBEjvjJYsAc+tY9+xmvi11Ejyr8u3dkD6VrafcTTQSbkidV6BQQwrHZY7nUDLh0OcFcn9aAJop2t7dVMuxt3CMDgj2rWngSSBiXcSHlJI3zk+61Vt4ILiQND/rM7dkgxg+oqWGN7PeL7CxHovDZoAz4Qgt5GdSrodrIeC3vSPiBPMjh3Iw6A8L+FZ98B9u860lbDDJjcfdq9ab/I3RCOP5cEHjLUAVhDE3mXFqEaQg/uyM89uKyLySPykDBlumPKMCu010U8b5LxQQAMedr4wfWmXdgZVjlmuow+7gbcgH0oAzJdQkRrQy+dKMbXVWytbVre3rxlrXbGwxtdiDgelWEshhWt7ZCxGWnH3fyFV1ZpHjkjOyJCQ2+PA6dfegCy+p6nqBMU0iyhcDO0DHucVN/a01pYTgTI6cjKr0/OrDBJtsU8SxqFykkYPP1qnYaUxhnae2wh+4SOM+tAGKb6eNFuVEtwXYck4/ACrC3DSNmKV4hL8zxOcdP5VHrlg1iqxyToZTyBGDgHtVGztJlkia32mccbWOeT9aANu2aSGZWQNNGVOdzbgx9OO9LLrFyY44InjtChwVRMgfj2qymq32lvIt5ZohePptCqTjBOazrVbuaYGR1G75tgYKAewzQBW1aC6dTI95Pc8ZVWPGapWhupA4njUq45kLbCoFaF6bqeJ4oXkSQsctv+UfT1qL7PCoEdwTLlT87OSFP9aAKFmTaNgXKyuTgDnkUoM+ycMOScjAyTx61OsS+WrwCRnLEMTwcDsPSpY7RVbzISxUj5/nyB7UAS6IEjgkFzMHjQZRTwc1j30cqXBmupQVR8rH1YCrV/ITcJD9oCo3yhUGSPcmqyWSW8w89jdSn7vJbI96AHxQxTK1xdrIsJGQEz8319BWWLmWEu8VsscB4OD1HtW26G4iNuzPAznOcYVVqmYoZp2AYypAMcD5fxoA5ySN/tLSSptj64J6VVl2id2j3tnsOgFa95KbvehiYKCPmUYGKy9RthbQu7ux3DqDwBQBmSSRStnaEcdOKkikQbE4xn5g3es+aVVdWizx/epY3fBc4XPPSgDqp7qOawaCSKM25XBjx1FeaX1s1rcsjKwXOUJGMj1rpYfnU72P8AwE03UtNF1ZFkYGSMZVmPJHpQBydFKRSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdB4L0CbxBq6xJE0lvBiWfAPKg/dyO557+vpWABk4HWu/8ABmp/2FbkQx7ZXP7yZD970/KgD1CxtrSMwfYwsWBs8ojaFA7Y7VcuUSAo6gxRnq2e/wCFcvBrr3Uat5wdgckMvU+5FdLbuha3JYkOOUk5AoAzJb17vzYpV822Q8Mv3lrPWWNSwhheSTqj5wRWxqdktncs0b7AxzkDjHuKhe1aWQGz8p2UZ3btpoAowarHBM0csjgE/Mj5OD7V0GmtbS3AMNxuRucnjb7Vz93p0l9GPNRPOTruHJFaGhW01sWaBEuYlGCmOB7UAdh9hgMvyPFOWHBA2lfxFVLi2MLsJJJAehLKGArLstehh1ARNC0L9lc8fT2rfujNPp6XMBmyW5TG7NAEQltljEimOKQj8GP0rKu2ad+XEXmHG8AYU1Jew3UMOJ4flY7gyrnFSxljZeTcQwvGDnc64yKAKbJeWLxxyANCeshPX6VJstm2MrzGUNuRwwP8+1Tqpm2qFSRRwqucgD29qWS2gvYnWMqXiPzqOBn0FAGTqMdy8q3LxK6YIOR/hUFrctdIYEVkK4J4yD+FX7qRrSWLy0eTAxsByfyp738jSKUtBEoGMMmDQBXX7QP3czrAhPViMH2wK0ZtOjlaCGaXzGI4P3Uqq0XntHmU78jaijOD71orDdyxSpNCuxerqMNigAltpdFEVuLjETDO2NcsaqW5gmWdhLcMeVQMpwtTWl+jztayuox/sg4x7mr8ZMnn29unlhhuDK4ySKAM62M0ZAiiW5QjbIsjnOfUf4VoTAy24GoArEv/ACxXg+3SorAy+W0ZdI534ZmTJPtipzJLGjFpXV14+WMkN7YoAxZLfT0XcJ54yx6ySbsfQVXVFlv2htm2/LnzG4z75remhaSEfaFilAAYSbcbfqPSsT7PtjdrCQeZ3KqeOetAFm8RJxFCzxzrFj97JnI/xoW3l82N4IIZEjPOTtDH8eac9rPcRwG4l8ySPIUL1P8Ate1XLOY30ohvPs8CNwQ4BY496AMy7lvH/ePZwJclhhQdoA9KryQtsQ6gxEoGEihUY69MmtnULZrqQ2z3Rhhj+bCg9KheyvhYNNbb5A2QrOv3h+FAFC8ltrSKMvOwfPyoq5CDHU1BJZRJbSyLEDGTkSk4X8qmvba6+wECGIznCkkgfhTYILY6cFvp5GBG3apyA3PYUAZfmWyJI4zyMDvk+nFV9Ou4oo5JLxjEAduwZDH2qXV5IVihS0V4kiIUvjg++KtvYruE8L/eGSZQDnpyPSgClLc2xmLRMyE8lAMsR7k1FOw8wiSZILVxkLwGJ96luIYzIHMwZRyXbjBqqUivbWQkMzIc72QAEe2aAKep3W6NYrCI+Wv3nHPP8q5y8YSB4ZHy56AHoa09jXN7FCZgsXaJSfmrdm0a0tbc3CQEMP4zyAfagDz6XTZUj3SfIOufWlCgkEplMYHHU102oXoKIojDlfvccVzU119puXZ/3QHTA/kKAInhhUHzXw/90CnxXkLbAYm+TjGOKhj+ZGcKS2eCRSafE5uN0xIjXk570AZuv6cYiLyCIpbSnkAHCH/69YlerRRWd/p00E6J5bDjeeh7H2rzG+tms7uSB2DbDgMAQGHqKAK9FFFABRRRQAUUUUAFFFFABRRRQAUUU+JN7gdu/wBKALFiq7yzLk/w56VetbqS2yEbCN1Hao0XcQqDIUcGpyoABCDPf0oAu2WpvbzK4UmMeneuvXxe9wLYLjCeq8iuDFvkF1/IHpThazDbsJAPIOaAPV5vFsOvxJBeCJJIhgOvG4e9aukRWUs8dur7J24Qs/yn8a8UVjHICfldT1Nb0GppcQnfM1rcLjYy5waAPZ5J5LRhFdRbZI/lD4G0/jWNfSOLkxo32ZZD95DwTXKaL44vrICDUUF2mOGcZyPrXXWfibRNRsyJWSMEfcljztPsRQBFbRw/aGDxpcPtwSx/ka39N1JLBY4x5iRscOhOfxFYtvZzajbvPpckMsS5BjB5NOsBPFF5d2JY2BxGACc0AdXLKZv3lvOrnOBHKuT+BpNTint4hKkcbzsvUAECsm3XypI1vY5YQP8AloAc/lWtqlpPb28MkDLcW8o5deCv1oAzlHkDdcCfz8fdRcAfXFJa2Ur3PmpAIXPASTjePY1oWNzbzA+UZfNj/u/Mcj1qfVNXivYkE4BbgAx9VPuD0oAq36RQTRi5iVmPocY/Gs64s/MLSgyO/O0tyAP61dj1W0RXjvCw52sTg4HrT7q705VhEbSeVjh92Rn0oArWRtnsFWVi8sfzE+Xir1rexScebJHux8wXAJqrc3kEltmOJQF+V3yMMKjSaVlxGscsB4OCBQBWshAmoSvLPEmWPLA4IrRik80uwUS22eJYwAQfrTbeZYVVYLWJiTl2fk1d8lpt3mwMtox4B6D3GKAFubwRvCrW7RsFIU9CPfNIUSERLFMzLI3zuz7s57cVJNJARFC9y9zbx4wph+YgdqtW10k5YaY1rEn/ADzlQZoApNAllM5e5CxycqgTJz/hUEwjW3S3tVSaSQ5Lv8hUntxVk3FrbYe7l/eSNhF+UgVZ0mCBlJjuVaKYnIcYGfrQBlR6f9gkNtfMsc0y7gEmB49yelZ9pZWs91GJSPO3YU9QAPcVqXun6cHlV7dpJnYqJYn4AHQ1LYzwWkIhBzInQk4I9jQA+yguF1KWJLeSVQv8QwjfjTdTn1Tzo4JIQy4wqxS7Qn1FTJeTTWu+O5gjbdwc5f8AWst9S0mwuJDe3iXd0RneXOE9qACOC3topSUaa5cFSWbJU1jXfn29q0QVI9vdMbs54qHUPHHh+yhl+zeZLcP95gvH4Vymp/EO3nMUlpbszRnJE3NAHTXNmglgM2ZIHwXwM80/VLm1s4mazulO/wCUApnHHSvN9Z8d6tqCuiJBCH6mMcgelc7NfXLbZC8gZR2NAHoK6tHZRySXh89i3yq7BVIz2AqjrXjBbt1z5UQAAAjXGK4MXTYLzPubsG5qIOsqsZW255oA6c+JILFy9omZSMbjyarXfi7ULuMJJMFjTooGATXMErv+UMQOmaRsyOCBjFAGodYuhkrLyecdqrG/nYHeVBJyTjmq/lDYWZuelIqAng/nQBcgupmIZd7AdB2q1JPLKQZHGT6VRUhIisbEsfen26MyqqsAe5JoA17ZGd0AZtzdBmrPiTSPP0oT7v8ASIR8qAkkr34FUYTIpBEg355YnpWvaTypEYzMdzf3Rz+dAHndFbniXSJNPmWcKBBMfl+bJB7+9YdABRRRQAUUUUAFFFFABRRRQAtXbeEhcdGPXNR2cDStuABANaojwP3g+hoAjhQo248r39quLAJATlsDr71A24qAi89CD3rQtCFRAinf3VulAFdbVpMNF0H8PQ1ettPmbH7t3Hoa7zwl4NfWbcThlRsZANdTYeHV065WSRcr0ckcUAcHYeDpL+2EjYQEZUEdakPw9ef5Q/kuODnpXqXk2NuzGylbeOWizuRvp6Vr22pWs1rGvlLHOjch1/nQB4jP8ONYA2RSwzA/cw/WsweFte0dn+0abNtBwxIytfQWofZrxk3Qrasf4h0J9ciqjatLbQSWtxcC4ToN/IP40AeJ6ZBrVvOTYvPbuewBxXTWGp+JY3EN0Udeo8xc8/Wu1+02EtuxSGaO46bhj+fSob3UrgxCCWyDccMB82PrQBnW8mu3TbrkWqIV4LMTiren372VsytOyMWw4TGB71zWpXOqliBCyheF3c4Fc1qs16bkPMJo0xjIQ7T+NAHol3qdil3uttQj3vwXX5WH1qCTUbWOfIfzXxy+fvV58LQSZ2h9x5yKWSwmk8tV3oR2IoA7lVh1KUvHcLFIDzuXG4elWbe2nhmaRY42AGdhOVPviuUg8P38dv5kVx+8b/lmSRmopdK1yHy57aKVt3yna5YUAdnKyGYttRZMZaNU4q1bTCXarExqc5BBGK5C30fW3dJ5LS7BX7wQHBrTs5ry0ujFqDyIpPCSLkigDoBZieYECaQDoQORV6xcKrCSW5dlPA6AfhVS2huvsqtZSKIicu/K1eiuZphHJd+SHU4A2n880AVpYppJI5xNEX3YAZueTyPapX0uzjjMlwJVmY8+S2QvvWlHbpcTeVKlshYZyFyT9anlto7CE/asSxfwpEcDPuaAOel0NGieRZtxXkCQD5vpWfFp1zJIFdZI19Vc7fy7V3MUWn6pBH5qNCU7AjP6VAbWBbhwqSpAoySOC34GgDktRg1RUVBOWRFwAvB/OuEupZlkk8ya5Wct90H+tesXE1oxLWyzqn8W7jA9zTRa2j/vo41OeBvUY/WgDxO7t7wIW+0XGOmCxrE1JLmNUySWz90819C3/hyzljM6IXnxlguCF/CuY1jwesFut1JHFKnTGOSaAPDLqWRlKeY3vxVcO/DEnpjFd/4j0DzgVt7cJIfTgCuPvNLubNPmICgdBQBmgCGTzeCOmBT7icbQFBVTyc96idXDAsuM8UkzEuofCjpigCJwJGJ6D0omYMFy3I7AdKn8hcl92R2ANQNGAckhW9OtABGWLDd07E8UxlUzlVyBTx8ijO0j602RlGdh470AKVyPvDA7VEpGRlTim5zycjHTipVxIvJJPpigB6vhsLwPSpPNYMARn8KjB2DIA/rTJR/EzYJ7UAaNtKHYKuQc8k9q2Eu9q4txgj5dx6n6VzlszHAzjPAArVEIijDPjdjsc4oA17+FLrTvs88oLPyFB+6exNcJcwvbzvFLgOhwcHNdtocERuUe4H7vrgnk1X8aWJuc31tBtijG1mAwCP60AcZRS0UAJRRRQAUUUUAFORS7BR3ptXrWNVRhIMO3r2oAnilVIgm3Y6jAI71ahZnTLHcPQ1SHluoXJBrQtIGYrgZB4yDQBZtrSS4YLHlgx6eld74V8Nxw4mvsB0OTG4xx6iqvh/SLcqjNKY5BjCsMD866u+1O7gEMMgRivGVwTigDTl10aeESwg8ljxuT7rioNR1W5SzaeWFhu7xv/StDQ9GgvMTrHI7YyynhaqeJNPee0ZQpVlzhT0P40AYOn6g7yGVojIp6hX2sPwrobHVyw8tyQF5G88iuHsJEgaRZ/Mhdc4IORWhZ38c8J3SDcOhH+FD0A9X0S4bVo2tYYYZpFUuSMAhR1Jz1qeTw7DexDy/LC5ztIIP4GsHw3faf/akcHhAav5wt3a6e4WBgsXGSgJGee2QfSu+0fUdPubKA6fNOydJPP25A9cA/1rzaWOlKs4OLtp0d1/i9ehbjocyvh5LWRPs5dXb+CYEK341TutBu03vvaLBz8rfyNekfaAsW3fGydQX5A/mapRTwicF0Ty2ON3Vc+tehzr+kyDzJNJeabe085jJwcx55q4m6yBghijnjznDqCPyNd9Pf2clwEdY4mHG9V4P1xWhYXlmEMbQWkh6HJA/HmjnXUDzG5it7i133OjxBzn5rdfmHvgVyVzHZWiSJO86ybvkDKRx+Ve6eVZXE7AKkRJxuTAI/EGon03TG4nhWU5x5jsp/U0c8e4WPCnuIJoWkjdonjHDM+f0qrY6vfxOqW8gIGed3GK93OhaFLc7Taxg9MhFI/Omf8IpozZEMCgjoBEOaOaO9wPK9N+IN/afu5JVVugGyp/8AhNn1GSRLz7Ju7bogQa79vA+mTTt5cMBZuCskWOadB8N9IDbp7GLPT92M/wBaOePcDi7HUbfMURhZ1kyWEXNOk1mzhnFtbzTI27ARl+5+Fdgnw90Y3BOnxXMMg43BiMH6Vn3nwxcXLSwXUxlJydzAk/pTTT1QGBcXySwSPaTPNJj5mxgCudl1q+twI0geaIt99vmC16DB8PNYWEx2d+IWYYyyckfWmt4I161ZUmkgmQEAgr1/KmBg6XrcccYfKi6T7pcna3tii88RwTOxvLZkuCMgAEKPxrtNU8HSy6aifZIIJlHDxHn8ay9a0G202S1+2Rpdp5CtIJmB2Sc7gAAOPrWUqqjOMHux26nHnWiI/l25P3m64+narVlrirJGFjlkdupwCBXTrf6FLb7PsVsiL1DAA1z2ry6ZdrMmnN5LjjbEf61qI6C11a2kRosmE9TjAz+NTz3OnpYGdmaSb+EN2NeX6mlxZMjK0rJ1YuwOTU1jrpjKGfbgHCqpzkn60AaGpWg1EPI3nS7QeOgrzXX7FreQibaiHLAA5OK9SfXp7qM2ttEqkjl25xXN6ppKyx4mVSP73cmgDx+5iUyEtuVe2aoyIqvnkn3rq9ZsWilaBQCSeGPNc3eQmGUhgWOMZ60AVSQrgsST7DpQ7ncxIwW6Ukg6Fc7vQionLnAzggelAAxIckjFNIY9Bj8KVQx+cHgetAcMDk4+lAArDqxJ7c03zShIU8nvSIAW9RSPgOen50AOO7qSAfU0pHQkrn9aiGWOO/qacq7XzjNAF212KS0hx6VvWkEcsO/kkc896wrdTMM4/ACup0q3VYFTksf4RQBPo5jSYmRN7E4GRmu2vtIabTRPdSBYwuEiUfzrmLVPIuEDbVkz1B4Wuyktrmez3vIHBHDP2HsKAPCdesBYX7IhJib5kJx+VFdn4g0w3sskThvlbg8DFFAHnVFFFABRRTkUuwVepoAfAuXyw+UVqQgTAZ+VvWobaFMEb9rD9aRBLFJnqoNAGhaWccsxS4wmfusK6TRrKC1bM6F9vPHINcoXckMAcjoa6Xw/LIzKS3yL1GM0AddZ3duY5Vt8hMZCN1B/GiPWY55o1utuFOMYz+tXXS2urLdEiRybeJFHDfWuPELwTtJPjbuoA9c0vxRZoEtrYEkjqrbSPzqXWryC6syYpgZ1Odv3WrzmyhlU+fG6SIfwIrVso57gkyXESbfzoAjuY4blZDIyIO4Yc1lSWCrDm0kiYr6Ng/lWlcFYbncVIzwccg1Rv5FilRTGAjeooAdpOo6poU8l1ps/kzyRtC7bVc7G6jBB9OtbvhnXXtSBJK654LkcH61x97HMMPu2ejdcilgmMcWT+8Z+p7fjUqEVJyS1e7C56zceK2to9s1zE0X8LxnkfWsNvGFzFOWjnLL229D9a8+S+TzDFKm5W9T901o58tEQTly3IUVQHaDxXcXToAY0kY/ewBmrK+LLpJ9l0qvgfKRyCPrXKW8VnOoimjdZOxPai40+YRZt72NQnQOcH8KAN658WF5CETyGHBIJzVu08RuQEjuDIh9OoP41w63EoDpIwLnoxqa3aSPaDjk9RQB3E/iS8WNfKlMOD1BAJqfT/GmoRyETTl19CelcPNGmPmkYqDyc5p0d/ErpHGvmDoW70AekJ48u3PloyOV5zgVqWPjcyELcTxp6rivN47i0KCMLtf1yAaZcWrpKrx3MGCcAYBoA9rs/EZePesnmL6KcfrUqeIbRizSzzxyj0NeTLaT2dn57X9tED2Xk/pWSNUaW4KozSMPQkGpcYvVoD6Bg8QSPD/oiSTpjBduMVbTVmRB5u8oOxU5/OvAbTW9Qt2EKTTQQnrvbB/CtSLxvfWSYN3FMg/v0ckewXPZpPENv5chhRI2HOGOCTXG+KvEeoaTPDNpl0DFPAkkzHY5V8n5enGP61wF14/WdSHhj8xzjIBUfnULXUliqahaTyQzcsGidlxkdmH1NcOIwFGbc+Ra7qytK219OnTsWpMh1b+0I3mW6tjaywt9x1KkDGRkHnvWN/aspjWHbCSTwwG011PxYupk8f6zGmPKAiyCO/kpXPwaYl1pplEUiNtwWdcAn2rbBV3iMPCq1bmSf3ikrNo0Y4L25to0W33sRkFjhaz9U8PaiJVlmtWLDn5BwPyrZ8M3lra24jlnka6Q5AKkgDNbmseLraez8qJZJJFGC/wB3+VdRJwNss1teKZGZZCemOBWz5xfcpDTseF4x+lYFxdCa/Z5pJEUtgKDk1v8A2u0MaxRAiUL97PNAHK6/p48t5LhCsueADzXD6hDFGmR98Hkt1r03UI55bdliTd6Beo/GvOdXtWivH875n649KAObnfa5KZBqFW5xxuNWr+IpKG6Z9qreX8xZif5UAMLZzkdO1ITuGdoA7051P3UbrVi2jYIWkiLqOgoAqBc+oHbJxTduWHIqWd9zElQuO1IkZZS3P1NADTjPJ49qeHymAnTuaaFHQt+FPOxBknmgCxbTPHH3AJ+ldhpfmfZUYbY8/wARHJrjdOjeaZSAvB6tXY29rJM4XzSz9OOn4UAPnuGinQx7iBW1a+Ibm5T7NGFjAGN2efzrIudKuYyuVZQe7HrV3SNI/ej7Q2xM9ur0AR3sUEbEeeZpTywBziitDU9PVXY7VgjHCr0/GigDxuiiigAq3aps2yHGT09QKitojLJjsOTWkLfe4XjBHA6flQBJMkUir5Y2TD8mot9u4rKePSpbVRGxWcFlHfoRTp4olbIG5PXvQBIUQACM7W9+hq9pFxLa3WNoGeuOc1kMfLYMjBk9DVqznQ3CEZU54OaAPRdNkknj2WsPzHqoOPypbyzYy/6n5z1ifvWn4Omt0uYfP+bgZyOD9DXV+JPC7aw63OnuI2UZBY8GgDy1ku7QmQJLEG/gPIqtFqm+dkkRlK89Miuju7bWbKVra7gEijo6msp9Duptz+UwY9zQBe0/WLOaHy7xFVj0OOKpavNZt+6gOHHYnINVk0a6K/Nn5e/Sq+pabc6eqXHzAN1yMj86AK8t7LEoSSQY/hzTjIZgG3jb6Z6VSkdrwZMQBHenLA6BSyj8TQBoEI8YdQHx1GcVYh8sxpI8TkL2XrismCVPNK7gPY9KkikfzsOxQdtp4oA6A30EiqYi428bZRyPoatrbXNxb72aEr1AZ+ayI3YqRuPH8ZUHFVnc7y/nkspzjoKANkLOGVCiBz04/rUEokJJdJQw9OaSy1S485WzlQMcjNa81xIV3xlGJHPHSgDlmldpiIwwA65J5pyGcyMI4ZDkZ47VrySQli2Ard/mxV9NMDwebBqCICORuFAGbYb7po4sSI4+8Rgk1evrSOHaDPICezLim2OmDzDvJ2n/AJaRtzVi/sMKrG8eQL0DLQBUZFjYBJSA3XjitgSWa2vEivcL0fZggVQSzn8oMY2aM9QvWlaBBG7RZQYOd5NAFTUdWlcILiWSSEHA+UZ/Sqh8gL5qoJFPIz1FOjsZ3lLBAFxkEnrRc2rlGG+NEXnGe9AFTbJ8zbjtHO0V0fh691jUbP7Ja2U1zGDxtQkVipcLAm1F3ydiV4Fdb4e8bT6XEsNo3lsBg/IKAHzvqcN4ZdWjka8mbDyzAyNwMDJPXgYrc0e5jvpHS6lL7RkL91RVPUtaTXLPzJWke4HXPGPpXNF5oopESQ7XHCsuPzpJKKstgJPEWpCyv5BDIjNu7c8enFUbjWrm8t/LJEUWOWVcZ/GsK9tzHMShJdh/DwBQq3skASQ7U7Zxk0wGzl5LgZZ8dQxPWrtvOBcRRhiCTzt64pljL++VbuAOo4wvFakl7bh9tvZGEH7znrQBevVlEAeO4VIQOn8Rrz/XW8x/ljbcTya6pWsoJfMlMjBj931Nc34kaaaRzbwiJDzkigDlbpcHLbs+5zUHlg4YKT75qWRSh/eHcfpUU0m0DAy3t2oAuQw20cReQkse1Vrq4Z8JFhUH+1UaR5USOx9gajCCV8D5fegBqx/MSWXHrSO5ZdgJP0p4TkhTvNQvGFOO9ACdON1PZGAUA/nQoVSCeKnYCTG05PvQBd06M71AyzHsvU16Fp0VxDGjR2624A/i5Y1yPhS2ka8QIyq+eWIzivTrHSt0RLTuin78jj+VAGXBp99fXCvLlxnjccV2I0tLG2EggWS4xksThVqppFnCsoFsS6j+ORuW/CujmiZ7WQ3RURqONx60Aed38Mdxcs805lJ7ICcUVo/bZoJ2jtbJXJJI3DIxRQB8+UqqWYBQSTwAO9JXXeB9OiaRr25QnHywjkD0J9/T86AKNppzRIoI3N1JHf6VrJpxkALgZ/hYdRXSXFgkXzrgelVMDzQABtPBoAyvssnIdFZ16+4rPuYdnzIrBf5V2D2u5QwB4H4isK/YbmCkZHVT1oA5qTcGJAGDTIZDncSp29ulS3bKXO04PpiqTg43AD3xQB2/h7XHiiEDFcHsx/ka9N8MayZQLRbskY6M2PyNeAwbdv3yCK1rTV5oSnlSNuXgc0Aez64ZorgmLzpWHVTg8fhVXTkuNTIWJ3SQenH6V57H40vYsEsNyjAJrSt/HsrBHCLHOv8AEvegDsdXg1CGIxz7GYdmGCa4zWru8CNFLLIqY6elS6l46u71R5hjk29M9RWPd6omoENONvuOlAFXayx71YMfUHFSo7yKC4YKO4OarrDtlJhZCh6ZNOkcZHyFH9QaAJGjTduZgAeM4rRspordQsyqQehx1rGKuFaRwSKfb3oZACu4DtnFAG+5t1+aJyCedvamyK94oSFV39gMc1hySjzPkJGezVdtm248rAc853YoA2Le3nii2NZyo3ZwvSoozMJ9k5ZsD124pqajqlsoMM7le6ucimTamblw16qM44+QYP40ATTMqEBC7sTgd6twS3EiBCUAz3AGKz4DCyyFkKns2ahj3o5K72z0J5FAHYaWIEjPmvKSDjg8VJe3lvIBFBKAMYwRyKxbe6tlg+cMJfTGKzLiZfMJy2O56GgDpAvkIElu2Ct/CO/40xnMcDLbyqy5yVPNc6lxPEM24EoPQkZxUbajc/cIB3cEgYNAHUW1sbhf3kisD2UgU+azwh3RxpGO+cmuTF28TARSuh64zVxNSZItzgy+uTQBddpZkaIMCei8c1oaf4bu79tqsVmODkRnNZNvrQtZ0lt4FRvUHpXoHhzxvLB5btPDk/eUpjj60Aa3hX4eOVV7y5lODltwwK29e8P6VLbeUs8hZRjEcYAqG9+IUQsXFpdZnI5VF6VxU3iYOzSTTSluuGFAHPeK9Ca0dtqyeSTncwxiuciSCEZDO49Sen0rY8Qa9Jfq0YlV4fT3rMtZ8wqkduGbOeBmgB0U9zEd1omxG/ibk1bnuY4ot/nPNKeuF4FVPInKlSXTn7tWrmO4tbRCIgpPtzQBo6HZpMfOugxJ5AYVD4sSLYY4RggcnGBWt4WaCAeZqG9iR1I6VheNdUgZ2W0ixETyWHJoA4trATiRmljwPWsWSAxyN02g1sbvPPBWJB68VWniRs7TyehFAGTM+49PlFRSdlRTz3q7IqwjLAufc8VA5MoBxtX0HegCI7Izgl8+1N8sMxJzj/aNPZGlOV+XHrQIiSNxP0oAYSOgBzV+xhG8HAYn1qJFj3AMAorV063WSdEiG5M8nNAHY+E7NHeN1i3sOo7V36Q2shXzlklY9Y4zwPrWD4Y04WkJlLAP1wTgCus8OiS6v0Yyx+Uh5VVzuNAHRaNsjtiy6UhVB8objJ9TWXrbRSIz6jcIjk5WKPnbXS6pZy3LKpLjI6BtoA965PUdPELSb492eAF7/jQBhSTXNw22xiVV7FjjiiqWpJcQnEEywjvt5P0ooA8I0bT31K9WFB8i/PIQQCEBGce/NduZBBGkUWQiKFUdwB0rK0K3fToMnKyyYL85HsK0pH82Qb1JPrQBILqcIUZtyHsetEVwu0lucfnUbLlhGwxjoT3qGaRYiVwQw9utAF1bpzH5kMwBXsaxNTuVlYyAKH7ilnbYplQkBuwPFZ0ls0mXRsjvQBVuHR3yOKYAOcNmpZLN9m7GQaQW3AIJB96AFHzLkIpxSNGMbkP1FW4LWUlcKCp9at/Z44eZoWKnrigDFLkN8wyRTVlO7DArmul+xWNzGTFKFfHAcVntpfzZTB9cGgDPR8YyD7HFacczeVggY+mRTUsJMHy2BI/hpy7omBZAMdRQAgZvMGFH4GrCMM4xz61HthlGVY57qKjVthxtxQBa+0SRuN5wKSaZFOQmc88CqplVzh1I+p4qWVQYx5bY9hQAye4WRNwXkdu9RRXTIOin0B60z7xxjB96ZIsmQBj8qALo1CXACuynuDyKWG8ZW+YZJOc1ngEcmI7h705HdyFU7fY0AdBbXm5iCxwR0I61sadcBIsxF1ZexHFcdbxyg4dgPXFbVlIxUopyp7+lAGxMPtN3vLxgtzt21LNbhVAbaT7c1UtG2IVkZs+ueasW7IXLLv2jqXbqaAFjBiX7jMD6DFNZyJVKAEjnDitm207z4BNFqFvEx/hbtVe/0+4towXvLaUf7J5oAfHqbPEUlt7IEDgmPmsO6uZzM7KqMCOiLgVJJN5SFZWyD2GOajN9BCowSuezDmgCCBmkJVEYuT0xXbeFfDFxcxlzZSTA8kqeRXG2eo/6TuYfJnqK7vRdbMGwWm8hhkkPigBt9oDxXLIIJYUHPDDd9Ky3huWMkPlzpDnHmSDIxXZXOswMQ0k1w0/dewrSjmuNThCC2862Ud8AGgDzK60aGyIZF3hs5J/wqpaTskxjhTaQPvbea67xiJ44d1jagKOCQMAVw2nTGa923G4N1wp60AXJb+a3mQI26Qnow5q5czzSRI06rJIf4B1qUyWqzKJLQy7f4VbJNbun3XmurwaXDAo/jkO7FAENul9JpyiO2SBSOS3auK8TwFSSZDLIvOB0r0DxDfLFYs3nSucfwjCivMLi9E16ouJWWInnHWgCgLWZiJbhQkfUCk1C7tPs/lqoL/Sr2q3untGEtjIW6ZNc3exMo3jI92FADWiYReZKFx2BNQoC4J3Ko7AGkQGVeeT6k1Kw8tBgjB/uigARSgCgk59Kk8nkncAR6nNRBZtw8tDj/aqxCkkbqZUUj3oAZBbSTSjIFegeFNOW3T7RNtOOg96xtH0pr2ZSGdEbqEXmvSbfTxZ6YkEEcEakcyTtlz+FAGfO0j52yjB7Rj+Zrp/ANvciYmJ9iZxufjP41Fpel24VC0rOgI3bV613dlp0CJ54j3QIPlVuBn6UAbch021hDXsnnzY/vcfhWDrszX1g4W3itbVf7/VqVbOa4mWQIkSE/KCMsf8ACqOvtNaybJjuz0AOSaAOJuIJJ0fy4d0an7x+UH6UVcvhNdErciRIxyFB2CigDykWrQIJY3EkLdQe1VblhE37tw0R7Hqppge4XKj7h6q3es+4DDICtn9RQBoJd4YeYoI7EVdieKZ1MiA9ga5mOcpIA4Kn9DXU6ZDHcRqwYI3egCddBiuiyj5AenPBqKfwdf2yGSOJnUf3f8K6u1sSkSFJd47EV33haIzqis8cuOqPwaAPELCxmV8PHvXuuORW3HottcgMFAX+JSMEV9BxeENGvHLNELa4b+GQfI30YVg694Dns5PMtsbO6kZ/WgDzWw8L6ZNHhHKydsGkk8HvcF1h2tKv/LNuCw9q29V0pbSX5kmgdepAyp+hqDzb51QxTpNs+6c4cUAeda74fltZDmCSJvQjBrDBeHKSda9mu9aEto1vqMUbt0IkHP4GuB1iwspZCUJiY9M8igDl7e43Pydp74qd9rkkMv4jNQXljHby/PkH1XoahDbCNr5HuKAHOhV8oq/VaiP387gPYmpDIFIIkAJ/hI4NNaXONyAg9qAI2VSeXOKRPkPJJ+lKzAnKLxUcjN1AoAl8tC288n0zzTWbYfu5H05pnJAwTn0NLIpK5YkEUASoYyNwz+NPilZWOVG2q0RAI/djJ71bRjGQSmQfxoAcskbScIffca1NK0+e+l22Uqo+cAFqoxiGR8kkZ68VcjQRc2su0/WgDro/AuuFld1gm+jVBf8AhrV9NQtLDGiH0Oaxor2/RQUvJlPoGNTXGsXLxbWupWJ6gsTQBTaObeQzZGeQTinXDoigbfm7fMTURumfmZgSDwcUjFphvIDD2OKAKsp3nJyCOlHmCZNoQKR3NRTGdvuKFx0OKbK67VDsBJ64oAkhWRSQPmXvxXSeGvNM67WjCL/ebbXLKJQRkuynutdFpGnI6rLE8gI5OVzQB3msaw0tqlqsMK8YJiIJq5oN24i8r7W1vkcK3U1ztpCZFVbudYQOhZcGtvSI5bOcy20STR/89JefyoAbrtlJcW8qx3U0pPYniuMtfDU9vJvupPLU9Fzya729mu7rMrQjYO68fpWHPb34ukmtoJR05lYfyoAji01ohGISCpOTlSP1roGtzFbqScnHA3YA/AVo2enTXNsZb+Xy+MgZAArm/E+pm2jaGz8qRjxnOTQBynim+YMYnm8yQ/wg8LXGuQ7MPMVPrya15BPJcu91EvPfFZ2pyxK5RRGAfSgCg3lo4WJt8nqBWpZ+Hru+HmSIUQ9DI3WqFiVWb92m7nPJxXSNfyMgiztyMFt3AoA5rUNP+wzFHlUkdgeKpqJfMUBeCeCRW7dW9koJEpmmY+nQ0+x0ya5mUhcD1f8ApQBmJavI/DBj/dFdFoHh1ryQG5t5Mdj1zW9o3hG4nfdGiBByzsOa7+ysY7GySMRHrgtjH5UAQaDp9rpFuoWwkMig/OzYAq1Fp+n6heIzW8ss7HoMkCtEJ3m3Adt3P6V1Glny4o4YYsbuWdV5b6UAQwaQtkkZ2FXXlY+M/pTdT1CVm2MASvWMEVryW08zOWiaIdBk8n61AIIrOMG3gRpepwM5NAGZPJezW33fJ3DG8DbtHtnmsGZbC0RjC11LcDhpnGcn2roJZ7q8uGSdMH0UZOPTFZ9/bTtMqC1UMTwCcsB6n0oA4m8n2XJN35z7uQu7kfWit/Ura1tWK3EYaY9guaKAOHl8LpGm8SHj70brz+FZ994TNxAZbF1kI7A816gn2adGgu1aKTPysoyp/wADWYtjFbTNthZJhn506OPcUAeLXvh+6RyzRHI68fzquUkgXZllbtivZpIQsreZA5QnqOcVm3ui6bfq24Kkw5yBwaAPOdL1C+iH7qYkZ5U122i+J5YHQzph16NnBqi3h6CNwAxVs8A9/wAall0a4RtyqH29V74oA9E0/wCIBVEWQs6HhkODXXaV4jt7uHEN4ikjmKT/AANeHQwQlx5qPAQevOK1gkKriVnZcfK6NyKAPRNYnZS0kckQ57jKn2x2rhNTitmuTKymB26+S2VJq3p+qvZJiVvtdqw/i+8tQXN9p96xS1lRc/wtQBi6ynlw5EhkQ/8APRSD+dcXqNwkiFBL8w7V2mpTXESGGaPfH/C2a4nWTE3yyxlWHRwKAMV5JPuu+R2yajQncQW49McVPJEuwFGUt23VWY4fDgg0APO1iRsVtvpULA4zGuD3BNWEcAfMVP1HNDRA/Mmee2KAKJaYMANv40SB15OeattESfmUj3qJkIfqWHoKAIAAB3J+tPiUyNtZio9DUyRgL0xn2qZFwR8wz/tUARwxhZQFyc+tWWRkbIdmUdsUwoQcsgLetSo525Ztg9jmgCAuGGCzAewqe3gLjIIKj3xSW6LJIQrkqfWp0slV8FyueRzmgB3nbF2KJR6nNQliASjbm/2jWrbQRIw8yUD3Oak8mBX3KY2z3xQBjCaQjhF5980K52ncfKH866BtMgmh3IpDf7LAVUXSZHJjChj67h0oAxkBz5hLMtS3MrPGMldg9ua0ZvD86YKZI9Owqi9tIHKbVGO9AFe1kTI3sQO3Fdn4ZfEeIpSCe4HSuTS2WP55XAI6bea39J1JbfCqDnt2oA72G3soIRLO6zSHk7+o+lXrXUYJ4vJiUogGAx+UCuVhvprrEjW27HctipneIjkFD15OaAOnvZbe2hzbyLJNj+GuVv8AxFdMNpaNWHAJ7VDPfOlq3lumz2XBrlbyffIdoXB7k0AWtU1+6ZCjzvIfQcCs+x1KeM7sNz1yM1kXlwysRuOB2FQQSzzKwV2RfQ0AdBqV8k0WWlCE+tc2djTZHz+54poguHkCr85z0HNb2n+G72Uoz277m6AjNADNLjh81fPEaD1PNampPZeQUgk+c/3VxXWaJ8MNS1SSLzri2tIm/wCehwa9M0f4T+DdHiEmrX0l/ddSqHj8hQB8/aJaTPP5dvZSXMx6YFem6N4S1OW3Wa+jt7SIfNhzyK9NTRbO2GNF0yC1gPHmSD5jViNtOskZXRJJejO4yPwzQByuk2ksUW2GRHjT+JsAGrBlaW4CtGplzhAqkge/vWmt7BLeYFvGqdiR1/oK2bKyWZ1n8rKjuvHH1oAi061is0SSa182YcncMn8q2z9su3Wb7MLaJB8rHANJ/adta5jtbNAx4J+8aJL2VrRh9nKKRgtIeaAMTU7qVVdVQYPGS53H8KZaTXDWu0IYx0zwv489abcyIThIn3A8kMP8ipYh5se5znHCoo3H86AFFxFEpVGVGx97GSfyrLmjeMPIjozt/Ez4xUlxakysDG7kjkFttUJrC8CbpDbhV5CgFsUAZc8VzLKyRNEc8tIOf1oq150hyG3SEdlwgFFAEl4oZPOdTFKvVk6N9RTJZftNmHjQS7eGA6itLUY45bQM1u7bOrRH5h/jVKz0lGj8/T5GZh1AON3sRQBiR3FvHIyzK7RNx/tJWPd2aSzedYyrKmex2sPqK2dUijjZpVRiwJ3I4xn/AArHvJYWtVnjiMb/AK/nQBQ1KV2TLjcqenUVAt+0UKyxuzsvboce4qjf3TibzCd2emO9Zl9cGc5RthH50Ael+GdTsb1kaeBXzwy8ZruF8GaFqkGbfNs55x0r56tJ7q1kDrnrw45Fdvo3jKe12pcHDdiDwaAOg1fwe+mSSCGYn0461wepWqW8zF4QjjqV/mK9NsPF9ne4SaRVY/3+hqHXbayvYSwhUk/3TuBoA8g1LU3W3KowcDqrLXLS37T7gp/4C3Neha94eheNms0ww7Zrgbm0e2mYSRbW9cUAUknYEo8eF9h0pWiYnKkjjrjNPdijhigPqR3p0s4RNyBvoKAKaKDLgjnvxitS2iKY8xD5fYis1G82QvGOa1YrseRscLn60ASSpEwwJB9GFQ/2eDltpz2wagaVWONpDfXipIrl4z8p/AmgCQWAk4OR9arz6csbc5I9QasnVWPyMFJ+lC3UZf50YN7HigCkIwThO1SrbseNq8+pq29xFjKod30qITRsPnjG78qAIxahD8iL74NWDGCozH+NQLPEHHO01Ol0C23cfrigBHRFGMvk+/FR7ynKqxHfmtZHt9med/rmnxNbc+dgqe2KAMiW4BjAjOeOVqqs8ytlBz7ZFbE66aH/AHKcn1FUNQ8rZmJwuOx5oAYbm6ZdsjPt9AaqXDtuA3EHtzS28sbNhy+7/Zpt3AA29ZTigCxC1wV2SMNv0qxbJN5o8nDN6kVmpLcNEV8wkdM1d0xpUIDnCnuDigDprGS8AT7QyIB/tcVuCO1kUOZRI/oBWPYXKhQkSRFz3Y5NX0jlRt0zxqhPPzYoAsS2Ml4MWgYRDrlOKqrpMQDC4jj474rcgvtNjhCyXJYn+EPWBrmoxiXbaqGB6dc0AY1zpELzFvIYoD0UgZqY2FlgAWgQ+702107VtQn220UjE13GgfDm+O2W/jK9yHOBQBxtnZw204Ih+Yn5QmD+tenaBo5u7WN3zFnngcmtQWFrp0O2KztywGC6gZ/OqE2rLHEM7FwcBd/AoA3obSFSkYtJpQP4wxwPxrpdPsCiK1oTb/3nbDfzrjLTxBJcWwSTUEhXoERMtU9rc3Es/kWk107E9xgUAd3cS6XHastxeSXEp6nHOfYVzMlhbSzh0ilZF5C5LH8ewrT0bw7dPMklysQX1lbcfriulNrbxrsKyXTjqsYwo+uKAOctbcMm6LT13nu5Brct9sUP+lNHHgdM5P5VS1MStKuy3a3hXpufao/xqvCyxP5rOsz4+UHoKALoOVLw2spP99hgVGLT7Q3mXjkqOxfAFVJ7m9uTma58uM9FBAFNMlpH/rboSyehfAH4DrQBN9mtC5IwI/fgH/GodqCXEUg2DuRwPoKSJ3nBEEfToWIA/KoJZBbuWujJOw6In3aAGXdl9plMkPmEd3Awufas29kaGF7dbnMh7YzWvcXl1dWjPK8dtbqOFU81zEl0AjeVC+4/xNyaAMyWO5kclG3Y9sAUVVv/ALTKmYVcqT1kO1aKAOmivJbUMksAB7vGcbvfFVLm7QIbi1cB/wCIpwR/vL3qrDqcUJEdzHJD/suMqR7GqFxBbyXP2rTvnAPzIHxmgC5JqjBSWSGUHnbn730NYuorZ3Q3RboX6mNugpuoW9pLGzI0kL9dp4wa5O9ubiGYo7K6DgEnnFAFy409xIV/dmM9DiqkWjSvIHjjwB1IGRin2l6SRuLr24PFdJpd41iwkbaY2OCQP5igDPg0uBYDndFJj0yrVEbDzkMUmxsdMDB/Cujn8u6kD2xEW45IHSti0sba7h8m5hVJx91+xoA8murS4s5yEkLAHOx8rT/7eubSP5GIA+8hOCK7/U9LMSvFeW3mIOkinNef6xpMTTMsU4QHoGoAp3HiyQnIdT9TzWbe62LxfnjGe5xWfqWlyW8hDR7vdec1FbW/BDBkPvQBE0qljyQPQ81BJcqMgK2T3NSXEEsb5UoVqLD9H/lxQBDDIUmyeh69qvXC4QSIA6nqKakQcheAx9RU40q8GWhUOD/Ch5/KgCsrKqghSD9aA6s+HkZT6Y4rRbw5rZi8wWE5jPfZVb+y7hEJdXjYdQetAEDpECczgD6UxTGpG2XcKuW9krtskYnPqKtR+HXnP+jSA+w60AZuZgdyNlfWjzHLZYqf0rUufD1xGoyJDjrxUK6KZE/cytvH8LCgCq80iDARD9RS2zSS/eUY/wB2r8OjXkmfMjcY6kCpRpskSMQS2Ow60AQxzFAVFueehFWYsBCZUPPqabbxTBw0ZYf73NSvH5vMkseB2oA07OKCaPLxqARgAmsu+0tRcE/Jg+hqNnlU/ulBPqDU4lYRjzvL3/73NAFT7JDA3MXPY54pVtNPZt83mgDsOlV53YyZO5vQA00oVXIlZSecE0Abdo2kCMCSwkIHcGti1Ph8w/uraXzD0BriYUuGcNI+I89q6rTZDFGoSQfimTQBu6PplhcSkzTG1TsdwrV1Dwnpc8HmJqm8Dnk81QtFkeEu0U0i+u0KK1LFF3GR4xuxgBhQByp0eGGcfZZTgH7xXrVe7sjFMHiQs46sea6W8kRJsXUMj+mzoKd+9C7tN0xGU/eeZ6AKOlapdw7VkLoBzuTjFdEdYlm2q96sqnsWOfzrERFmZluJFBbrHFwB+NbeneGkmjV7dGfPPL5xQBr+bG1mB5QJx91CTn8axn0u9uWJhtoIYz0ywya6u18NMsQQYGRySh/ma1rHw9Db4ad0nPZAQKAOV03Q5LeJmmm3S9kQcD610mhWN6Tlvki9hgn8a67SmtYIwjRRRL6bc1d1O5tAilHhhUc7zQBlx2QhQSXl03rgvtFXYNSeRhDaBXHQBOlVPtdrKAqCWdj3KYH61ZtmZGAijER7nOKAHX2lXMxEkpVMcneN1Zt1bSyJg42Dg9FBrfdZzHul2so/vv8A0rIvprrbuRYohnoDuNAGbLpkckeZC+f9lcD9earLocSYaeQRIx4C8NWrb3Vui77guZO+Tn+VZ19qO+XNrbE9vNkQ4H0zQBOVigjMVrkKOpDfMfxrHudQjdvLSJ5CP4QcjPuaqT3Z+0HzWdz3OeP0qSTbNBvV/IiX+FRjNAD70SnYZxGFHYNwP8ay765PzJb2xEfUuw61F58YuNzy72H3fMfn8BUFzqvmxNG8IwDyFPX6mgDL1bEoXzbgN6AfNj8OlFSB9y7hEMdgoooAyZNYuoSqXQEyKcMh4NMNxb7/AD9PmZSeTHnayn+tU/JM29WYjH8LDIP9azZisGUlyr/wMf8AGgCxe6ncx3JfJKnruX+lZl7dm7Db7ZC3qhp0tzvwJSHBGDiqQtJEfejEqTwR2oAvaGxE4SbcIzxyOldlKIrWNBLD8n8MsZ4rnLCPy0Eknzr3K8n8q2rfVoItotjFKueUPH6UAalrZJLJ5kMgVup2jIP1FdGLKR7QSW8kThfvIe309KpaXfaNdRAt/oF2Oh7Gm6jdSh8MInHaWFiCR70AZ+tGWFBKLl02j7rcg/jXB65OLr51COD128EGuh1Zmhido5XZW5IL5/Q1w+p/MxkhIU9x0oAoTeer4Rzt7AmnRiSY4liG71qNZNykyIzH+8DVi0nj3Y3lX7ZoAT7PGp/eR49vWnGztZjwPKAPXGQa0YpS/DtGQPUVegmsSCszbCO4XigDLfSoVjDxzL+fFWrG3khUPE0bN2wealnigYkQt5i+oOKtW9tGsYdcg46EYoAv2XiaezgKS3EysB93buU043sGpwgXlmrZ5Dx8E/hWM8chlyW49DT2eeDlJQv6UAEun6Y04aGaWMg/MpQHFO22Ec3CvKBxlTg/lVePWJYmbz0ilU+1V5bxZydtuFJ5yKANKRrd2PlrOUPYtgiqsk8EZ/cTMvZlkXJqm1zHEmJDIue/WolhSUZDK4P95SKANMaisMZxucH+6aovffaHGxFi/wBpqoCFoJjnKL+dadj9lVSzyh/ZhigCpM0UTZZk57gk1UvY2aMNFNGAeyjmtoIl03y2x2/7Nadnp1rHGvm2rbR1yvNAHDQRyFwASR6M2KuSWkjr8pjz7mvUNLOhQgGTTpWHq4GKram2nb5GtraGNCeDgHFAHBWWizTlRKUjHZs9K6Sx8Iaa67ri5YjuetV76cLGwSRWB7BRxVBb+crtZmVfTOBQB0k/hbSIYSIr1Rx0c4qjBoEG391dI+Om1qxft0u8M+ZOcfNzXYeH7yJHXfExfHRIxQBp6Ro1w9ll5JGXHAIOKsw+GpjnZdKFbkqOSK3BqLtAqoTbqeMuQtSW90UVUl1GOQtxtXqaAMX/AIRbyYzIs4Z/9v8A+tVeXSyflnmUL32OcV017Zts3b9qn1bJNYfmW9jKWZZZHJ+7QBe0rQY5olWzgzzzuIGfxNdjpGhzqFjZIrdV/u/MT+VcZYa1JlykJjPYsScV0Fr4nupEEQKRJ3Ij5P40AdNc2bWuCS0xJx8w4H4VSnijOVLvub+6gAFZp1WKVwLi5u39hGNtXotRDARwzCQf3NnP4mgC5BZ2jKkf2hd/cqOa04tKsw6sv71x0+XP86rWt4RFtKwQ/wC0x5qM38cchc7yo44bANAF6WK4WZcQt5ftjOKjneSBxJ9m8tM9X5Zqhg1GSdswRuv+0oLY/pTbm6mDgOGV24DSjJP+FAFyOe4lYutsgx/E5z+lU7opPGxnjYseNzfKop8UzKNmS/c4bP6Vn6tqjWqEi3ZMnCtIct+A7UAR3NtPHbFkcKFHA6D9K5fWPtJhDT3IkLH5VUcCpZr+a4lZrgXEsfXb2P8ASqs16cDeojjH3Yo+T+NAFSK6FoVMx3N3AXJqK5uZriRswFYf9tzk1pWrxS5Pkncf4pBk/gKqatfRRny2aQfUAfpQBnXMEWwNGsUT/wCyNzH8apXheKIK07Ox6IoCiroa1MRea4bceiLyayHSQyN9igYHu8rdKAGTXDwopuLhhnpGnUUVBcRSx/O2GbufWigDMu7t5eYmwR1VhyPpVY36SRmK6wT23cg1lf2g8YcSMPMXofSqsshu4sjb5n95ehoAsT7FkzGpXnoT/KtrSbiMbfOQY+nNc3avMjhJeVz35FaqCIxkJuRh2zkUAdPP9ikiDDCEc7o+P0rOWK2kn8yN1LKeQeCawEuHRmDSHPbFS2+o7W+ZUk9+hoA7N5rdrXbmOTHG1+GH0PesV73UbFxLYxebBnnDZ4+lZ011HMMBdh9CKgjvJrcN5UpT2ByDQBPqviD7SpE1qFbvjiuauJfMkygOPQ1cvi1ySZFbJ67e9UPL8o4IZfQsKABCHcZJU0kwAb5WyPyNSGN9hLDjsRT4LEyJvLZxQAtuxblWzjsatwurJwvze9LZac8vEbj8a0f7FuoE8xlKH1HQ0AR214isFniTA9RjP410kE+nzQJ5ReNx2YZH51gWukzXr/LneD9114NdFYeHbhVA+zPG/oOQaAKmoJBt+8GHqo5FV4jbmIoCz9uR0rck06YZjEXzjsRzUI05rdlkm+Rj03AigDnp4PLGVt1KdyTUlnpdvdMpjbbKf4VOa7mxh0ie0KXkzJcdiOhqCHSrRpDNGbdmXsG2GgDk73w5NuG8sFPTK1J/YNwkKAB5B6+ldm19FHF5ckbuO2Tn9alGuzLGIvsq+VjAJU/zFAHAtprJ/rEYkf3T/Q0lvb2schNyjkemzmu7tLOzvZj9r3wMeQWBwK1W0HRHUKZBO31xigDzd5YkB+yQMgHQ5wT+FRwXLySBZHlA9mNdTrGjR20uYJURewyP51kCxQkvcK4I6MrZH6UAVLq4zEY2vJAh/h4FZEIuGlKRnep6bnFWLqQ+aUiClf7zAHFCrEFyzwlvYHI/KgBZ7cLHtxCZD2LDNZoto+SCEb1Zjim3LS7z8qlfXGKhWIvkcsh6gMKAJ7HIkyWDNnAVeRXc+HA3lgTeTEeoO4Zrg7WC6WTdawNxx1BroNKt7syhpF59ClAHoscsKAFzHOeysuavxTuy+ZBa28Z9ABurF0+wmkVXmCDju4q/9tWxXypDFHn+MtuxQBHd3FzO5MsaJ/tMayzHF5rNNsfPUmQ/ypl1Il2WMbCfnqc4qNI9PQhrh40b0UHdQBJN5ZIS1fZ67j/jVmzkdPl86ORwOOeP0rLvFtJ1IgkmUDuy8VBa2is+5ZgZOgJJoA65L7bCBP8AMQOu7aKuaZdTz58l1hhH8SjOfxrjntQ6lZZSGzwFYnNdJ4ctZUUBmKxZyPMPX8KAOp06FDJ5kkjzMe3P8hXQQMmzdJZKXHQyHAH0FZlk7JCRBEBjq5bFVcndlLxmkPJUNu/nQBqX+pXaxslnDCCeMh8YrJWG5aLN/KVY8gKxNNvGZYNx84t3zhQKi0+3e4QuquF7sz0AJDcy6cT5RJyerjFXTfz3Ee5oVU/3yMmqFyqj5lThD96Q4H+NMmnnuIsSzbYuyqNin8epoAq38xnDILgc+wAFYsto6jP2pQP9nv8AjV/ZbSSmJVbA/wCeYwPzrL1QwqSkSsxHA39vwoAhe5kSTBnIA4CxcfmaqSnymZ3U7T1wCSfxNMRdh3PN5Z7ADJqwXG3a2Xcj5QTg0AWIzaC3LrGsfqxHJ+mayLy+t4gWaF0j7dy1UrxnWbO0PJ2G7IWoIY5pZ8zO0jDnaB0oAc14boYjh2J1zIcUVXu2aOQ7kQr2BbNFAHDyykEhwGXsR/Soo2B+aF/m7gjrSxXdrfxh7aVGx128EfUdulOSIN8kij2ZTQBf0ucM+2Zdr/zrYNrHcKflwB+BrPs4lZAsqhsdG7itWKx3gfZ59j/3WPWgCi+lS4JizKnXB+8KhWxeQnDKGHZhium00XdnJ++QSLnvWnqNvZ30QeKLypv4lIx+tAHBy29zG2NjDH4g1GcfdkO0+9df/Y90Y91tn6HkGsLVY2hOy5t2WT1FAGO7SrlcB19qsxRwzKFkQqfemxT5QplCw7MORUkELTHJcKPX0/CgB/8AY8ykG3fzEbsvOKmh0qaFi88MgX1UYq9p8U0DgiaKQeinBrprDXBFGY5wrdirqDmgDnrKeKLkIFPuoOa37W4t5Yv3MhUkfMhGRVG8NnPMZbZVQ5y0fQGtbRm0n7zpJbTAY3CgBI1uoWVoBHLGf4Tjj6Vv2jXUoDBpImUdMZAqg8duF3JqCSk/w7cZ/CtLR9T06MhHSUHv83H60AWJpGli3eXulHcDOayZ/s8ysszAv/d3Y/nWtcXEcTPNBcExHnYWwRWLqHl3cgnj2yj+IcZFAFjR7bT2JW4imTnAyAQfxFdbBpmnpa/uo3DkcHZuzXnV3qcNk4+yRyeYOvORSjxndDaoAidRxk7TQB2stlCiAvawv3ygCn8RTEkj3KEEcK5/iP8AjXHzeJrm8jxcfZ3bszcEfiKx7vWWBCeXn6NuFAHudle6ctmIbmONz/z0VlauV8TW1nM2+2KBuzxrtYflXnNnqUc/yyKVPqpxirMlxNbYkt7lph3Vzn9aANme0jkgIK3E3+9zXLagYrdysUUtuc8nmr6+Knt3LNF5Z74YYxVO98QWF0/myQTMx4yCMUAJaWWm3sREtyxlPqtVLzRFjk2wyYj65Cmo3l80l40hCf7R5/Ssq6up4yWRiE9ASaAItSiaMldz/VjVOHzUyA8WD1JIGKg1CVnIYb92KpREo2ZdpX0zQB0ligDbpHw3ba/FdFo0xWTAcA54JOa5HT0Mo3hNoHocV0WkzzxzKbaCOTH98igDsEhQxl7u8uNvogGP0qFIbAEvHJICP4nXP86sWmq5QJdWqxueOOn50+YgqdkO7d/d+bNAGatyqO4idpfoQB+lVrx2uZFLxtuHTDACrdx/ooLS2SDP95gP5VRmuoHQ7hDED2Tj9aAI3cqhTO313Nn+VEOqSW6FYljf0O2qqPCCxGCP71ZeoeYzYhupMdyOBQB0Vpd3l7NtC4xzy20CtqG8NqwQkvLjP3g1edwXRiIjMrNk9d1a0V40cWWuI0TrtXkmgD0/SfEc0cJRlCdgGFTWtyk87SNJmU9SBgCuI8PalayK2+Vm/wB58Yrdt9WgikPlSwpGT3wTQB21jNMqbR5c57ZXAFSXF/NZxbpyhz0WMZrm/tl1PDmzaaQcfcGBUE1/lTG8cjzD+FmoAv3WrxzAEQ4cn+I4P5VTW9Z5PnRVXoBJnH1xWczzo291jgHomCxonmup4hlvJiHUseTQBoTXS+UyoGkY9lG0Vz9xqDxliyqqjgLjJ/Op1uiqlYpUUDuetZV7LDuHlkvL3KjP60ALLqspXiCND2OKy7i+2uXbDSe1XlWaZMGMj1YisO8t1aZhI7MB0weKAFSWTzjI/Q+hq2l7GHAmxEh6nOWNZdzGYIgwVs9uKrRMr581Xdz2x/WgDpHks25tFBPdmorIUSpH8kQjz680UAeEqxRgykqwOQQeQa3NL8RT2zKt0vnx9M9HA4/P8fzrBooA9R0jWLG+ZUguRvIH7tvlYcZxg9eh6ZrX5XaFbcOowcGvGK2tL8SahYyDdIbiInLJKc+nQ9R0+ntQB7TpmqpbjZIrsf7rjrW5p15ptzLz50DD+6en4GvOdA8ZaPfQrFfytYzkhQso3xkknowHA6ZJxjNdVaSwsizW08F1EclWjkBzjrg9+aAOwmWKOIvbXMU49vkf/CuD8SamjMwfn2ZeRVXVNQlE2I5GUdww5FZNy0snLMHNAFLz1EhZRlfpVqK8DAbflPrVIxuc4TB9qnt4yEIYDHtQBcgnZXHzGr6M7t87Efjmuf8AK2y5jdvXBNW4r9Uwsm9SO4oA3ow0ZDJJuPoea27O6ia023Nsd56MDiudsJVlIZHJ9QehrroZ4DZrhwNo5Vx/I0AYNzem0kyI2UZ4Y1q2/iMzW6x3EcMgP8W3aR+NZ2sNBKBgkg9R1FZ0ZRGH7vC+tAHRRMyyLKs5VD2yGFWbx1JDRyqpx96IYP5VzkV09s2+3D++MEflUt1qoniUOiq46lY8GgCzcRRTOcXQMh9VINV10yd2GyeN/Yk1mrqEStgkg9ic1Mxv5FElus0kfqpzQBv2/hfUp0Bj4U91IqDUdB1fS/3gKMP9sZrCGp30PLXE0YU9D1qRdavbhsLM83s+QKAILmW5eYLMmD3wMVpWl3dQRgw224Dr0OaWO8uXXbLb2wPqyk5quy3jzAW1u59ox8tAF2XXvPTy5rFIyOrZ2/pWNqMMM4Li5AXrswBijUbQ7SZVkjl9HWs1Id0bCQMwHoaAE8sAf6PI26jzp1AS4YLH/exj+VUXd0fbFGqj8aS5efb8yHb9aALlzGsS7opC+eeTWZcyFmAA3Me1RSycdGb2zT4GDkHym/AUAWLMFnAkE+PRTXX6JahnHlJOPqRXKWzRxvlonBrotFntDOvmzSQ8/wB2gDsjaReUBPuBHqw/pTN5jXYl5GkY/hya0H1Cxgsdn2iViR1CAmsGKX5nkgEsynPWMNQBDdzWoBY3DO3+yN36msxREZMtMxY9NzipLmeMykywjd6Yx+lZVzJMCWgjRf8Atn0oA0rxD5Y8tcj/AHc1Qc4TMyuij0XGalstRnjj/eIWY+i4pZ7xJlJmT8N1AGUrw+YWRCfd6niulI+45GecJjNQPdxq2Ej/AHY7DmomuXkbLLNGg9KAOktbmJ4lVbVIlz1Ybj+Vb2nyadCVJt5pJT0LAKBXFW08L+WUa43D15rWh8uSQebcTIvZe9AHotprDhWje4McYHCIeapT6hb7y6oZMdNxrnLe9trbaJVkKH1bk/lWjbapaS5BtdyngEjFADhqwlnJCsFHXJGB+VXH1WOWBo494JHUjFULuENuNmhi3dcelU7eMxv80mD6vQA1pJFuOrOPQrVh558Y2lfyFW8wIm6SYlvYVDFEkuSkUzZ6EnrQBmy3UgJWRyF74NVIpw8xFvb7iP4pDxW3PppMZZ1WJe/NZbrBCSIwrepLUARX0kkmN7IdvTB6VVgeITAsjv64OBUkoikUkMM/3UGf1qkZY4QRJIc+g4xQBvy6narGsdvaebIOvoPxornRPbuuBKw/GigDxiiiigAooooAWp7S8uLNt1rPJESQTtbAOOmR3/Gq9FAHRW/im7Chbv8Aff7fQ/4fyrWtNetLgDzHCNjo/wApH49K4eloA9J8+KQgfMD/AHgaesoVwS4Y+pGDXnVtdz2zAwSunOcA8Z+nSta28RSgBbqJJBx8y8H3Pv8ApQB27zwyJ++gjJH8Sn+lV3ki8wfKAPzFYVvrtrIRg7DnGJBj9elXopY5lDqVdT3VqANmGaKIZEewnowPFadneySLsM2F/OueRwi/eJX+64p8V1Fv+Vwp9BQB2VvZOq+YghkB55bFZmpedu2lFjAPQHOahstf8mPaYQ3b5lqC91GK7fcojST0GRQA6BJFbKsceiiknWQ/M7yIPXFR2d/c2sodGTGejc10kXiGGaHZd2iscdVbFAHOnZxtdZD9MGtXT7rUrePFtHP5Z7bciqmoPbyZa2jMeTUEF9eW+BBebR6dKAE1Se98/dLGdh/vLis8Sgtlwyn24rdEj3+1Luff/wACFbdrpOlfZ9kkMpk/vFhxQBydpqj2z/63C/7QzWtB4sntmDRElT3WteTwfBcxlrW5fH91UDf1rPfwNe7SfPzGP76bcUANufFkVyQ08LBv9rFYNxqMcjOzYCk8bDVy98Mzq5UvuA7oazJ9JaLghvxI/pQBPFq8MUYCxBwP7w5qnfaq9zkJCFX03YqJ7dY1OWUHsDVX5mOFC/nQAnGcyKFHtQh3P+4Uv64OKZOAVwGXd70luBFwWBz6UAXIY5TKpZAOe5NdlpWl/aoU/dKW9VbFcfHJKMeXKMHtW7pOpXMOAJGXHYmgDrBpD2SBzFK4HYSCntrTJEYorOYN05YAVmnWVnXbcRzkeqyZqC71GJFHkxSY7ll5oApamtx5onli29wM5qjJfhl+csuewGKfPqDysCFk2+pJxTGkilG7fj6LQBUaeQ8xDavucmqzru+aRpM+74FWDdwBtoQgD1PWqtzchiAqqF9jmgB0fyrwQoPTAzUgMqjj5wfWqpm5ChOfYU9pWYjKsv1OKANG0lYYHklR6gVo2k1qsmWEjP6ngVl2srRqTLIiL6YJNStdxO4GM/hj+VAHRRzoCXjjjUf3nBNXrFpZyX+zNIfbIrM029tEA3k7v9lNx/WuhXxRaWg2LZyzNj/ls+F/IUAX7KzvHQLFGsKtyRGNzfnVr+yYLZfOuyoI/inb+lc7P4yv7seUk0dpCONsMeKzLt47g75Lm4lf1fGKAOpk1jTEYpBDHIw/ibkVFLrLEYXy1T1XtXJLJwcypHEvLMzAYHc1S1PxToenw4W+FxLjOIBvzz69PzIoA6C/uWum+aUpH9ck1n3MlrDGREJJJPpmuKvPiEke4abp4d8grLdNn6/Iv/xVcpqniHVNULfa7uQo2QY0+RcehA6/jmgDv7zxBY2Lss8yq4PKKdxB9CB0/Guc1Txikm4WNpyRxJN2/wCAj/GuOpKALd5qN3eZ+0Tu4P8AD0X8hxRVSigAooooAKKKKACiiigAooooAKKKKAFp0cjxtujdkbplTg0yigDTtdbvbfH73zABjDjP/wBerqeIFZgZoCrY5ZDnJ+h/xrn6KAOzt9dt2KAT7WPZwRj6npW1ZvFdKJEaNx0ypBFeZ0AlSCDgjoRQB6qc7yFIHsVyDTjllKFAD/s15vb6xqFuxMd3Lk/3zv8A55rRtPFmoQEFxDKc8sy4OPwIH6UAdxFBGp+bIY/3qnRWV/kWNiO+7FcqfHJnlQXNq4iHBxIGI+nyj+dWR4p0ybj9/DjkGROvt8pNAHXw6va26FLvTYpSe5Iz+FVHvtPeRnje4gz0TqBWdpvifSHbEpjYgZ+Ztv6sK0V1jSbzckCQM2MnawJH5UAQx6xeQv8A6NezKOxxUr+ItXdCHuLuROhyacbFDDvhZwD/ALQNZjQzl8PcMq/pQBINSumJG4oP9uq0t/NnO8H8KdLb5GDJu/Ems+4gUHCyKD7GgBbi6eU4Krn1NV3kdQBvQGlYbVJbHHfOaqGV9xwQR9KAJSTuySGp8UhXO0LUKO7t9zB9+KGEmcsygexoAsmSQnhRu9q0bSeRFHm7B7kZNZCTBQOWH61MsqNz5v4YoA7LT7uElQZYwfeMVqX15bPahGlVjjGAuK4i2nRVyHbd2ytaFrdu45COfpigCSeCHk+aE9iTVOeJNufMcJ64qzPAZOWMSMfVuaQxMIiZnVlA4waAM5B5pIiDuB3bimOhRvnjSP360txcxIQGulhB6bmAz+dV5tS02HDT3fmsegR938ulACMzFuG59cVNEihgXO4j0rKm16yVv3au4PZR0+ucVTk19N58u2JXsS2D/WgDpLidCOY8D1Jqe2nRl+TA92NcXNrtw4YJHCmeh25I/Pj9Kqy6pey43XDjH9z5P5UAejfbEiUszoqDq7cAfiarTeIdMgZhNfGR1GdsSls+wPT9a83Zi7FnJZjySTkmkoA7yfxzbxAizsXkyvDSsFw30Gcj8RWBfeKtTuzxJHApGCsSdffJyc/jWDRQBNPczXBBnmklI4Bdi386ipKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAnsolnuoonJCscHFdhoHgW88Q3otdFtL28m4yI8YX3ZiMKPckVyelf8hGD/er1v4SgH4k+H8gHF0D+hrnxdWVGhOpDdJvXy+4cVd2OAn8PQwTSQyPKJI2KMAynBBweQPWmf2Hbf35vzH+Fb2qf8ha/wD+vmX/ANDNVa1hJyipMRof8Ku1IT2du/2aO6vI0lt7eTU7VZpVcfKVjL7jnsMZrCvfDH2C6ktr6K8trmM4eKZdjr35BGRXo/xZ3/8ACSaH5W7zP7Dsdu3rnDYxUfxfZD4stVJT7WNLtDeDjzPtG07vN778bc7uelebhMZWqun7S1ppvRNWt82XKKV7HJ6B4B1LUYku9KEqK832eKR7uKAyykZ8uPeVLtjsuTWZcabPFNJFcXeoJNGxV1kkIZSDgggjg5r0Cwd4R4Ul8Y2V3d6XlhpghuYY1SPzB5hKKhd/mxwXT2PNZvxKh1KDx7rceuXsV7qInBklhj8tMFFKBV7AIVGOec8nrWtDE1J13Tla1rq3r3u7+ei+YnFWuZuneBtf1CxhurRr145xI0CG8RJZxGMuYoyQ8gHfaDVLSfCWoaxHdTWk9wYLYKZp7i7jgij3HCgvIVUEngDOTXsOtzabceMvAWmT6Sv2u40eyjOqRXcsVxDvysZi2napRgWyQ27gcYzXP61aS23w01O0tLi4u7q38USR6hOrMZZURWCPMQSdplGRuJG73rgpZrWqWTSTla11sm2r6PXb+6/ItwSPNNW8OXWk6jPY6k9/b3cDbJI3k5B/qO4I4I5FVP7NH/P1d/8Afz/61e661Z2Vx4pvb+/t4LrUdG8JQ6jcW843b71FPFyv3mONhIYgkBc8cGh8L1i8SeJ/DR1bwxayIstxBPqCWyxWtx+4kdUeFY/LMgPIIIOByDgEbQzVypOo4bLXW2rV9L/8P6icNbHjX9mj/n7u/wDv5/8AWqK5sBFbSyLdXRKoWGZPQV6/HrcTfDe18Vnw/wCHf7Xl1kac3+gDyPs+w3G0RZ2buPL343bO+fmrlPi7o9n4f8Y+ItK0xXSztseWrtuKh4VkxnrgFyBnJwBkk8104XH+3m6bjZq/W+2/5ilG2p5x/a83/POH8j/jTW1W4IGwRoc5yFz/ADzWfRXoEGiutX68CcD/ALZr/hQ2s37KR9pYAjHCgH+VZ1FAFkX12DkXU+fXzDUc88s7hp5ZJWAwC7Fjj8aiooAWkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAJ7KVYLqOV8lVOTjrXUaT4tbSNRgv8ATnmgu4G3xyeWjbT64bIP4iuQoqZRU04yV0wOlfXoZJHeXz3kdi7MVUFiTkng4703+3Lb+5N+Q/xrnKKpJJWQHop+KGsGe2nF2vn20aRQTHTLNpYlQYULI0ZcY7HOawZ/ES3M8k95Le3VzKd0k1w/mO5wBksWJPAFcxRWNPD0aTvTgl6JIbbe53uk/ETUdItFttNu5oYVlE6K1tDN5cmMb08xW2N7rg1l2/iRLcXRTzHlulZZZZ4Y5nYscs2XBwxP8Qw3oRXLUU1QpJuSirvfTf1C7O+tPiPqtlp0VjZahdQQRLIsTLBC0kIkGHEcjAvHn/YI65qpovjSbRLae30yR4recKJYZLeKeN9rblJSQMpIIyDjI9a4yil9Wo2a5FrvotfXuF2dtbeOr638QNri3182rvKZmun2lmYjGCOm3HG3G3HGMcVZi+JOrRatYalHqE6XenxvHZ7LaBIrcOCHKRKojBbccnbk8egrgKKHh6Ld3BbW2W3b0C7OuHi2QaBBoomuP7Miuftgg8uPmby/L3Fvvfd4xnHtTfEfiybxBfX+oapNPc394P3krRogJCBF4XAAAUDp2rk6KqNKnF80YpP0C7CiiitBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal view of a fetal femur of a second trimester fetus. The femur is hyperechoic with shadowing as compared to the surrounding soft tissue. The length of the femur is indicated by the calipers, which are placed on the proximal and distal diaphyseal borders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33027=[""].join("\n");
var outline_f32_16_33027=null;
var title_f32_16_33028="Antithrombin III: Patient drug information";
var content_f32_16_33028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Antithrombin III: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/36/8774?source=see_link\">",
"     see \"Antithrombin III: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atryn&reg;;",
"     </li>",
"     <li>",
"      Thrombate III&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Antithrombin III NF;",
"     </li>",
"     <li>",
"      Thrombate III&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat antithrombin deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antithrombin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to milk, talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is made from human plasma (part of the blood) and may have viruses that may cause disease. This drug is screened, tested, and treated to lower the chance that it carries an infection. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11742 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33028=[""].join("\n");
var outline_f32_16_33028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135930\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135931\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023824\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023823\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023828\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023829\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023831\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023826\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023827\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023832\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023833\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/36/8774?source=related_link\">",
"      Antithrombin III: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33029="Nesiritide: Drug information";
var content_f32_16_33029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nesiritide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/1/22547?source=see_link\">",
"    see \"Nesiritide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Natrecor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5736663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Natrecor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Natriuretic Peptide, B-type, Human",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute decompensated heart failure:",
"     </b>",
"     I.V.: Initial: 2 mcg/kg (bolus optional); followed by continuous infusion at 0.01 mcg/kg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     Should not be initiated at a dosage higher than initial recommended dose. There is limited experience with increasing the dose &gt;0.01 mcg/kg/minute; in one trial, a limited number of patients received higher doses that were increased no faster than every 3 hours by 0.005 mcg/kg/minute (preceded by a bolus of 1 mcg/kg), up to a maximum of 0.03 mcg/kg/minute. Increases beyond the initial infusion rate should be limited to selected patients and accompanied by close hemodynamic and renal function monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients experiencing hypotension during the infusion:",
"     </b>",
"     Infusion dose should be reduced or discontinued. Other measures to support blood pressure should be initiated (eg, I.V. fluids, Trendelenburg position). Hypotension may be prolonged (up to hours); once patient is stabilized, may attempt to restart at a lower dose (reduce previous infusion dose by 30% and omit bolus).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maximum dosing weight:",
"     </b>",
"     According to the manufacturer, the PRECEDENT Trial capped dosing weight at 160 kg and the VMAC Trial capped dosing weight at 175 kg. There are no specific guidelines on maximum dosing weight and clinical judgment should be used.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F200833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required but use cautiously in patients with renal impairment or those patients who rely on the renin-angiotensin-aldosterone system for renal perfusion. Monitor renal function closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4088850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natrecor&reg;: 1.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer through a heparin-coated catheter (concurrent administration of heparin via a separate catheter is acceptable, per manufacturer).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Prime I.V. tubing with 5 mL of infusion prior to connection with vascular access port and prior to administering bolus or starting the infusion. Withdraw bolus from the prepared infusion bag and administer over 60 seconds. Begin infusion immediately following administration of the bolus.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1.5 mg in 250 mL (concentration: 6",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F200851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, NS.",
"     <b>",
"      Incompatible",
"     </b>",
"     with injectable drugs containing sodium metabisulfite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, argatroban, digoxin, diltiazem, fentanyl, inamrinone, milrinone, nicardipine, nitroglycerin, nitroprusside, propranolol, quinidine gluconate, torsemide, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Bumetanide, enalaprilat, ethacrynate sodium, furosemide, heparin, hydralazine, insulin (regular), micafungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dobutamine, dopamine, epinephrine, lidocaine, meperidine, metoprolol, morphine, norepinephrine, phenylephrine, procainamide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acutely decompensated heart failure (HF) with dyspnea at rest or with minimal activity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Natrecor [U.S., Canada, Argentina, Venezuela] may be confused with Nitrocor brand name for nitroglycerin [Italy, Russia, Venezuela]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies cited below were recorded in VMAC trial, unless otherwise noted, at dosages similar to approved labeling. Higher frequencies have been observed in trials using higher dosages of nesiritide. The percentages marked with an asterisk (*) indicate frequency less than or equal to placebo or other standard therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (total: 11% [27% in ASCEND-HF trial]; symptomatic: 4% [7% in ASCEND-HF trial] at recommended dose, up to 17% at higher doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Increased serum creatinine (28% with &gt;0.5 mg/dL increase over baseline)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ventricular tachycardia (3%)*, ventricular extrasystoles (3%)*, angina (2%)*, bradycardia (1%), tachycardia, atrial fibrillation, AV node conduction abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (8%)*, dizziness (3%), insomnia (2%)*, anxiety (3%), confusion, fever, paresthesia, somnolence, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4%)*, abdominal pain (1%)*, vomiting (1%)*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction, catheter pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (4%), leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea, cough increased, hemoptysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Extravasation, hypersensitivity reactions (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to natriuretic peptide or any component of the formulation; cardiogenic shock (when used as primary therapy); hypotension (persistent systolic blood pressure &lt;100 mm Hg) prior to therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic/hypersensitivity reactions: Serious anaphylactic or hypersensitivity reactions may occur following administration; obtain careful history and use caution in patients with previous hypersensitivity to other recombinant peptides; nesiritide prepared through recombinant technology using",
"     <i>",
"      E. coli",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; administer in clinical situations when blood pressure may be closely monitored. Effects may be additive with other agents capable of causing hypotension. Hypotensive effects may last for several hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: May be associated with development of azotemia; use caution in patients with renal impairment or in patients where renal perfusion is dependent on renin-angiotensin-aldosterone system (eg, severe heart failure); avoid initiation at doses higher than recommended; increases in serum creatinine may occur at an elevated rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Should not be used in patients with low cardiac filling pressures, or in patients with conditions which depend on venous return including significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, and pericardial tamponade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged infusions: Use caution with prolonged infusions; limited experience with infusions &gt;96 hours.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4088849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, and licorice (may increase blood pressure). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse (may enhance decreased blood pressure).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7913235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in an animal reproduction study. Nesiritide is a recombinant B-type natriuretic peptide (rhBNP). BNP and NT-proBNP (which has been used as a marker of BNP), are endogenous peptides and NT-proBNP is measurable in the umbilical cord serum of normal pregnancies. Information related to the administration of nesiritide during pregnancy has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Natrecor Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $1051.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, hemodynamic responses (PCWP, RAP, CI), BUN, creatinine; urine output",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Natrecor (AR, BB, BM, BS, BZ, CO, GY, ID, JM, NL, SR, TT, VE);",
"     </li>",
"     <li>",
"      Noratak (CH, IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to guanylate cyclase receptor on vascular smooth muscle and endothelial cells, increasing intracellular cyclic GMP, resulting in smooth muscle cell relaxation. Has been shown to produce dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic arterial pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: PCWP reduction: 15 minutes (60% of 3-hour effect achieved within this time period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;60 minutes (up to several hours) for systolic blood pressure; hemodynamic effects persist longer than serum half-life would predict",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.19 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Proteolytic cleavage by vascular endopeptidases and proteolysis following binding to the membrane bound  natriuretic peptide  (NPR-C) and cellular internalization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Initial (distribution) ~2 minutes; Terminal: ~18 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily eliminated by metabolism; also excreted in the urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burger AJ, Horton DP, LeJemtel T, et al, \"Effect of Nesiritide (B-Type Natriuretic Peptide) and Dobutamine on Ventricular Arrhythmias in the Treatment of Patients With Acutely Decompensated Congestive Heart Failure: The PRECEDENT Study,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2002, 144(6):1102-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/12486437/pubmed\" id=\"12486437\" target=\"_blank\">",
"        12486437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colucci WS, Elkayam U, Horton DP, et al, &ldquo;Intravenous Nesiritide, A Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure. Nesiritide Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(4):246-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/10911006/pubmed\" id=\"10911006\" target=\"_blank\">",
"        10911006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coons JC, McGraw M, and Murali S, \"Pharmacotherapy for Acute Heart Failure Syndromes,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(1):21-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/21164062/pubmed\" id=\"21164062\" target=\"_blank\">",
"        21164062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels LB and Maisel AS, &ldquo;Natriuretic Peptides,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(25):2357-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/18154959/pubmed\" id=\"18154959\" target=\"_blank\">",
"        18154959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kocylowski RD, Dubiel M, Gudmundsson S, et al, &ldquo;Biochemical Tissue-Specific Injury Markers of  the Heart and Brain in Postpartum Cord Blood,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2009, 200(3):273.e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/19167692/pubmed\" id=\"19167692\" target=\"_blank\">",
"        19167692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lev-Sagie A, Bar-Oz B, Salpeter L, &ldquo;Plasma Concentrations of N-Terminal Pro-B-Type Natriuretic Peptide in Pregnant Women Near Labor and During Early Puerperium,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      2005, 51(10):1909-10",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/16189389/pubmed\" id=\"16189389\" target=\"_blank\">",
"        16189389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor CM, Starling RC, Hernandez AF, et al, &ldquo;Effect of Nesiritide in Patients With Acute Decompensated Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(1):32-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/21732835/pubmed\" id=\"21732835\" target=\"_blank\">",
"        21732835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Publication Committee of the VMAC Investigators (Vasodilation in the Management of Acute CHF), \"Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure. A Randomized Controlled Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(12):1531-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/11911755/pubmed\" id=\"11911755\" target=\"_blank\">",
"        11911755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sackner-Bernstein JD, Kowalski M, Fox M, et al, &ldquo;Short-Term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 293(15):1900-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/15840865/pubmed\" id=\"15840865\" target=\"_blank\">",
"        15840865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sackner-Bernstein JD, Skopicki HA, and Aaronson KD, &ldquo;Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(12):1487-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33029/abstract-text/15781736/pubmed\" id=\"15781736\" target=\"_blank\">",
"        15781736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10128 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33029=[""].join("\n");
var outline_f32_16_33029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200829\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5736663\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200845\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200831\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200832\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200833\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4088850\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200808\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200794\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200810\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472941\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200851\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200809\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200852\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200843\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200813\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200798\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299758\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200802\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4088849\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200804\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913235\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200836\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323489\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200806\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539899\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200797\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200812\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10128|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/1/22547?source=related_link\">",
"      Nesiritide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33030="Acetaminophen and diphenhydramine: Drug information";
var content_f32_16_33030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and diphenhydramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/36/39492?source=see_link\">",
"    see \"Acetaminophen and diphenhydramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aceta-Gesic&reg;;",
"     </li>",
"     <li>",
"      Excedrin PM&reg; [OTC];",
"     </li>",
"     <li>",
"      Goody's PM&reg; [OTC];",
"     </li>",
"     <li>",
"      Legatrin PM&reg; [OTC];",
"     </li>",
"     <li>",
"      Mapap PM [OTC];",
"     </li>",
"     <li>",
"      Percogesic&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      TopCare&reg; Pain Relief PM [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; PM [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Severe Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insomnia and pain: Oral: Adults: 50 mg of diphenhydramine HCl (76 mg diphenhydramine citrate) at bedtime or as directed by physician; do not exceed recommended dosage",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy is usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin PM&reg;: Acetaminophen 500 mg and diphenhydramine citrate 38 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Legatrin PM&reg;: Acetaminophen 500 mg and diphenhydramine hydrochloride 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap PM: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percogesic&reg; Extra Strength: Acetaminophen 500 mg and diphenhydramine hydrochloride 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TopCare&reg; Pain Relief PM: Acetaminophen 500 mg and diphenhydramine citrate 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; PM: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Severe Allergy: Acetaminophen 500 mg and diphenhydramine hydrochloride 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Captab, oral: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, rapid release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; PM: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Geltab, oral: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin&reg; PM: Acetaminophen 500 mg and diphenhydramine citrate 38 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; PM: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; PM: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg per 15 mL (240 mL) [contains sodium benzoate; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Goody's PM&reg;: Acetaminophen 500 mg and diphenhydramine citrate 38 mg [contains potassium 41.9 mg and sodium 3.15 mg per powder]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Acetaminophen 500 mg and diphenhydramine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aceta-Gesic&reg;: Acetaminophen 325 mg and diphenhydramine hydrochloride 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin&reg; PM: Acetaminophen 500 mg and diphenhydramine citrate 38 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes caplet, gelcap, powder, and liquid",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aid in the relief of insomnia accompanied by minor pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Excedrin&reg; may be confused with Dexedrine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Percogesic&reg; may be confused with paregoric, Percodan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylenol&reg; may be confused with atenolol, timolol, Tylox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylenol&reg; PM may be confused with Tylenol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11507012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use with other products containing acetaminophen or diphenhydramine (including topical)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11507013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: May cause severe hepatic toxicity on acute overdose; in addition, chronic daily dosing in adults has resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient's age, the product should not be administered without the guidance of a physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dosage limit: Limit acetaminophen dose to &lt;4 g/day (adults) or &lt;2.6 g/day (children &lt;12 years of age).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had emphysema, chronic bronchitis, glaucoma, enlarged prostate, or are currently taking sedative drugs or alcohol. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of liver damage.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9834367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Coricidin Nighttime Cold-Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-325 mg/15 mL (180 mL): $4.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tylenol Cold Relief Nighttime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-500 mg/15 mL (240 mL): $5.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tylenol PM Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-50 mg/30 mL (240 mL): $5.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tylenol Sore Throat Nighttime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-500 mg/15 mL (240 mL): $5.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Goodys PM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     38-500 mg (6): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aceta-Gesic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-325 mg (100): $2.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Acetadryl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-500 mg (50): $210.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diphenhydramine-APAP (sleep) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-500 mg (50): $5.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Excedrin PM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-38 mg (24): $3.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medi-Tabs PM Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-500 mg (50): $4.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Percogesic Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-500 mg (40): $5.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Cold Relief Nighttime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-500 mg (24): $3.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Cold Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-500 mg (48): $7.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol PM Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-25 mg (100): $10.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Severe Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-500 mg (24): $5.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Unisom PM Pain Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325 mg (30): $5.87",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acamol Night (IL);",
"     </li>",
"     <li>",
"      Dexamol PM (IL);",
"     </li>",
"     <li>",
"      Insomed (PH);",
"     </li>",
"     <li>",
"      Panadol Night (NZ);",
"     </li>",
"     <li>",
"      Tylenol PM (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barker JD Jr, de Carle DJ, and Anuras S, &ldquo;Chronic Excessive Acetaminophen Use in Liver Damage,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1977, 87(3):299-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/900673/pubmed\" id=\"900673\" target=\"_blank\">",
"        900673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Campbell RA, Cooper SA, et al, &ldquo;Suppression of Postoperative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen, and Acetaminophen Plus Codeine,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1983, 23(1):37-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/6341415/pubmed\" id=\"6341415\" target=\"_blank\">",
"        6341415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Licht H, Seeff LB, and Zimmerman HJ, &ldquo;Apparent Potentiation of Acetaminophen Hepatotoxicity by Alcohol,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1980, 92(4):511.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/16/33030/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9165 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33030=[""].join("\n");
var outline_f32_16_33030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129540\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129551\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129541\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129546\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129542\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129543\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129533\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129524\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129534\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129556\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129549\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507012\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507013\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129547\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129530\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129539\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9834367\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322958\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390208\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129536\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9165|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/36/39492?source=related_link\">",
"      Acetaminophen and diphenhydramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33031="Extraintestinal Entamoeba histolytica amebiasis";
var content_f32_16_33031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extraintestinal Entamoeba histolytica amebiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33031/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/16/33031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amebiasis is caused by the protozoan Entamoeba histolytica. Most infections are asymptomatic; clinical manifestations include amebic dysentery and extraintestinal disease. Worldwide, approximately 40 to 50 million people are infected annually [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/1\">",
"     1",
"    </a>",
"    ]. Extraintestinal manifestations include amebic liver abscess and other more rare manifestations such as pulmonary, cardiac, and brain involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extraintestinal manifestations of amebiasis will be reviewed here. Issues related to intestinal infection with E. histolytica are discussed separately, including epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AMEBIC LIVER ABSCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amebic liver abscess is the most common extraintestinal manifestation of amebiasis. Amebae establish hepatic infection by ascending the portal venous system [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amebic liver abscess (and other extraintestinal disease) is 7 to 10 times more common among adult men than other demographic groups, despite equal gender distribution of colonic amebic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. It is observed most frequently in the fourth and fifth decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/8\">",
"     8",
"    </a>",
"    ]. The reasons for these observations are not fully understood; suggested mechanisms include hormonal effects and a potential role of alcoholic hepatocellular damage in creating a nidus for portal seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, amebiasis is generally seen in migrants from and travelers to endemic areas. Amebiasis is relatively uncommon among short-term travelers, but amebic liver abscesses can occur after travel exposures as short as four days [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/9\">",
"     9",
"    </a>",
"    ]. In one study, 35 percent of travelers with amebic liver abscess had spent less than six weeks in an endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors predisposing to progression from intestinal amebiasis to amebic liver abscess are not fully understood. Conditions that affect cell-mediated immunity increase the chances that E. histolytica infection results in invasive disease with liver involvement. It has been suggested that immunosuppression secondary to HIV may increase the likelihood of presenting with an amebic liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For travelers returning from an endemic area, clinical presentation usually occurs within 8 to 20 weeks (median 12 weeks), although a longer lag (sometimes years) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Patients with amebic liver abscess usually present with one to two weeks of right upper quadrant pain and fever (38.5 to 39.5&ordm;C). Pain may be referable to the epigastrium, the right chest, or the right shoulder. The pain is usually dull but may be pleuritic or aching. Other symptoms may include cough, sweating, malaise, weight loss, anorexia, and hiccough. Concurrent diarrhea is present in less than one-third of patients, although some patients report history of dysentery within the previous few months. Jaundice occurs in less than 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/4\">",
"     4",
"    </a>",
"    ]. Physical examination reveals hepatomegaly and point tenderness over the liver in approximately 50 percent of cases.",
"   </p>",
"   <p>",
"    Rupture of liver abscess can occur into any adjoining space or organ; extension into the chest occurs almost four times as often as extension into the peritoneal cavity. In up to 7 percent of cases the abscess ruptures into the peritoneum, causing peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/13\">",
"     13",
"    </a>",
"    ]. Hepatic vein and inferior vena cava thrombosis secondary to amebic liver abscess have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally patients have a more chronic presentation with months of fever, weight loss, and abdominal pain with or without hepatomegaly.",
"   </p>",
"   <p>",
"    In a study comparing the presentations of HIV-positive and HIV-negative patients with amebic liver abscess, no differences in clinical manifestations or radiographic findings between the two groups were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with amebic liver abscess often have a leukocytosis",
"    <span class=\"nowrap\">",
"     (&gt;10,000/mm3)",
"    </span>",
"    without eosinophilia. Liver function testing demonstrates an elevated alkaline phosphatase (80 percent of cases), and hepatic transaminases may also be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/16\">",
"     16",
"    </a>",
"    ]. Other common nonspecific findings include an abnormal chest radiograph and proteinuria. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Uncommonly, patients with amebic hepatic abscesses may also have localized colonic infection resulting in a mass of granulation tissue forming an ameboma, which may mimic colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Patients with amebomas usually are found to have a tender palpable mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link&amp;anchor=H5#H5\">",
"     \"Intestinal Entamoeba histolytica amebiasis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with secondary cardiac or pulmonary involvement may present with symptoms primarily due to these complications. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Other extraintestinal sites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amebic liver abscess should be suspected in the setting of fever and right upper quadrant pain together with relevant epidemiology (resident in, migration from, or travel to an endemic area). In such circumstances the diagnosis is generally established by radiographic imaging of the liver. In the setting of suggestive findings on imaging studies, confirmatory serologic or antigenic testing should be pursued, perhaps supplemented with stool microscopy or antigenic testing of stool, with or without evaluation for the parasite in liver abscess fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging of the liver can be pursued with ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). Ultrasonography usually demonstrates a cystic intrahepatic cavity. Amebic liver abscesses are most commonly found in the right lobe; 70 to 80 percent are solitary subcapsular lesions, although multiple lesions can be present [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Localization in the left lobe predisposes to extension into the pericardial sac. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Cardiac infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On ultrasound, the abscess appears as a round, well-defined hypoechoic mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71420 \" href=\"UTD.htm?10/10/10406\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/21\">",
"     21",
"    </a>",
"    ]. On CT scan, it appears as a low-density mass with a peripheral enhancing rim. On MRI, the abscess appears as low signal intensity on T1-weighted images and high signal intensity on T2 weighted images. After healing, the periphery of the abscess may calcify as a thin round ring [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On gallium citrate and technetium-labeled sulfur colloid radionuclide liver scans, amebic abscesses are \"cold\" (with a bright rim in some cases), whereas pyogenic abscesses are \"hot\". Radiographic findings must be interpreted in the appropriate clinical context with consideration of the differential diagnoses, including pyogenic abscess and malignancy.",
"   </p>",
"   <p>",
"    Serial imaging is generally not helpful since lesions may appear to increase in size or number on ultrasound following initiation of treatment, even with appropriate therapy and clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/22\">",
"     22",
"    </a>",
"    ]. Treated lesions may become anechoic, calcified or may persist as cystic-appearing lesions. Complete radiologic resolution may take two years or more. Therefore, persistent abnormalities on ultrasound imaging should not prompt retreatment or additional testing in a patient who is clinically well.",
"   </p>",
"   <p>",
"    A chest radiograph abnormality will be observed in approximately 50 percent of patients with an amebic liver abscess, most commonly elevation of the right hemidiaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/23\">",
"     23",
"    </a>",
"    ]. This finding does not necessarily signal pulmonary involvement in the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Serology and antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 99 percent of patients with amebic liver abscess develop detectable antibodies, but serologic testing may be negative in the first seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/12,13,19,24\">",
"     12,13,19,24",
"    </a>",
"    ]. Serum antibodies are detectable in 92 to 97 percent of patients at the time of presentation.",
"   </p>",
"   <p>",
"    In endemic areas up to 35 percent of uninfected individuals have anti-amebic antibodies due to previous infection with E. histolytica [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, negative serology is helpful for exclusion of disease, but positive serology cannot distinguish between acute and previous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New serologic tests based on recombinant E. histolytica antigens have been developed. In one study of two different antigens among 20 patients with known amebic liver abscesses, patients lost seroreactivity with the recombinant antigens more rapidly than with conventional serologic tests; such assays may be especially useful in endemic areas. [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other assays include a rapid enzyme immunoassay and antigen detection assays [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Additional issues related to serology and antigen detection for diagnosis of amebiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link&amp;anchor=H6#H6\">",
"     \"Intestinal Entamoeba histolytica amebiasis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle aspiration under ultrasound or CT guidance is not routinely required but may be warranted if the cyst appears to be at imminent risk of rupture (particularly for lesions in the left lobe), if there is clinical deterioration or lack of response to empiric therapy, or if exclusion of alternative diagnoses is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/29\">",
"     29",
"    </a>",
"    ]. In some cases aspiration may be therapeutic as well as diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amebic liver abscesses contain acellular, proteinaceous debris, and a brown fluid likened to \"anchovy paste,\" consisting predominantly of necrotic hepatocytes. Trophozoites are seen on microscopy of the aspirate in fewer than 20 percent of cases and are often present only in the peripheral parts of the abscess, invading and destroying adjacent tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/32\">",
"     32",
"    </a>",
"    ]. This is in contrast to aspirates from pyogenic liver abscesses in which bacterial organisms and polymorphonuclear cells are usually readily apparent by Gram stain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antigen testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polymerase chain reaction (PCR) on aspirated material may also be helpful in establishing the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/8,12,33,34\">",
"     8,12,33,34",
"    </a>",
"    ]. In rare cases amebic hepatic abscesses can become secondarily infected with enteric bacteria, so aspirated fluid should also be sent for bacterial culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For circumstances in which amebic liver abscess is suspected based on epidemiology, clinical manifestations, and radiographic findings, it is reasonable to initiate empiric treatment pending further diagnostic evaluation (including confirmatory antigenic or serologic testing and evaluation for the parasite in stool and liver abscess pus).",
"   </p>",
"   <p>",
"    In general, amebic liver is managed with a tissue agent and a luminal agent (to eliminate intraluminal cysts).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Tissue agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an amebic liver abscess should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 to 750 mg orally three times daily for 7 to 10 days). The cure rate for this therapy is &gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/1\">",
"     1",
"    </a>",
"    ]. Shorter duration of metronidazole is not generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/35\">",
"     35",
"    </a>",
"    ]. Metronidazole is well absorbed from the gastrointestinal tract; intravenous therapy offers no significant advantage as long as the patient can take oral medications and has no major defect in small bowel absorption. Metronidazole resistance in E. histolytica trophozoites has not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link&amp;anchor=H7060848#H7060848\">",
"     \"Intestinal Entamoeba histolytica amebiasis\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    , ornidazole, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Tinidazole (2 g once daily for five days) has been approved for the treatment of extraintestinal amebiasis (including amebic liver abscess) by the US Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/35,37-39\">",
"     35,37-39",
"    </a>",
"    ]. Nitazoxanide (500 mg twice daily for 10 days) has been shown to be highly effective in a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of slow response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or relapse following therapy, therapeutic aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a prolonged course of metronidazole may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Luminal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following therapy for invasive amebiasis, treatment with a luminal agent to eliminate intraluminal cysts is warranted, even if stool microscopy is negative. Intraluminal infection can be treated with one of the following regimens:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (25 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally in three divided doses for seven days), diiodohydroxyquin (650 mg orally three times daily for 20 days for adults and 30 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for 20 days for children), or diloxanide furoate (500 mg orally three times daily for 10 days for adults and 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for 10 days for children). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link&amp;anchor=H7060848#H7060848\">",
"     \"Intestinal Entamoeba histolytica amebiasis\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncomplicated amebic liver abscess has a mortality rate of &lt;1 percent if diagnosed and treated early. In one study of 135 patients with amebic liver abscess in India with overall mortality rate of 17 percent, independent risk factors for increased mortality included bilirubin level &gt;3.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    serum albumin &lt;2.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    large volume of the abscess cavity, multiple abscesses, and encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER EXTRAINTESTINAL SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, amebic disease involves other sites outside the liver. Lung disease, cardiac involvement, brain abscess, perinephric or splenic abscess, vaginal or uterine involvement, rectovaginal fistulae, and cutaneous disease can all occur [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pleuropulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleuropulmonary involvement following E. histolytica infection is rare. Risk factors for development of pulmonary amebiasis include malnutrition, chronic alcoholism, and atrial septal defect with left to right shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural manifestations may include development of a sympathetic serous effusion. Liver abscess rupture into the pleural space results in an amebic empyema; rupture into the lung can lead to consolidation, abscess formation, or a hepatobronchial fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Other mechanisms of pleural involvement include lymphatic spread from the liver through the diaphragm, or hematogenous embolic spread from the liver or colon [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/43,44,46\">",
"     43,44,46",
"    </a>",
"    ]. Hematogenous spread is an unusual disorder and should be suspected when there is pulmonary amebiasis in the absence of hepatic disease, or noncontiguous pulmonary and hepatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10069497\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations include pain, cough, hemoptysis, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/47\">",
"     47",
"    </a>",
"    ]. The pain may be pleuritic or localized to the right upper quadrant. Cough can be nonproductive, but more often is associated with expectoration of material ranging from small amounts of sputum to large amounts of amebic pus. If a hepatobronchial fistula develops, the patient may expectorate necrotic material that can include liver abscess contents; such material may have a reddish brown or &ldquo;anchovy sauce&rdquo; appearance.",
"   </p>",
"   <p>",
"    The liver may not be palpably enlarged if the original abscess is high up in the right lobe or if it has been decompressed by rupture. Pulmonary consolidation is common in the right lower and middle lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/44,48\">",
"     44,48",
"    </a>",
"    ]. A case of pulmonary amebiasis presenting as superior vena cava syndrome has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10069504\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of amebic pleuropulmonary disease can be established by the same tests used to diagnose hepatic amebic abscesses. Amebic serology is positive in over 90 percent. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10069511\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, amebic pleural effusions should be aspirated. Drained pleural effusions resolve rapidly with drainage and antimicrobial therapy, which consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (750 mg orally three times daily for 7 to 10 days).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     Tinidazole",
"    </a>",
"    is an acceptable alternative agent (2 g once daily for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/50\">",
"     50",
"    </a>",
"    ]. Most patients respond to a single course of treatment with resolution of symptoms before the end of therapy. In rare cases, a second course of metronidazole or tinidazole is need because of failure to achieve complete resolution after the initial regimen. Relapses are rare.",
"   </p>",
"   <p>",
"    Treatment with a luminal agent to eliminate intraluminal cysts is also warranted. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Luminal agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiac infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement in amebic disease is rarer than pleuropulmonary disease. When it occurs it usually results from rupture of a liver abscess into the pericardium, particularly abscesses involving the left lobe of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/51\">",
"     51",
"    </a>",
"    ]. This can result in severe chest pain, congestive cardiac failure, and pericardial tamponade with high associated mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Brain abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral amebiasis results from hematogenous spread of infection. It is characterized by abrupt onset of symptoms and rapid progression to death if untreated. Findings on CT scan may consist of irregular foci without a capsule or surrounding enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33031/abstract/52\">",
"     52",
"    </a>",
"    ]. CNS abscesses due to E. histolytica are distinct from CNS lesions caused by free-living amebae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=see_link\">",
"     \"Free-living amebas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For circumstances in which amebic brain abscess is suspected based on epidemiology, clinical manifestations, and radiographic findings,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    should be started immediately; surgical intervention for decompression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue biopsy may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5027298\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extraintestinal manifestations of Entamoeba histolytica include amebic liver abscess and more rare manifestations such as pulmonary, cardiac, and brain involvement. Amebae establish hepatic infection by ascending the portal venous system. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In developed countries, amebiasis is generally seen in migrants from and travelers to endemic areas. Amebic liver abscess (and other extraintestinal disease) is more common among adult men than other demographic groups. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with amebic liver abscess typically present with one to two weeks of right upper quadrant pain and fever. Concurrent diarrhea is present in less than one-third of patients, although some patients report history of dysentery within the previous few months. Physical examination frequently reveals hepatomegaly and point tenderness over the liver. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of relevant epidemiology and suggestive symptoms, the diagnosis of amebic liver abscess is generally established by radiographic imaging and confirmed with serologic or antigenic testing, perhaps supplemented with stool microscopy or antigenic testing of stool, with or without evaluation for the parasite in liver abscess fluid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Needle aspiration of amebic liver abscess is not routinely required but may be warranted if the cyst appears to be at imminent risk of rupture (particularly for lesions in the left lobe), if there is clinical deterioration or lack of response to empiric therapy, or if exclusion of alternative diagnoses is needed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, treatment of extraintestinal amebic disease is managed with a tissue agent and a luminal agent (to eliminate intraluminal cysts). We suggest treatment of amebic liver abscess or with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest subsequent treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      to eliminate intraluminal cysts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is outlined above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleural space involvement of E. histolytica can occur in the setting of liver abscess rupture into the pleural space, resulting in an amebic empyema. Rupture into the lung can lead to consolidation, abscess formation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatobronchial fistula. Clinical manifestations include pain, cough, hemoptysis, and dyspnea. Cough may be productive of necrotic material that can include liver abscess contents. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pleuropulmonary infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10069497\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of amebic pleural effusions should consist of aspiration and antimicrobial therapy. We suggest treatment of pulmonary infection with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest subsequent treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      to eliminate intraluminal cysts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10069511\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/1\">",
"      Li E, Stanley SL Jr. Protozoa. Amebiasis. Gastroenterol Clin North Am 1996; 25:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/2\">",
"      Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med 2003; 348:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/3\">",
"      Aikat BK, Bhusnurmath SR, Pal AK, et al. The pathology and pathogenesis of fatal hepatic amoebiasis--A study based on 79 autopsy cases. Trans R Soc Trop Med Hyg 1979; 73:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/4\">",
"      Maltz G, Knauer CM. Amebic liver abscess: a 15-year experience. Am J Gastroenterol 1991; 86:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/5\">",
"      Acuna-Soto R, Maguire JH, Wirth DF. Gender distribution in asymptomatic and invasive amebiasis. Am J Gastroenterol 2000; 95:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/6\">",
"      Stanley SL Jr. Amoebiasis. Lancet 2003; 361:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/7\">",
"      Nattakom S, Serrato P, Bright T, et al. Amebic liver abscesses masquerading as pyemic abscesses. Clin Infect Dis 2001; 33:E145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/8\">",
"      Salles JM, Salles MJ, Moraes LA, Silva MC. Invasive amebiasis: an update on diagnosis and management. Expert Rev Anti Infect Ther 2007; 5:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/9\">",
"      Aucott JN, Ravdin JI. Amebiasis and \"nonpathogenic\" intestinal protozoa. Infect Dis Clin North Am 1993; 7:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/10\">",
"      Knobloch J, Mannweiler E. Development and persistence of antibodies to Entamoeba histolytica in patients with amebic liver abscess. Analysis of 216 cases. Am J Trop Med Hyg 1983; 32:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/11\">",
"      Park WB, Choe PG, Jo JH, et al. Amebic liver abscess in HIV-infected patients, Republic of Korea. Emerg Infect Dis 2007; 13:516.",
"     </a>",
"    </li>",
"    <li>",
"     Petri WA, Singh U. Enteric amebiasis. In: Tropical infectious diseases: Principles, pathogens, and practice, 2nd ed, Guerrant R, Walker DH, Weller PF (Eds), Elsevier, Philadelphia 2006. p.967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/13\">",
"      Adams EB, MacLeod IN. Invasive amebiasis. I. Amebic dysentery and its complications. Medicine (Baltimore) 1977; 56:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/14\">",
"      Sodhi KS, Ojili V, Sakhuja V, Khandelwal N. Hepatic and inferior vena caval thrombosis: vascular complication of amebic liver abscess. J Emerg Med 2008; 34:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/15\">",
"      Wu KS, Tsai HC, Lee SS, et al. Comparison of clinical characteristics of amebic liver abscess in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. J Microbiol Immunol Infect 2008; 41:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/16\">",
"      Ravdin JI. Amebiasis. Clin Infect Dis 1995; 20:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/17\">",
"      Stockinger ZT. Colonic ameboma: its appearance on CT: report of a case. Dis Colon Rectum 2004; 47:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/18\">",
"      Misra SP, Misra V, Dwivedi M. Ileocecal masses in patients with amebic liver abscess: etiology and management. World J Gastroenterol 2006; 12:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/19\">",
"      Katzenstein D, Rickerson V, Braude A. New concepts of amebic liver abscess derived from hepatic imaging, serodiagnosis, and hepatic enzymes in 67 consecutive cases in San Diego. Medicine (Baltimore) 1982; 61:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/20\">",
"      Pritt BS, Clark CG. Amebiasis. Mayo Clin Proc 2008; 83:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/21\">",
"      Park MS, Kim KW, Ha HK, Lee DH. Intestinal parasitic infection. Abdom Imaging 2008; 33:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/22\">",
"      Benedetti NJ, Desser TS, Jeffrey RB. Imaging of hepatic infections. Ultrasound Q 2008; 24:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/23\">",
"      Thorsen S, R&oslash;nne-Rasmussen J, Petersen E, et al. Extra-intestinal amebiasis: clinical presentation in a non-endemic setting. Scand J Infect Dis 1993; 25:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/24\">",
"      Patterson M, Healy GR, Shabot JM. Serologic testing for amoebiasis. Gastroenterology 1980; 78:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/25\">",
"      Joyce MP, Ravdin JI. Antigens of Entamoeba histolytica recognized by immune sera from liver abscess patients. Am J Trop Med Hyg 1988; 38:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/26\">",
"      Stanley SL Jr, Jackson TF, Foster L, Singh S. Longitudinal study of the antibody response to recombinant Entamoeba histolytica antigens in patients with amebic liver abscess. Am J Trop Med Hyg 1998; 58:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/27\">",
"      Kraoul L, Adjmi H, Lavarde V, et al. Evaluation of a rapid enzyme immunoassay for diagnosis of hepatic amoebiasis. J Clin Microbiol 1997; 35:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/28\">",
"      Abd-Alla MD, Jackson TF, Gathiram V, et al. Differentiation of pathogenic Entamoeba histolytica infections from nonpathogenic infections by detection of galactose-inhibitable adherence protein antigen in sera and feces. J Clin Microbiol 1993; 31:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/29\">",
"      Chavez-Tapia NC, Hernandez-Calleros J, Tellez-Avila FI, et al. Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. Cochrane Database Syst Rev 2009; :CD004886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/30\">",
"      Soentjens P, Ostyn B, Clerinx J, et al. A case of multiple amoebic liver abscesses: clinical improvement after percutaneous aspiration. Acta Clin Belg 2005; 60:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/31\">",
"      Khanna S, Chaudhary D, Kumar A, Vij JC. Experience with aspiration in cases of amebic liver abscess in an endemic area. Eur J Clin Microbiol Infect Dis 2005; 24:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/32\">",
"      Salata RA, Ravdin JI. The interaction of human neutrophils and Entamoeba histolytica increases cytopathogenicity for liver cell monolayers. J Infect Dis 1986; 154:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/33\">",
"      Sharma MP, Dasarathy S. Amoebic liver abscess. Trop Gastroenterol 1993; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/34\">",
"      Khan U, Mirdha BR, Samantaray JC, Sharma MP. Detection of Entamoeba histolytica using polymerase chain reaction in pus samples from amebic liver abscess. Indian J Gastroenterol 2006; 25:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/35\">",
"      Khokhani RC, Garud AD, Deodhar KP, et al. Treatment of amoebic liver abscess with tinidazole and metronidazole. Drugs 1978; 15 Suppl 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/36\">",
"      Ravdin JI, Skilogiannis J. In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. Antimicrob Agents Chemother 1989; 33:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/37\">",
"      Lasserre R, Jaroonvesama N, Kurathong S, Soh CT. Single-day drug treatment of amebic liver abscess. Am J Trop Med Hyg 1983; 32:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/38\">",
"      Quaderi MA, Rahman MS, Rahman A, Islam N. Amoebic liver abscess and clinical experiences with tinidazole in Bangladesh. J Trop Med Hyg 1978; 81:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/39\">",
"      Vanijanonta S, Bunnag D, Looareesuwan S, Harinasuta T. Low dose tinidazole in the treatment of amoebic liver abscess. Southeast Asian J Trop Med Public Health 1985; 16:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/40\">",
"      Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 101:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/41\">",
"      Sharma MP, Dasarathy S, Verma N, et al. Prognostic markers in amebic liver abscess: a prospective study. Am J Gastroenterol 1996; 91:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/42\">",
"      Kenner BM, Rosen T. Cutaneous amebiasis in a child and review of the literature. Pediatr Dermatol 2006; 23:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/43\">",
"      Shamsuzzaman SM, Hashiguchi Y. Thoracic amebiasis. Clin Chest Med 2002; 23:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/44\">",
"      Adams EB, MacLeod IN. Invasive amebiasis. II. Amebic liver abscess and its complications. Medicine (Baltimore) 1977; 56:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/45\">",
"      Brandt H, Tamayo RP. Pathology of human amebiasis. Hum Pathol 1970; 1:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/46\">",
"      Lyche KD, Jensen WA, Kirsch CM, et al. Pleuropulmonary manifestations of hepatic amebiasis. West J Med 1990; 153:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/47\">",
"      Kennedy D, Sharma OP. Hemoptysis in a 49-year-old man. An unusual presentation of a sporadic disease. Chest 1990; 98:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/48\">",
"      Wilson ES. Pleuropulmonary amebiasis. Am J Roentgenol Radium Ther Nucl Med 1971; 111:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/49\">",
"      Lichtenstein A, Kondo AT, Visvesvara GS, et al. Pulmonary amoebiasis presenting as superior vena cava syndrome. Thorax 2005; 60:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/50\">",
"      Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005; 27:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/51\">",
"      Miyauchi T, Takiya H, Sawamura T, Murakami E. Cardiac tamponade due to intrapericardial rupture of an amebic liver abscess. Jpn J Thorac Cardiovasc Surg 2005; 53:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33031/abstract/52\">",
"      Schmutzhard E, Mayr U, Rumpl E, et al. Secondary cerebral amebiasis due to infection with Entamoeba histolytica. A case report with computer tomographic findings. Eur Neurol 1986; 25:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5728 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33031=[""].join("\n");
var outline_f32_16_33031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5027298\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AMEBIC LIVER ABSCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Serology and antigen detection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Tissue agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Luminal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER EXTRAINTESTINAL SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pleuropulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10069497\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10069504\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10069511\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiac infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5027298\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5728|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/10/10406\" title=\"diagnostic image 1\">",
"      Amebic liver abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=related_link\">",
"      Free-living amebas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33032="Birth control effectiveness PI";
var content_f32_16_33032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F88535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F88535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 640px\">",
"   <div class=\"ttl\">",
"    How effective are the different forms of birth control?",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 620px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33032=[""].join("\n");
var outline_f32_16_33032=null;
var title_f32_16_33033="Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum";
var content_f32_16_33033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Frederick Rand Ueland, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Andrew John Li, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33033/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/16/33033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1674838\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/1\">",
"     1",
"    </a>",
"    ]. Worldwide in 2008, ovarian cancer was the second most common gynecologic malignancy in developed countries and the third most common gynecologic malignancy (cervical cancer is the most common) in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epithelial ovarian cancer, the most common histologic type (95 percent of cases) of ovarian cancer (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ), typically presents at an advanced stage, which contributes to its poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, a definitive diagnosis of ovarian cancer requires surgery; however, many procedures performed for a pelvic mass ultimately identify a benign adnexal mass.",
"   </p>",
"   <p>",
"    Use of serum biomarkers for the diagnosis of epithelial ovarian cancer is an active area of investigation. Biomarkers or panels of biomarkers are generally used in combination with each other or with other findings (eg, ultrasound). Only a few biomarkers are commercially available. Cancer antigen 125 (CA 125) has been the focus of most investigations and is used most extensively. Other diagnostic tests for epithelial ovarian cancer include human epididymis protein (HE4), the OVA1 panel, and the Risk of Malignancy Algorithm (ROMA). &nbsp;",
"   </p>",
"   <p>",
"    There is evidence that high grade serous epithelial ovarian, fallopian tubal, and peritoneal carcinomas should be considered as a single clinical entity due to their shared clinical behavior and treatment. There is also accumulating evidence of a common pathogenesis for these carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/4\">",
"     4",
"    </a>",
"    ]. We will use the term epithelial ovarian cancer to refer to this group of malignancies in the discussion that follows. There is currently no serum biomarker that can distinguish between these types of carcinoma.",
"   </p>",
"   <p>",
"    Use of serum biomarkers for the diagnosis of epithelial ovarian cancer in women who have an adnexal mass is reviewed here. Related topics are discussed separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian cancer screening in women who are asymptomatic and have no adnexal mass (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"       \"Screening for ovarian cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      General principles of the evaluation of an adnexal mass (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"       \"Approach to the patient with an adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovarian cancer diagnosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epithelial ovarian cancer treatment and posttreatment surveillance (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-epithelial ovarian cancer histologies (germ cell tumors, sex cord-stromal tumors) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"       \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link\">",
"       \"Overview of sex cord-stromal tumors of the ovary\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1674945\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general definition of a biomarker is any indicator of disease. A tumor maker is a biomarker specific for malignancy. The United States National Institutes of Health defines a biomarker as \"a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic response to a therapeutic intervention&rdquo;. For epithelial ovarian cancer, this may include patient symptoms, physical examination, imaging studies, or laboratory tests. Biomarkers for epithelial ovarian cancer have been identified in serum, urine, ovarian cyst fluids, ascites, and other body fluids. In this topic review, the term biomarkers will refer specifically to serum biomarkers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19406252\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial ovarian cancer (EOC) presents several diagnostic challenges. EOC is most commonly diagnosed at a late stage, which contributes to its poor prognosis, and the difficulty differentiating between benign and malignant adnexal masses results in many surgical procedures for masses that are ultimately determined to be benign.",
"   </p>",
"   <p>",
"    Lymph node involvement or distant metastases are present in 78 percent of women with EOC at time of diagnosis, with a five-year survival rate of only approximately 30 percent or lower (compared with approximately 80 to 90 percent for women with disease confined to the ovaries) (",
"    <a class=\"graphic graphic_table graphicRef64569 \" href=\"UTD.htm?27/5/27740\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/5\">",
"     5",
"    </a>",
"    ]. Symptoms of ovarian cancer are usually present, but are often nonspecific and do not usually result in diagnosis at an early stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Definitive diagnosis of ovarian cancer requires surgery, and many procedures performed to evaluate a pelvic mass ultimately identify a benign process. As an example, in a large ovarian cancer screening randomized trial, among 570 women who underwent surgical evaluation for suspected ovarian cancer, 20 cases of malignancy were found (3.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, improving the methods for distinguishing malignant from benign masses would avoid unnecessary surgery.",
"   </p>",
"   <p>",
"    Currently, no serum biomarker is both highly sensitive and specific for the diagnosis of EOC. Thus, investigators have combined serum markers or used multimodality strategies to improve the detection of malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2990065\">",
"    <span class=\"h1\">",
"     PROPERTIES OF BIOMARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will discuss the biochemical properties of serum biomarkers for epithelial ovarian cancer (EOC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782337\">",
"    <span class=\"h2\">",
"     Individual biomarkers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782344\">",
"    <span class=\"h3\">",
"     Cancer antigen 125",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of cancer antigen 125 (CA 125) as a biomarker for EOC was first described in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/7\">",
"     7",
"    </a>",
"    ]. CA 125 is currently the most widely used biomarker for EOC and it is approved by the US Food and Drug Association (FDA) for monitoring response to therapy in women with known EOC. CA 125 is often used off-label for evaluation of an adnexal mass alone or combined with other serum biomarkers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H695605\">",
"     'CA 125'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The gene for CA 125 was cloned in 2001 and is called",
"    <em>",
"     MUC16",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/9\">",
"     9",
"    </a>",
"    ]. The CA 125 antigen is a large transmembrane glycoprotein derived from both coelomic (pericardium, pleura, peritoneum) and m&uuml;llerian (fallopian tubal, endometrial, endocervical) epithelia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The antigen complex contains two major domains, A and B. A portion of the extracellular domain includes repeat sequences the bind the OC125 and M11 monoclonal antibodies. The original CA 125 test reacts with OC125 and the newer CA 125 II test utilizes both the OC125 and M11 moieties [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/12\">",
"     12",
"    </a>",
"    ]. Both tests are commonly used in clinical practice. While CA 125 II may be more specific, there are no data to support the superiority of one test over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/13\">",
"     13",
"    </a>",
"    ]. The normal values for the two assays are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CA 125: &le;35",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"     </li>",
"     <li>",
"      CA 125 II: &lt;20",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cutoffs remain somewhat arbitrary and may differ for premenopausal women. Some experts have suggested normal values may range from 20 to 200",
"    <span class=\"nowrap\">",
"     U/mL;",
"    </span>",
"    these variations take into consideration elevations in serum due to benign indications common in premenopausal women, such as menses, fibroids, or ovulation.",
"   </p>",
"   <p>",
"    There are many commercially available CA 125 and CA 125 II assays and the diagnostic performance appears to be similar across assays [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Experts advise that the same assay and same laboratory be used when serial CA 125 testing is performed in an individual patient to avoid unnecessary variation in results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1675676\">",
"    <span class=\"h3\">",
"     Human epididymis protein 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human epididymis protein 4 (HE4) assay was approved by the FDA in 2008 for monitoring for recurrent or progressive disease in patients with EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/16\">",
"     16",
"    </a>",
"    ]. It is also used for the evaluation of an adnexal mass as a component of the Risk of Malignancy Algorithm (ROMA).",
"   </p>",
"   <p>",
"    HE4 is an antigen derived from human epididymis protein, a product of the",
"    <em>",
"     WFDC2",
"    </em>",
"    gene that is overexpressed in patients with serous and endometrioid ovarian carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laboratory reference range of HE4 is &le;150 pM. This value represents the upper 95th percentile for both premenopausal and postmenopausal women, and is reported in the FDA package insert for the HE4 EIA Kit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9477712\">",
"    <span class=\"h3\">",
"     Other markers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9477797\">",
"    <span class=\"h4\">",
"     Carcinoembryonic antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoembryonic antigen (CEA) is a protein normally found in embryonic or fetal tissue. Serum levels disappear almost completely after birth, but small amounts may be present in the colon.",
"   </p>",
"   <p>",
"    In adults, CEA may be elevated in malignancies that produce the protein, particularly mucinous cancers associated with the gastrointestinal tract or ovary. CEA may also be elevated in the following malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breast",
"     </li>",
"     <li>",
"      Pancreas",
"     </li>",
"     <li>",
"      Thyroid",
"     </li>",
"     <li>",
"      Lung",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benign conditions that have been associated with an elevated CEA include [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Mucinous cystadenoma of the ovary or appendix",
"     </li>",
"     <li>",
"      Cholecystitis",
"     </li>",
"     <li>",
"      Liver cirrhosis",
"     </li>",
"     <li>",
"      Diverticulitis",
"     </li>",
"     <li>",
"      Inflammatory bowel disease",
"     </li>",
"     <li>",
"      Pancreatitis",
"     </li>",
"     <li>",
"      Pulmonary infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individual laboratory assays vary slightly, but the typical upper limit of normal for CEA in non-smokers is 3.8 micrograms per liter",
"    <span class=\"nowrap\">",
"     (mcg/L).",
"    </span>",
"    For smokers, the upper limit of normal is 5.5",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CEA testing may also be clinically useful in monitoring patients with pseudomyxoma peritonei, whether the cause is of a benign or malignant etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782358\">",
"    <span class=\"h4\">",
"     Cancer antigen 19-9",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer antigen 19-9 (CA 19-9) is a mucin protein that may be elevated in ovarian cancer, but is used sparingly in ovarian cancer management [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/21\">",
"     21",
"    </a>",
"    ]. CA 19-9 is used primarily to monitor disease response to therapy or detect cancer recurrence in patients with a documented gastric cancer, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, or adenocarcinoma of the ampulla of Vater.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782372\">",
"    <span class=\"h4\">",
"     Investigational biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many biomarkers for EOC are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/22\">",
"     22",
"    </a>",
"    ]. The following serum markers have been reported to be potentially useful: osteopontin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], mesothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/25\">",
"     25",
"    </a>",
"    ], LPA (lysophosphatidic acid) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/26\">",
"     26",
"    </a>",
"    ], haptoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/27\">",
"     27",
"    </a>",
"    ], transthyretin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/28\">",
"     28",
"    </a>",
"    ], apolipoprotein A1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/28\">",
"     28",
"    </a>",
"    ], serum C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/29\">",
"     29",
"    </a>",
"    ], and OVX1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782459\">",
"    <span class=\"h2\">",
"     Biomarker panels and multimodal tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782379\">",
"    <span class=\"h3\">",
"     OVA1",
"    </span>",
"    &nbsp;&mdash;&nbsp;OVA1 is a test that includes five serum biomarkers. It was approved by the FDA in 2009 to further assess the likelihood of malignancy in women who are planning to have surgery for an adnexal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/31\">",
"     31",
"    </a>",
"    ]. OVA1 is performed exclusively through Quest Diagnostics, which is available in 130 countries worldwide.",
"   </p>",
"   <p>",
"    The OVA1 test incorporates five proteins that are variably expressed in ovarian cancer. Two are up-regulated (CA 125 II, beta 2 microglobulin) and three down-regulated (transferrin, transthyretin, apolipoprotein A1) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/7,10,32-34\">",
"     7,10,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proprietary OvaCalc software combines the values for each assay and uses the OVA1 algorithm to generate an ovarian malignancy risk index score. The numeric result ranges from 0.0 and 10.0, and is interpreted as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Premenopausal women",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low probability of malignancy: OVA1 &lt;5.0",
"     </li>",
"     <li>",
"      High probability of malignancy: OVA1 &ge;5.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Postmenopausal women",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low probability of malignancy: OVA1 &lt;4.4",
"     </li>",
"     <li>",
"      High probability of malignancy: OVA1 &ge;4.4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Menopausal status is determined either by clinician report or some clinicians also test serum follicle stimulating hormone to determine menopausal status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with many immunoassays, there may be interference if triglyceride levels exceed 4.5",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    or rheumatoid factor levels &ge;250",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"    This information is provided primarily to assist laboratories with assay interpretation only. There is no need to routinely test for interferents, though if these levels are known to be elevated, OVA1 should not be ordered. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528228\">",
"    <span class=\"h3\">",
"     Risk of Malignancy Algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Risk of Malignancy Algorithm (ROMA) includes CA 125 and HE4. It was approved by the FDA in 2011 to further assess the likelihood of malignancy in women who are planning to have surgery for an adnexal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/36\">",
"     36",
"    </a>",
"    ]. ROMA is available internationally.",
"   </p>",
"   <p>",
"    ROMA uses CA 125 and HE4 testing and interprets the results using two separate logistic regression algorithms, depending on menopausal status [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/37\">",
"     37",
"    </a>",
"    ]. The algorithms are not proprietary, and may be determined with a calculator, through websites, or on smartphone applications. A ROMA score is then reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premenopausal women: High risk of malignancy &ge;13.1 percent",
"     </li>",
"     <li>",
"      Postmenopausal women: High risk of malignancy &ge;27.7 percent &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Menopausal status is determined by clinician report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11431417\">",
"    <span class=\"h3\">",
"     Risk of Malignancy Index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malignancy index (RMI) was originally developed in 1990 and is a multimodality approach that combines serum CA 125, pelvic ultrasound, and menopausal status into an index score to predict the risk of ovarian cancer in women with an adnexal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The RMI is primarily used in the United Kingdom, and the calculation for RMI I is included in the United Kingdom National Institute for Health and Clinical Excellence (NICE) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RMI I is a product of the ultrasound scan score (U), menopausal status (M), and serum CA 125 level (RMI I = U x M x CA 125). The NICE guidelines advise that all women with an RMI I score of &ge;200 should be referred to a specialist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The ultrasound result is scored 1 point for each of the following characteristics: multi-locular cyst, solid areas, metastases, ascites, and bilateral masses. U = 0 for an ultrasound score of 0 points, U = 1 for an ultrasound score of 1 point, U = 3 for an ultrasound score of 2 to 5 points.",
"     </li>",
"     <li>",
"      Menopausal status is scored as 1 = premenopausal and 3 = postmenopausal. &ldquo;Postmenopausal&rdquo; is defined as no period for more than one year or a woman over 50 years of age who has had a hysterectomy.",
"     </li>",
"     <li>",
"      Serum CA 125 is measured in",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of modifications to the RMI have since been proposed (the versions are referred to as RMI I through IV), which involve assigning different values to each variable [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/38,41-45\">",
"     38,41-45",
"    </a>",
"    ]. As an example, in the RMI II, the score for menopause is 1 for premenopausal status and 4 for postmenopausal status and the ultrasound score is expressed as 1 or 4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616782386\">",
"    <span class=\"h3\">",
"     Other biomarker panels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other serum biomarkers panels have been investigated for use for ovarian cancer screening, but not for the evaluation of women with an adnexal mass or symptoms associated with ovarian cancer. Use of biomarkers for ovarian cancer screening is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for ovarian cancer\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695224\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC PERFORMANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695605\">",
"    <span class=\"h2\">",
"     CA 125",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum CA 125 is the most commonly used laboratory test for the evaluation of adnexal masses for epithelial ovarian cancer (EOC), but the test has several shortcomings. The diagnostic performance of CA 125 is limited, particularly for early stage disease. In addition, it is mainly useful in postmenopausal women.",
"   </p>",
"   <p>",
"    CA 125 testing alone has a low sensitivity, particularly for early stage ovarian cancer, and a low overall specificity. The specificity is particularly low in premenopausal women. The diagnostic performance of CA 125 for the diagnosis of ovarian cancer was illustrated in a meta-analysis of 77 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/46\">",
"     46",
"    </a>",
"    ]. An elevated CA 125 (defined as &gt;35",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    had a sensitivity of 78 percent and a specificity of 78 percent. One factor that lowers sensitivity is that CA 125 is not consistently produced by some histologic types of epithelial ovarian cancer, including: mucinous, clear cell, and mixed m&uuml;llerian ovarian tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/10,47\">",
"     10,47",
"    </a>",
"    ]. For early stage ovarian cancers, some studies have reported a wide range of sensitivities, as low as 25 percent for stage I (range 25 to 75 percent) and as low as 61 percent for stage II (61 to 96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The performance of CA 125 in postmenopausal compared with premenopausal women was demonstrated in another meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/50\">",
"     50",
"    </a>",
"    ]. Among six studies that defined an elevated CA 125 as &gt;35",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    in postmenopausal women, the sensitivity for ovarian cancer was 69 to 87 percent, specificity was 81 to 93 percent. For premenopausal women, the sensitivity was 50 to 74 percent, specificity was 69 to 78 percent (one study reported a specificity of 92 percent). The low specificity in premenopausal women is because an elevated CA 125 is also associated with many conditions other than EOC, and many of these are found in reproductive age patients (",
"    <a class=\"graphic graphic_table graphicRef81621 \" href=\"UTD.htm?12/48/13069\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to the association of an elevated CA 125 in conditions other than EOC, serum CA 125 levels may vary with other factors. As an example, in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial of over 25,000 women, in women without ovarian cancer, an elevated CA 125 levels (defined as &ge;35",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    was significantly more likely in women age 60 years or older compared with ages 55 to 59 years and in those with a history of cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, the level was significantly less likely to be elevated in women who were obese (body mass index &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or had a previous hysterectomy.",
"   </p>",
"   <p>",
"    Based upon the poor diagnostic performance of CA 125 in premenopausal women, there has been some discussion of using a higher CA 125 level as the threshold for suspicion of malignancy. Serum CA 125 &gt;200",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    had been used as a criterion for referral to a gynecologic oncologist for premenopausal women in a 2002 guidelines from the American College of Obstetricians and Gynecologists (ACOG) and Society of Gynecologic Oncologists (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/52\">",
"     52",
"    </a>",
"    ]. A retrospective study of women with pelvic masses at tertiary care centers found that, for the diagnosis of ovarian cancer in women &gt;50 years old, a CA 125 of &gt;200",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    had a positive predictive value of 70 percent and a negative predictive value of 85 percent; the combination of all the criteria in the guidelines had a sensitivity of 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/53\">",
"     53",
"    </a>",
"    ]. These guidelines were replaced by a 2011 ACOG statement that referred only to a &ldquo;very elevated CA 125 level&rdquo; rather than a specific value as an indication for referral [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695638\">",
"    <span class=\"h2\">",
"     OVA1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The OVA1 test is a panel of five serum biomarkers that was introduced in 2009 (see",
"    <a class=\"local\" href=\"#H616782379\">",
"     'OVA1'",
"    </a>",
"    above). It is intended for use to further assess the likelihood of malignancy in women who are planning to have surgery for an adnexal mass. It has not been studied for ovarian cancer screening.",
"   </p>",
"   <p>",
"    The largest study of OVA1 was a prospective series that included 524 women who were scheduled for surgery for an ovarian tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/55\">",
"     55",
"    </a>",
"    ]. The study compared the diagnostic performance of OVA1 to CA 125 II alone (the thresholds values used were &gt;200",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    for premenopausal women and &gt;35",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    for postmenopausal women) and physician assessment (based upon history, physical examination, imaging, and CA 125). For a diagnosis of an ovarian malignancy, OVA1 had a better sensitivity than other measures, but a lower specificity than CA 125 alone. The results were as follows: OVA1 sensitivity 93 percent, specificity 43 percent; CA 125 sensitivity 69 percent, specificity 84 percent; and physician assessment sensitivity 75 percent, specificity 79 percent. The combination of OVA1 and physician assessment had a sensitivity of 96 percent and specificity of 35 percent.",
"   </p>",
"   <p>",
"    Results were also stratified by menopausal status and stage for OVA1 compared with CA 125. By menopausal status, the sensitivities for EOC were as follows: premenopausal (OVA1: 96 percent; CA 125: 56 percent) and postmenopausal (OVA1: 100 percent; CA 125: 92 percent). In addition, OVA1 had a higher sensitivity than CA 125 for the diagnosis of a primary ovarian cancer in women with stage I or II disease, particularly in premenopausal women (82 percent versus 29 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/55\">",
"     55",
"    </a>",
"    ]. The specificity of OVA1 for ovarian malignancy was 52 percent for premenopausal and 33 percent for postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study evaluated use of OVA1 compared with CA 125 as part of the ACOG referral criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/57\">",
"     57",
"    </a>",
"    ]. Use of OVA1 rather than CA 125 was associated with an increase in the sensitivity of detecting ovarian cancer (from 77 to 94 percent), but a decrease in the specificity (68 to 35 percent). For premenopausal women, the test performance for the ACOG referral criteria with use OVA1 had a sensitivity of 91 percent and specificity of 43 percent compared to sensitivity 58 percent and specificity 71 percent for the original ACOG criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695646\">",
"    <span class=\"h2\">",
"     Risk of Malignancy Algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Risk of Malignancy Algorithm (ROMA) consists of serum CA 125 and HE4 values that are computed in an algorithm that includes menopausal status (see",
"    <a class=\"local\" href=\"#H528228\">",
"     'Risk of Malignancy Algorithm'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The results of a prospective multi-institutional study of 531 patients considered high risk for ovarian cancer (incidence was 24 percent) initially validated this model and reported a sensitivity for ovarian cancer of 92 percent for postmenopausal women and 76 percent for premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/37\">",
"     37",
"    </a>",
"    ]. To validate this model in a lower risk population, the ROMA investigators performed a second prospective multi-institutional study of 472 women (ovarian cancer incidence 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/58\">",
"     58",
"    </a>",
"    ]. In this low-risk cohort, the sensitivity of ROMA was 92 percent and the specificity 76 percent in postmenopausal women, and 100 percent and 74 percent in premenopausal women.",
"   </p>",
"   <p>",
"    A meta-analysis of 11 studies of women with a pelvic mass found that the overall sensitivity of ROMA for EOC was 89 percent and specificity was 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/59\">",
"     59",
"    </a>",
"    ]. For diagnosis of early stage EOC, the sensitivity was 81 percent and specificity was 76 percent. For premenopausal women, the sensitivity was 82 percent and specificity was 82 percent. For postmenopausal women, the sensitivity was 93 percent and specificity was 79 percent.",
"   </p>",
"   <p>",
"    When ROMA, HE4, and CA 125 were compared, ROMA was the most sensitive (ROMA: 86 percent; HE4 80 percent; CA 125 84 percent) and HE4 was the most specific (ROMA: 84 percent; HE4 94 percent; CA 125: 78 percent); however, these differences were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/59\">",
"     59",
"    </a>",
"    ]. This analysis did not include a study of 389 women that found that the combination of HE4 and CA 125 (ROMA) did not improve the performance over the individual biomarkers alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/60\">",
"     60",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695654\">",
"    <span class=\"h2\">",
"     Risk of Malignancy Index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malignancy index (RMI) is a multimodality score that combines serum CA 125, pelvic ultrasound, and menopausal status (see",
"    <a class=\"local\" href=\"#H11431417\">",
"     'Risk of Malignancy Index'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    A systematic review of 109 studies evaluated RMI I through IV compared with 79 other ovarian cancer prediction scoring systems [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/45\">",
"     45",
"    </a>",
"    ]. RMI I and II (using a cutoff score of 200) had the best diagnostic performance: RMI I (sensitivity: 78 percent; specificity: 87 percent) and RMI II (sensitivity: 79 percent; specificity: 81 percent). Similar results were reported in a meta-analysis of 66 studies, with the only notable difference being that the specificity of RMI II was 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of the RMI system over other serum biomarker tests is that it combines the three most important clinical elements in predicting the malignant risk of an ovarian tumor. Conversely, the challenge for the RMI is that the formula includes the actual CA 125 value (rather than assigning a point value to different ranges of CA 125 levels). This can be problematic in early stage cancers and in premenopausal women, in whom the CA 125 level is often misleading.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19406350\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum biomarkers are used as part of the evaluation for malignancy in women with an adnexal mass. This evaluation also includes a medical history, physical examination, and imaging studies. The clinician uses this information to arrive at the degree of clinical suspicion that a mass is malignant. Based upon this, the clinician decides whether the patient should undergo diagnostic surgery or continued surveillance. For masses that are highly suspicious for ovarian cancer, referral to a gynecologic oncologist is appropriate (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    General principles of the evaluation and management of an adnexal mass are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of women with symptoms associated with epithelial ovarian cancer, but with no adnexal mass, has not been well studied. There may be a role for serum markers in the assessment of these women.",
"   </p>",
"   <p>",
"    Preoperative measurement of biomarkers in women with possible ovarian cancer has other potential functions. A baseline level is established for use for further monitoring during and after treatment. In addition, biomarkers may play a role in predicting whether optimal cytoreduction is feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H11#H11\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Preoperative issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H9#H9\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Predicting optimal cytoreduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1676120\">",
"    <span class=\"h2\">",
"     Women with an adnexal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of suspicion for malignancy in an adnexal mass is based upon all the available clinical information, including: appearance of the mass on imaging; evidence of metastatic disease; menopausal status; risk factors; biomarker testing; and symptoms. The clinician must determine whether to proceed with surgical exploration and whether referral to a gynecologic oncologist is appropriate.",
"   </p>",
"   <p>",
"    Use of the combination of these factors to determine the management of an adnexal mass is discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11429477\">",
"    <span class=\"h3\">",
"     Deciding to proceed with surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision whether to proceed with surgical evaluation for a woman with an adnexal mass depends mostly upon the appearance of the mass on imaging and other factors, rather than on a biomarker test.",
"   </p>",
"   <p>",
"    The only biomarker that has been studied for use in the initial evaluation of an adnexal mass is CA 125, although this is not its FDA approved indication. OVA1 and ROMA have been studied only in women who have already been evaluated and for whom surgery is planned, and thus likely have a higher prevalence of ovarian cancer than the general population of women with an adnexal mass. In the absence of data regarding the use of OVA1 and ROMA in the initial evaluation of an adnexal mass, we do not recommend use of these tests to decide whether to proceed with surgical exploration for an adnexal mass.",
"   </p>",
"   <p>",
"    CA 125 provides adds limited information to the decision to proceed with surgery. It has a low sensitivity overall and particularly for detection of early stage disease. In addition, it has a low specificity, particularly in premenopausal women, as discussed above. (See",
"    <a class=\"local\" href=\"#H695605\">",
"     'CA 125'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In premenopausal women, the decision whether to proceed with surgical evaluation of an adnexal mass is a diagnostic dilemma. Pelvic ultrasound can identify ovarian masses with characteristics of malignancy, but many benign tumors in younger women also have complex ovarian morphology. For some women, the decision to proceed with surgery remains uncertain, even after consideration of the ultrasound findings combined with risk factors, symptoms, and physical examination. In such cases, many clinicians draw a serum CA 125. However, the result is informative only if it is very elevated. The sensitivity and specificity of CA 125 is low in general and particularly in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/50\">",
"     50",
"    </a>",
"    ]. Many benign conditions found in this population are associated with a slightly elevated CA 125 (",
"    <a class=\"graphic graphic_table graphicRef81621 \" href=\"UTD.htm?12/48/13069\">",
"     table 2",
"    </a>",
"    ). The definition of a very elevated CA 125 is not well established; a level &gt;200",
"    <span class=\"nowrap\">",
"     U/ml",
"    </span>",
"    has been proposed, but is supported by few data [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/53\">",
"     53",
"    </a>",
"    ]. Ultimately, referral to a gynecologic oncologist is appropriate for a premenopausal woman with an adnexal mass who have a very elevated CA 125 or for whom there remains diagnostic uncertainty [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, the test is not useful solely for determining which patients should proceed to surgery. If a CA 125 is drawn, the patient should be counseled about its limitations.",
"   </p>",
"   <p>",
"    The risk of ovarian cancer is significantly higher in postmenopausal than premenopausal women. Surgical exploration is typically performed for most complex ovarian masses in postmenopausal women. Exceptions to this are apparently benign masses that are stable in size and appearance (eg, a mass with an appearance consistent with an endometrioma that was documented prior to menopause). Ovarian cysts with a simple sonographic appearance (unilocular, thin walls, anechoic fluid) that are &lt;10 cm in diameter are unlikely to be malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/61\">",
"     61",
"    </a>",
"    ]. In our practice, for postmenopausal patients with a simple cyst, we draw a serum CA 125 and if the results is &lt;35",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    and no symptoms or risk factors associated with ovarian cancer are present, we follow with serial ultrasound. &nbsp;",
"   </p>",
"   <p>",
"    Prior to surgical exploration, another indication for drawing a CA 125 is as a baseline to monitor response to therapy, if ovarian cancer is ultimately diagnosed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841768#H250841768\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Evaluation after chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12758113\">",
"    <span class=\"h3\">",
"     Referral to a gynecologic oncologist",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the decision to proceed with surgical evaluation of an adnexal mass has been made, referral to a gynecologic oncologist is appropriate for women with a high likelihood of ovarian cancer.",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) has published guidelines regarding referral of a women with an adnexal mass to a gynecologic oncologist (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/52\">",
"     52",
"    </a>",
"    ]. As noted above, one study found that the use of OVA1 with these criteria had a higher sensitivity for ovarian cancer than the referral criteria alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33033/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the available evidence, we suggest OVA1 or ROMA rather than CA 125 to decide whether a patient who is planned for surgical evaluation for an adnexal mass should be referred to a gynecologic oncologist. Test availability and expense may factor into which test is most appropriate for each clinical situation.",
"   </p>",
"   <p>",
"    The ACOG referral criteria are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1246228\">",
"    <span class=\"h2\">",
"     Women with ovarian cancer symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women develop symptoms of epithelial ovarian cancer (EOC), but no adnexal mass is found on evaluation. The role of serum markers in this patient population is not well defined.",
"   </p>",
"   <p>",
"    The usual indication for a surgical evaluation for ovarian or fallopian tubal carcinoma is the finding of an adnexal mass that is suspicious for malignancy. In general, other features (eg, symptoms, risk factors, laboratory results) may contribute to the clinical suspicion of malignancy, but are usually not a sufficient indication for surgery. One exception to this is that some experts perform diagnostic laparoscopy for women who have both EOC-associated symptoms (",
"    <a class=\"graphic graphic_table graphicRef76135 \" href=\"UTD.htm?28/28/29132\">",
"     table 4",
"    </a>",
"    ) and an elevated serum biomarker.",
"   </p>",
"   <p>",
"    Symptoms associated with EOC are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1676145\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. Epithelial ovarian carcinoma (EOC) is the most common histologic type of ovarian cancer. It is typically diagnosed at an advanced stage. (See",
"      <a class=\"local\" href=\"#H1674838\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of serum biomarkers for the diagnosis of EOC is an active area of investigation. Biomarkers or panels of biomarkers are generally used in combination with each other or with other findings (eg, ultrasound). (See",
"      <a class=\"local\" href=\"#H1674838\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2990065\">",
"       'Properties of biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Only a few biomarkers are commercially available, including: cancer antigen 125 (CA 125), human epididymis protein (HE4), the OVA1 panel, the Risk of Malignancy Algorithm (ROMA), and the Risk of Malignancy Index (RMI). (See",
"      <a class=\"local\" href=\"#H2990065\">",
"       'Properties of biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum CA 125 is the most commonly used laboratory test for the evaluation of adnexal masses for EOC, but the test has several shortcomings. CA 125 testing alone has a low sensitivity, particularly for early stage ovarian cancer, and a low overall specificity. The specificity is particularly low in premenopausal women. (See",
"      <a class=\"local\" href=\"#H695605\">",
"       'CA 125'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The OVA1 test is a panel of five serum biomarkers that was introduced in 2009. The Risk of Malignancy Algorithm (ROMA) consists of serum CA 125 and HE4 values that are computed in an algorithm that includes menopausal status that was introduced in 2011. Both of these biomarker tests are intended for use to further assess the likelihood of malignancy in women who are planning to have surgery for an adnexal mass. (See",
"      <a class=\"local\" href=\"#H616782379\">",
"       'OVA1'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H528228\">",
"       'Risk of Malignancy Algorithm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision whether to proceed with surgical evaluation for a woman with an adnexal mass depends mostly upon the appearance of the mass on imaging and other factors, rather than on a biomarker test. The only biomarker that has been studied for use in the initial evaluation of an adnexal mass is CA 125, although this is not its approved indication. OVA1 and ROMA have been studied only in women who have already been evaluated and for whom surgery is planned, and we do not recommend use of these tests to decide whether to proceed with surgical exploration for an adnexal mass. (See",
"      <a class=\"local\" href=\"#H11429477\">",
"       'Deciding to proceed with surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For making the decision whether to refer a patient with an adnexal mass to a gynecologic oncologist, we suggest OVA1 or ROMA rather than CA 125. Test availability and expense may impact which test is most appropriate for each clinical situation. (See",
"      <a class=\"local\" href=\"#H12758113\">",
"       'Referral to a gynecologic oncologist'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed., Robboy SL, Mutter GL, Prat J, et al..  (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/4\">",
"      Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012; 10:296.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/6\">",
"      Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/7\">",
"      Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/reviews/K042731.pdf (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/9\">",
"      Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276:27371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/10\">",
"      Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/11\">",
"      Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila) 2011; 4:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/12\">",
"      Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993; 39:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/13\">",
"      Eltabbakh GH, Gupta MK, Belinson JL, et al. Comparison between Centcor CA 125 and CA 125 II assays. Eur J Gynaecol Oncol 1996; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/14\">",
"      Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem 1998; 44:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/15\">",
"      Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 2006; 125:921.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/ohrms/dockets/ac/08/briefing/220028-4403b1-02-Proposed%20HE4%20EIA%20Package%20Insert%20%20.pdf (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer (abstract #5535). J Clin Oncol 2008; 26:5535.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/18\">",
"      Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65:2162.",
"     </a>",
"    </li>",
"    <li>",
"     Menon U, Jacobs I. Tumor markers. In: Principles and Practice of Gynecologic Oncology, Hoskins W, Perez C, Young R (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.165.",
"    </li>",
"    <li>",
"     file://www.medizin.uni-koeln.de/institute/kchemie/Diagnostik/Parameter/Testkits/Roche/CEA.pdf (Accessed on November 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/21\">",
"      Canney PA, Wilkinson PM, James RD, Moore M. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125. Br J Cancer 1985; 52:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/22\">",
"      Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/23\">",
"      Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/24\">",
"      Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/25\">",
"      Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/26\">",
"      Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/27\">",
"      Zhao C, Annamalai L, Guo C, et al. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 2007; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/28\">",
"      Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/29\">",
"      Hefler-Frischmuth K, Hefler LA, Heinze G, et al. Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol 2009; 147:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/30\">",
"      van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92:2837.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/reviews/K081754.pdf (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/32\">",
"      Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/33\">",
"      Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200:639.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/34\">",
"      Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5:4589.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ova-1.com/physicians/using-ova1 (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/pdf10/K103358.pdf (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/37\">",
"      Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/38\">",
"      Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/39\">",
"      Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     file://pathways.nice.org.uk/pathways/ovarian-cancer#path=view%3A/pathways/ovarian-cancer/ovarian-cancer-establishing-the-diagnosis-in-secondary-care.xml&amp;content=view-node%3Anodes-rmi-i-score-and-referral-to-specialist-mdt (Accessed on August 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/41\">",
"      Manjunath AP, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001; 81:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/42\">",
"      Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996; 103:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/43\">",
"      Tingulstad S, Hagen B, Skjeldestad FE, et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999; 93:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/44\">",
"      Yamamoto Y, Yamada R, Oguri H, et al. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 2009; 144:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/45\">",
"      Geomini P, Kruitwagen R, Bremer GL, et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/46\">",
"      Dodge JE, Covens AL, Lacchetti C, et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/47\">",
"      Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/48\">",
"      Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/49\">",
"      Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/51\">",
"      Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol 2008; 110:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/52\">",
"      American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/53\">",
"      Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005; 105:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/54\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/55\">",
"      Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117:1289.",
"     </a>",
"    </li>",
"    <li>",
"     Vermillion, Inc. Austin, Texas.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/57\">",
"      Ware Miller R, Smith A, DeSimone CP, et al. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011; 117:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/58\">",
"      Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/59\">",
"      Li F, Tie R, Chang K, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 2012; 12:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/60\">",
"      Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011; 104:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33033/abstract/61\">",
"      Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16557 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33033=[""].join("\n");
var outline_f32_16_33033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1676145\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674838\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674945\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19406252\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2990065\">",
"      PROPERTIES OF BIOMARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616782337\">",
"      Individual biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616782344\">",
"      - Cancer antigen 125",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1675676\">",
"      - Human epididymis protein 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9477712\">",
"      - Other markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9477797\">",
"      Carcinoembryonic antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H616782358\">",
"      Cancer antigen 19-9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H616782372\">",
"      Investigational biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616782459\">",
"      Biomarker panels and multimodal tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616782379\">",
"      - OVA1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H528228\">",
"      - Risk of Malignancy Algorithm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11431417\">",
"      - Risk of Malignancy Index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616782386\">",
"      - Other biomarker panels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H695224\">",
"      DIAGNOSTIC PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695605\">",
"      CA 125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695638\">",
"      OVA1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695646\">",
"      Risk of Malignancy Algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695654\">",
"      Risk of Malignancy Index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19406350\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1676120\">",
"      Women with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11429477\">",
"      - Deciding to proceed with surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12758113\">",
"      - Referral to a gynecologic oncologist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1246228\">",
"      Women with ovarian cancer symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1676145\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/5/27740\" title=\"table 1\">",
"      Ovarian cancer survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/48/13069\" title=\"table 2\">",
"      Causes of an elevated CA 125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/38/7787\" title=\"table 3\">",
"      Referral to gyn oncologist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29132\" title=\"table 4\">",
"      Consensus statement ov ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=related_link\">",
"      Overview of sex cord-stromal tumors of the ovary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33034="Acute asthma exacerbations in children: Outpatient management";
var content_f32_16_33034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute asthma exacerbations in children: Outpatient management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Richard J Scarfone, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/16/33034/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/16/33034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical decision making in the management of the child with an acute asthma exacerbation includes the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How sick is the child?",
"     </li>",
"     <li>",
"      Which drugs should be used for treatment?",
"     </li>",
"     <li>",
"      What are the optimal doses and delivery routes?",
"     </li>",
"     <li>",
"      When is more aggressive management necessary?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the outpatient management of the child with acute asthma exacerbation will be presented below. Inpatient management of asthma exacerbations in children and chronic management of childhood asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of acute asthma exacerbations in adults is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings, occasionally supplemented by objective tests, should be used to assess the severity of an acute asthma exacerbation (",
"    <a class=\"graphic graphic_table graphicRef76344 \" href=\"UTD.htm?8/32/8718\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Clinical evaluation should be repeated frequently during the management of an acute asthma exacerbation to assess response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief focused history and examination should be obtained before therapy is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/4\">",
"     4",
"    </a>",
"    ]. The history should include [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The time of onset of exacerbation",
"     </li>",
"     <li>",
"      Current medications and allergies",
"     </li>",
"     <li>",
"      Recent use of beta 2-agonists",
"     </li>",
"     <li>",
"      Risk factors for severe, uncontrolled disease, such as emergency department visits, hospital and intensive care unit admissions, repeated courses of oral glucocorticoids, and history of intubation, rapidly progressive episodes, or food allergy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The focused examination should include [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vital signs and pulse oximetry",
"     </li>",
"     <li>",
"      Assessment of level of consciousness, anxiety, and agitation",
"     </li>",
"     <li>",
"      Assessment of breathlessness, wheezing, air entry, accessory muscle use, and retractions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pulmonary index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pulmonary Index Score (PIS) is an asthma score based on five clinical variables: respiratory rate, degree of wheezing, inspiratory to expiratory ratio, accessory muscle use, and oxygen saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/8\">",
"     8",
"    </a>",
"    ]. Each variable is assigned a score from 0 to 3 (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    ). Total scores range from 0 to 15.",
"   </p>",
"   <p>",
"    As a general rule, a score of 7 to 11 indicates an exacerbation of moderate severity and a score of &ge;12 indicates a severe attack. However, the PIS may underestimate the degree of illness in an older child; bradypnea, caused by a prolonged expiratory phase, will result in fewer points for the respiratory rate component.",
"   </p>",
"   <p>",
"    The PIS has been validated and used as an outcome measure in several clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. It can be used to assess initial severity, judge response to treatment, and facilitate admission and discharge planning [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peak flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peak flow meter may be used to assess airflow obstruction, providing an objective assessment of disease severity. However, children younger than six years may not be able to cooperate with peak expiratory flow rate (PEFR) assessments and severely ill children may not be able to stand and provide three consecutive recordings, as is recommended. In addition, the reading is most helpful when the child's personal best PEFR measurement is known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of pulmonary function testing in children\", section on 'Peak expiratory flow rate (PEFR)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs (CXRs) rarely provide information that alters the management of children with acute asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/12\">",
"     12",
"    </a>",
"    ]. Viral upper respiratory tract infections are the most common trigger for wheezing in children and the presence of low grade fever in children with acute asthma exacerbation often prompts clinicians to obtain chest radiographs to exclude pneumonia. However, the rate of specific chest radiograph findings in this setting is extremely low, except in the presence of focal examination findings (eg, rales or decreased breath sounds), fever (&gt;39&ordm;C), or severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arterial blood gas",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is rarely necessary to obtain arterial blood gas (ABG) samples in children with acute asthma. Oxygen saturation can be assessed with pulse oximetry.",
"   </p>",
"   <p>",
"    Many severely ill children have hypercapnia on arrival to the emergency department (ED), but this usually improves after therapy. In children who require admission to the intensive care unit (ICU), measurement of PaCO2 via ABG after a clinical plateau has been reached provides an objective measure of disease severity. In moderately or severely ill children, ABG's obtained before aggressive intervention often are abnormal, but rarely affect management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy for acute severe asthma include [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid reversal of airflow obstruction by repeated administration of inhaled bronchodilators and early institution of systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pharmacotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Correction of hypoxemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe hypercapnia; hypoxemia is alleviated by administration of supplemental oxygen as necessary; hypercapnea usually improves with reversal of airflow obstruction. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Oxygen therapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Pharmacotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reduction of likelihood of recurrence by intensifying baseline therapy. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Discharge meds'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care for children with acute asthma exacerbations includes administration of supplemental oxygen and fluids as necessary, and frequent monitoring of response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Oxygen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with acute asthma have hypoxemia as a result of ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch. Beta-2 agonists may worsen this mismatch by causing pulmonary vasodilation in areas of the lung that are poorly ventilated. Humidified oxygen should be provided as needed to maintain an oxygen saturation of &ge;92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/14\">",
"     14",
"    </a>",
"    ]. All nebulized medications should also be delivered with oxygen, generally at a flow rate of 6 to 8",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical status of children who are being treated for acute asthma should be monitored frequently. The frequency of monitoring varies depending upon the severity of illness and response to initial therapy, but for most patients is typically every 20 to 30 minutes for the first hour of therapy. Patients who require continuous nebulizer therapy continue to be monitored every 20 to 30 minutes.",
"   </p>",
"   <p>",
"    Ongoing monitoring of respiratory and heart rates, oxygen saturation, degree of alertness, accessory muscle use, retractions, and PEFR (in children who are able to perform it) is crucial to decisions regarding disposition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the management of acute asthma exacerbations described below is geared toward management in the emergency department. Initial treatment (beta 2-agonist therapy and oral glucocorticoids) may be provided in the primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]. However, children with moderate to severe exacerbations require close observation for clinical deterioration, frequent treatments, and repeated evaluation. Thus, most children with moderate or severe asthma exacerbations should be managed in an emergency department setting.",
"   </p>",
"   <p>",
"    Inhaled short-acting beta 2-agonists are the mainstay of emergent treatment of acute asthma exacerbations. For children with mild exacerbations, systemic glucocorticoids are usually added if the symptoms and signs of airway obstruction fail to resolve after the first treatment with inhaled beta 2-agonists. Children with moderate or severe exacerbations should receive systemic glucocorticoids as soon as possible. Additional pharmacotherapeutic agents that may be indicated in children with moderate or severe asthma include nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , and parenteral beta 2-agonists, as discussed below (",
"    <a class=\"graphic graphic_algorithm graphicRef76087 \" href=\"UTD.htm?16/52/17230\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef52015 \" href=\"UTD.htm?4/12/4302\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mild exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with mild asthma exacerbation (PIS &lt;7, (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    )), we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       Albuterol",
"      </a>",
"      inhalation therapy administered via small volume nebulizer (SVN) at a dose of 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 5 mg) or metered dose inhaler (MDI-S) at a dose of one-quarter to one-third",
"      <span class=\"nowrap\">",
"       puff/kg",
"      </span>",
"      (maximum eight puffs). If repeated doses are needed, they should be given every 20 to 30 minutes for three doses [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Inhaled beta agonists'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administration of systemic glucocorticoids to those who fail to improve after one inhalation therapy (",
"      <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Moderate exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with moderate asthma exacerbation (PIS 7 to 11, (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    )), we suggest the following approach (",
"    <a class=\"graphic graphic_algorithm graphicRef76087 \" href=\"UTD.htm?16/52/17230\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of supplemental oxygen if oxygen saturation &le;92 percent in room air. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Oxygen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       Albuterol",
"      </a>",
"      nebulization (0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 5 mg) combined with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (250",
"      <span class=\"nowrap\">",
"       microgram/dose",
"      </span>",
"      if &lt;20 kg; 500",
"      <span class=\"nowrap\">",
"       microgram/dose",
"      </span>",
"      if &gt;20 kg) every 20 to 30 minutes for three doses or continuously.",
"      <br/>",
"      <br/>",
"      Patients who have received three doses of intermittent therapy and require additional albuterol therapy may be treated intermittently every 30 to 45 minutes or may be switched to continuous therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Inhaled beta agonists'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H26\">",
"       'Ipratropium bromide'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administration of systemic glucocorticoids soon after arrival in the emergency department or after the first inhalation therapy is initiated (",
"      <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administration of IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2.5 g administered over 20 minutes) if there is clinical deterioration despite treatment with beta 2-agonists,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide, and systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Magnesium sulfate'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Severe exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with severe asthma exacerbation (PIS &ge;12, (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    )), we suggest the following approach (",
"    <a class=\"graphic graphic_algorithm graphicRef52015 \" href=\"UTD.htm?4/12/4302\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of supplemental oxygen if oxygen saturation is &le;92 percent in room air. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Oxygen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       Albuterol",
"      </a>",
"      nebulization (0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 5 mg) combined with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (250",
"      <span class=\"nowrap\">",
"       microgram/dose",
"      </span>",
"      if &lt;20 kg; 500",
"      <span class=\"nowrap\">",
"       microgram/dose",
"      </span>",
"      if &gt;20 kg), every 20 to 30 minutes for three doses or continuously.",
"     </li>",
"     <li>",
"      Alternatively, epinephrine or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"       terbutaline",
"      </a>",
"      (0.01",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of a 1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      solution) with a maximum dose of 0.4 mg (0.4 mL) may be administered intramuscularly or subcutaneously for children with poor inspiratory flow or children who cannot cooperate with nebulized therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Inhaled beta agonists'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H26\">",
"       'Ipratropium bromide'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H28\">",
"       'Parenteral beta 2-agonists'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have received three doses of intermittent therapy and require additional",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    therapy may be treated intermittently every 30 to 45 minutes or may be switched to continuous therapy.",
"   </p>",
"   <p>",
"    Subsequent management depends upon response to initial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who improve after the initial treatment, the approach is as described above for moderate exacerbations. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Moderate exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a poor response to initial treatment, we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administration of IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 125 mg). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administration of IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2.5 g administered over 20 minutes). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Magnesium sulfate'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who do not respond to these interventions, administration of IV",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    may be indicated: bolus with 10",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    over ten minutes, then 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute; infusion may be increased by 0.5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute every 30 minutes to a maximum of 5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    minute. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Parenteral beta 2-agonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Inhaled beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled short-acting beta 2-agonists are the mainstay of emergent treatment of acute asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     Albuterol",
"    </a>",
"    is the most widely used short-acting beta 2-agonist in the acute setting.",
"   </p>",
"   <p>",
"    Inhaled beta 2-agonists can be administered by intermittent nebulization, continuous nebulization, or metered-dose inhaler with a spacer (MDI-S). These delivery systems are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Nebulizer versus MDI-S",
"    </span>",
"    &nbsp;&mdash;&nbsp;When administering inhaled beta 2-agonists intermittently, clinicians may use either small volume nebulizers (SVNs) or MDI-S. These methods appear to be equally effective for children of all ages and with a wide range of illness severity. Advantages of SVN delivery compared to MDI-S include the ability to simultaneously deliver humidified oxygen and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide and to passively administer drug therapy to a child in respiratory distress.",
"   </p>",
"   <p>",
"    However, when using SVNs, up to 90 percent of drug remains in the machine or is lost to the atmosphere [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, the portability of SVNs is limited by the need for an external power source, and the use of SVNs increases respiratory therapy costs since each treatment takes approximately 10 minutes to administer, compared to approximately 10 seconds per puff of inhaler with 30 to 60 seconds between puffs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H6#H6\">",
"     \"The use of inhaler devices in children\", section on 'Spacers and holding chambers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials and meta-analyses indicate that the administration of beta 2-agonists via MDI-S (4 to 12 puffs) is at least as effective, and possibly superior to delivery of medication by SVN in reversing bronchospasm in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3,21,22\">",
"     3,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H12#H12\">",
"     \"The use of inhaler devices in children\", section on 'Pressurized MDI or nebulizer?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Continuous delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies comparing continuous versus intermittent nebulized delivery of beta 2-agonists have found similar outcomes and side effect profiles with both methods [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/16,17,23-25\">",
"     16,17,23-25",
"    </a>",
"    ]. Continuous nebulizer therapy is less labor-intensive than intermittent nebulizer therapy, resulting in reduced respiratory therapy costs. However, young children may not tolerate wearing a face mask for long periods of time.",
"   </p>",
"   <p>",
"    When administering inhaled beta 2-agonists, clinicians may begin with either intermittent or continuous administration. However, continuous therapy insures that the goal of three treatments within the first hour of care for moderately ill children is met. Therefore, we recommend continuous therapy over intermittently nebulized or MDI-S therapy for children who require multiple treatments in the first hour or for an extended period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link&amp;anchor=H1352583#H1352583\">",
"     \"Use of medication nebulizers in children\", section on 'Continuous nebulization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Levalbuterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Racemic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    (RA) is an equal mixture of two mirror-imaged enantiomers: the active R-albuterol and S-albuterol.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18245?source=see_link\">",
"     Levalbuterol",
"    </a>",
"    (LA), on the other hand, is pure R-albuterol. Data from animal studies suggest that S-albuterol, thought to be inert, may in fact be a weak bronchoconstrictor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. Thus, in theory, pure active R-albuterol could be more effective than RA because there is no bronchoconstricting effect from the S-isomer.",
"   </p>",
"   <p>",
"    Studies of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18245?source=see_link\">",
"     levalbuterol",
"    </a>",
"    for acute asthma in children have had conflicting results. In the earliest trial, 547 children with acute asthma who were treated in the ED were randomly assigned to treatment with 1.25 mg LA or 2.5 mg RA every 20 minutes for a maximum of six doses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/33\">",
"     33",
"    </a>",
"    ]. The hospitalization rate was higher among children who received RA (45 versus 36 percent). Three subsequent studies comparing RA to LA in the ED treatment of children with acute asthma found no differences in outcome measures (changes from baseline clinical asthma score, changes in FEV1, number of treatments, length of ED care, rate of hospitalization) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. It is worth noting that the baseline admission rates in these three studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/34-36\">",
"     34-36",
"    </a>",
"    ] were substantially lower than in the first study [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its lack of proven superiority,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18245?source=see_link\">",
"     levalbuterol",
"    </a>",
"    is substantially more expensive than racemic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    . We suggest racemic albuterol rather than levalbuterol as the drug of choice for children with acute asthma exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The doses of medications commonly used in the management of acute asthma exacerbations in children are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      nebulization &mdash; The standard dose for nebulized albuterol is 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (minimum 2.5 mg; maximum 5 mg) (",
"      <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3,37\">",
"       3,37",
"      </a>",
"      ]. Nebulized albuterol can be administered every 20 to 30 minutes for three doses [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"       3",
"      </a>",
"      ]. Beyond that, frequency of therapy may be limited by side effects, such as tachycardia, hypertension, or tremors. Patients who have shown little or no improvement after three doses and who are not experiencing significant adverse effects may be treated every 30 to 45 minutes or switched to continuous therapy.",
"      <br/>",
"      <br/>",
"      Drug delivery is maximized by having a total solution volume of 3 to 4 mL and an oxygen flow rate of 6 to 8",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/38-41\">",
"       38-41",
"      </a>",
"      ], tapping the sides of the reservoir to renebulize droplets, and having older children use a mouthpiece to avoid nasal deposition of drug (",
"      <a class=\"graphic graphic_picture graphicRef66857 \" href=\"UTD.htm?27/4/27717\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Continuous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      nebulization &mdash; The optimal dose for continuous albuterol nebulization therapy has not been determined. One dosing schedule stratified by weight is:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children who weigh 5 to 10 kg, the dose is 10",
"      <span class=\"nowrap\">",
"       mg/hr",
"      </span>",
"     </li>",
"     <li>",
"      For children who weigh 10 to 20 kg, the dose is 15",
"      <span class=\"nowrap\">",
"       mg/hr",
"      </span>",
"     </li>",
"     <li>",
"      For children who weigh &gt;20 kg, the dose is 20",
"      <span class=\"nowrap\">",
"       mg/hr",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       Albuterol",
"      </a>",
"      via MDI-S &mdash; Optimal dosing for albuterol administered by MDI-S is not well established. The 2007 National Asthma Education and Prevention Program (NAEPP) guidelines state that \"equivalent bronchodilation can be achieved either by high doses (4 to 12 puffs) of a short-acting beta agonist by MDS with a valved holding chamber or by nebulizer\"; they suggest a dose of 4 to 8 puffs [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a randomized parallel-group trial, in 64 children (12 to 60 months of age) with moderate to severe wheezing, the efficacy of albuterol therapy (150",
"      <span class=\"nowrap\">",
"       microgram/kg)",
"      </span>",
"      by SVN was equivalent to albuterol therapy (50",
"      <span class=\"nowrap\">",
"       microgram/kg)",
"      </span>",
"      by MDI-S [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When albuterol is administered via MDI-S, we suggest one-quarter to one-third",
"      <span class=\"nowrap\">",
"       puff/kg",
"      </span>",
"      (22.5 to 30",
"      <span class=\"nowrap\">",
"       microgram/kg)",
"      </span>",
"      with a maximum of eight puffs (720 microgram). Thus, proportionately greater doses are provided for young children weighing less than 20 to 30 kg (44 to 66 pounds), who are the least efficient users. As with nebulized albuterol, the dose can be repeated every 20 to 30 minutes for three doses, then every one to four hours as needed.",
"      <br/>",
"      <br/>",
"      To maximize drug delivery, a spacer should be employed by all patients and infants and young children should use a spacer with a face mask, low dead space, and a low resistance valve (",
"      <a class=\"graphic graphic_picture graphicRef66857 \" href=\"UTD.htm?27/4/27717\">",
"       picture 1",
"      </a>",
"      ). Mouthpieces are preferable to face masks for older children to avoid nasal filtering of drug, which may reduce lung deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/9,43\">",
"       9,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H7#H7\">",
"       \"The use of inhaler devices in children\", section on 'Spacer devices'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiinflammatory action of glucocorticoids effectively reduces the airway edema and secretions associated with acute asthma exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are indicated for most children who present to the ED with acute asthma exacerbation. Exceptions include children who respond promptly to a single",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    treatment, children with mild exacerbations, and children who have not received beta 2-agonist therapy within a few hours of presenting for medical care (who may respond to the initial dose of albuterol administered in the ED). The effects of systemic glucocorticoids may be noted within two to four hours of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/8,44\">",
"     8,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of early administration (within one hour) of systemic glucocorticoids versus placebo in patients presenting to the ED with acute asthma exacerbation was evaluated in a meta-analysis of 12 trials involving 863 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/45\">",
"     45",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early administration of systemic glucocorticoids reduced admission rates (pooled odds ratio 0.40, 95% CI 0.21-0.78); eight patients (95% CI 5-21) would need to be treated to prevent one admission.",
"     </li>",
"     <li>",
"      The benefit was more pronounced in those not receiving systemic glucocorticoids before ED presentation (OR 0.37, 95% CI 0.19-0.7) and in those with more severe asthma (OR 0.35, 95% CI 0.21-0.59).",
"     </li>",
"     <li>",
"      Oral versus",
"      <span class=\"nowrap\">",
"       IV/IM",
"      </span>",
"      &mdash; The NAEPP guidelines suggest that oral administration of glucocorticoids is preferred to intravenous administration because oral administration is less invasive and the effects are equivalent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"       3",
"      </a>",
"      ]. Intramuscular administration of glucocorticoids may be warranted in patients who vomit orally administered glucocorticoids, yet do not require an intravenous line for other purposes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/46-48\">",
"       46-48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the meta-analysis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/45\">",
"     45",
"    </a>",
"    ], three studies evaluated oral glucocorticoids versus placebo in children with acute asthma exacerbation and found that, compared with placebo, oral glucocorticoids were effective in reducing hospital admission (OR 0.24, 95% CI 0.11-0.53).",
"   </p>",
"   <p>",
"    Another study examined outcomes before and after initiation of a medical directive that allowed triage nurse-initiated glucocorticoids before physician assessment in 644 consecutive children presenting with a moderate to severe asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/49\">",
"     49",
"    </a>",
"    ]. Nursing initiation of glucocorticoids was associated with a reduced likelihood of admission (OR, 0.56; 95% CI, 0.36-0.87), as well as significantly decreased times to clinical improvement and discharge.",
"   </p>",
"   <p>",
"    Children with acute asthma exacerbation who are critically ill usually require placement of an IV catheter for the administration of medications other than glucocorticoids. We suggest that children with acute asthma exacerbation who have an IV catheter, or are likely to need one placed because of critical illness, receive systemic glucocorticoids intravenously. We suggest that children with acute asthma exacerbation who do not require intravenous access for other reasons, receive systemic glucocorticoids orally. Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    phosphate is an alternative for children who vomit oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose &mdash; The dose of glucocorticoids depends upon the agent and route (",
"      <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Oral",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      . The initial dose of oral prednisone is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 60 mg). In a controlled trial, 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of prednisone (maximum 60 mg) administered early in the course of ED care resulted in a significant reduction in the need for hospitalization among the sickest patients [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      <strong>",
"       phosphate",
"      </strong>",
"      . Dexamethasone phosphate is another glucocorticoid that can be administered orally [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/50\">",
"       50",
"      </a>",
"      ]. It has a longer half-life than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (36 to 72 hours versus 18 to 36 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/52\">",
"       52",
"      </a>",
"      ]. The dose is 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 16 mg) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      . The usual does of intravenous methylprednisolone for acute asthma exacerbations is 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 60 mg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of inhaled glucocorticoids to treat children with acute asthma is an area of ongoing clinical research. Studies comparing the use of oral to inhaled glucocorticoids in the ED management of children with acute asthma have thus far had mixed results, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies have found benefits of inhaled glucocorticoids compared to oral glucocorticoids (eg, earlier discharge from the ED, less vomiting, decreased relapse rate, improved clinical parameters, improved pulmonary function) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/9,53\">",
"       9,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies have found oral glucocorticoids and inhaled glucocorticoids to have similar outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/54-56\">",
"       54-56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study found improved pulmonary function and a lower relapse rate with oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      compared to inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One randomized trial found no additional benefit to adding nebulized",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      to standard therapy (systemic glucocorticoids, and inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      ) early in the course of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until more conclusive data are available, we do not suggest the routine use of inhaled glucocorticoids in addition to, or instead of, systemic glucocorticoids in the management of acute asthma exacerbation in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ipratropium bromide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide is an anticholinergic agent. Anticholinergic agents provide bronchodilation through smooth muscle relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20870?source=see_link&amp;anchor=H6#H6\">",
"     \"Anticholinergic agents in the management of acute exacerbations of asthma\", section on 'Use in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    is indicated in the treatment of children with moderate to severe asthma exacerbations. It is inexpensive and safe. In randomized trials, systematic review, and meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/60-64\">",
"     60-64",
"    </a>",
"    ], multiple doses of inhaled ipratropium combined with inhaled beta 2-agonists have been shown to reduce hospital admissions and improve lung function in children with severe asthma exacerbations. In contrast, ipratropium has not been shown to reduce the length of hospital stay or to prevent admission to the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Hospitalization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A systematic review of 13 randomized trials comparing combined inhaled beta 2-agonists and anticholinergic agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    sulfate and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide) with inhaled beta 2-agonists alone found the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single doses of combination therapy improved lung function 60 and 120 minutes after therapy, but did not reduce hospitalization (relative risk 0.93, 95% CI 0.65-1.32).",
"     </li>",
"     <li>",
"      Multiple doses of combined therapy reduced the risk of hospital admission (RR 0.75, 95% CI 0.62-0.89) in children with moderate and severe exacerbations; 12 children (95% CI 8-32) with asthma exacerbation of any severity would need to be treated with combination therapy to avoid one admission; 7 children (95% CI 5-20) with severe asthma exacerbation would need to be treated to avoid one admission.",
"     </li>",
"     <li>",
"      Multiple doses of combined therapy also resulted in improved percent predicted FEV1 60 minutes after the last treatment (weighted mean group difference of 9.7 percent, 95% CI 5.70-13.7 percent improvement).",
"     </li>",
"     <li>",
"      The use of combination therapy did not result in increased incidence of nausea, vomiting, or tremor compared to the use of beta 2-agonists alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    can be administered via SVN or MDI-S. The MDI formulation should not be administered to highly sensitive patients with allergy to peanut or soy because it contains soy lecithin, which may precipitate an allergic reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of food allergy: Avoidance\", section on 'Soy lecithin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that children with moderate to severe asthma exacerbations be treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide (250 microgram per dose for children who weigh &lt;20 kg; 500 microgram per dose for children who weigh &gt;20 kg). We administer ipratropium bromide with each of the first three",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/60\">",
"     60",
"    </a>",
"    ]. Alternatively, ipratropium may be administered with the second and third treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If administered by MDI-S, the NAEPP guidelines recommend a dose of four to eight puffs (each puff is 18 microgram) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]. The NAEPP guidelines also comment that the MDI dose is low and has not been studied in asthma exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is accumulating evidence that intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    benefits adults and children with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/67-72\">",
"     67-72",
"    </a>",
"    ]. Magnesium is inexpensive, has minimal adverse effects at the doses indicated, and is widely available.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    in the emergency department setting for treatment of children with asthma has been evaluated in several small studies. Four of the five prospective, randomized controlled trials of intravenous magnesium sulfate (25 to 40",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in children demonstrated benefit (improved pulmonary function or clinical asthma scores) in children who had failed to respond to conventional therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    and glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/70,71,73,74\">",
"     70,71,73,74",
"    </a>",
"    ]. A fifth study found no significant effect of magnesium sulfate (75",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    on pulmonary index score, admission rate, or time to discharge when administered as a component of initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/10\">",
"     10",
"    </a>",
"    ]. Serious adverse effects (eg, hypotension) were not noted in any of the studies.",
"   </p>",
"   <p>",
"    A meta-analysis of these studies found that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    was effective in preventing hospitalization in children with moderate to severe acute asthma when added to bronchodilators and glucocorticoids (absolute risk reduction 0.26, 95% CI 0.12-0.39) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/75\">",
"     75",
"    </a>",
"    ]. Four children would need to be treated to avoid one hospitalization (95% CI 3-8).",
"   </p>",
"   <p>",
"    We suggest that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    be used in children with severe asthma exacerbations and in children with moderate asthma exacerbations who have clinical deterioration despite treatment with beta 2-agonists,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide, and systemic glucocorticoids. We use a dose of 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 2.5 g) IV administered over 20 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Parenteral beta 2-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral beta 2-agonists include epinephrine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    ; these drugs may be administered subcutaneously, intramuscularly, or intravenously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Subcutaneous or intramuscular",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid subcutaneous or intramuscular administration of beta 2-agonists may be superior to inhaled beta 2-agonists for children with severe exacerbations and poor inspiratory flow or anxious young children who are uncooperative with or have suboptimal response to initial aerosolized therapy. The intramuscular route may provide for more rapid drug absorption, although direct comparisons are lacking. In this setting,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    may be expected to produce fewer adverse effects than epinephrine.",
"   </p>",
"   <p>",
"    The dose of subcutaneous or intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    for bronchodilation is 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (0.01",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of a 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    solution) with a maximum dose of 0.4 mg (0.4 mL); the dose may be repeated every 20 minutes for three doses. The dosing interval may be decreased for children who continue with severe respiratory distress.",
"   </p>",
"   <p>",
"    The dose of subcutaneous or intramuscular epinephrine for bronchodilation is 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.01",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 1:1000 solution (1",
"    <span class=\"nowrap\">",
"     mg/mL)),",
"    </span>",
"    with a maximum dose of 0.4 mL (0.4 mg); the dose may be repeated every 20 minutes for three doses, then every two to six hours as needed. The dosing interval may be decreased for children who continue with severe respiratory distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely ill patients who are poorly responsive to conventional therapy may be treated with a combination of intravenous (IV) beta 2-agonists and inhaled beta 2-agonists, although additional studies are needed to clarify the role of IV beta 2-agonists. A systematic review of studies published through September 2012 found only two randomized trials that met inclusion criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Limited evidence from these two trials suggests that there is shorter recovery time and improved pulmonary index scores with the addition of IV beta 2-agonists in children poorly responsive to conventional interventions (including inhaled beta 2-agonists and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    , systemic glucocorticoids, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ). However, this possible benefit needs to be weighed against increased side effects associated with the therapy. These can include dysrhythmias, hypertension, and myocardial ischemia. There is no role for initiating therapy with IV beta 2-agonists, even for severely ill children.",
"   </p>",
"   <p>",
"    Dosing for intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    in the emergency department setting is as follows: 10",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    bolus over 10 minutes, followed by 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute; every 30 minutes the infusion may be increased by 0.5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute to a maximum of 3",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute (higher doses are sometimes used in the intensive care unit setting). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nonstandard therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data to support the routine administration of heliox,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    , or leukotriene receptor antagonists in the treatment of children with acute asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Heliox",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mixture of helium and oxygen theoretically may enhance beta 2-agonist delivery because the lower gas density would result in decreased flow resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link&amp;anchor=H6#H6\">",
"     \"Physiology and clinical use of heliox\", section on 'Use in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of continuous beta 2-agonist administration delivery by heliox compared to oxygen were evaluated in a controlled trial in 30 children (2 to 18 years) with moderate to severe asthma (PIS &ge;8) (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/79\">",
"     79",
"    </a>",
"    ]. After initial treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    inhalation and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    , the patients were randomly assigned to receive continuous albuterol nebulization delivered by heliox or oxygen. At 240 minutes, patients in the heliox group had greater decrease in PIS score from baseline (decrease of 7 versus 3 points). In addition, more patients in the heliox group were discharged from the hospital in less than 12 hours (73 versus 33 percent).",
"   </p>",
"   <p>",
"    The 2007 NAEPP guidelines suggest that administration of beta 2-agonists with heliox may be warranted in patients with life-threatening exacerbations or who are not responding to conventional therapy. However, the use of heliox should not delay intubation once it is considered necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to its bronchodilating properties, the dissociative agent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    is the drug of choice to provide sedation and analgesia before intubating a child with asthma. Although several small case series of nonintubated children treated with ketamine suggest that ketamine improves acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], the one randomized trial found that ketamine was no better than standard therapy in nonintubated children with severe acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H27#H27\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Sedation and paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Leukotriene receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data do not support the routine use of leukotriene receptor antagonist (LTRA) therapy to treat children with acute asthma exacerbations requiring urgent or emergent care [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/84\">",
"     84",
"    </a>",
"    ]. LTRA add-on therapy in acute asthma has shown promise in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. However, it does not appear to provide additional benefit in children when added to standard therapy for acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/87\">",
"     87",
"    </a>",
"    ]. In one randomized trial of over 600 adults, fewer patients treated with a single 160 mg dose of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41316?source=see_link\">",
"     zafirlukast",
"    </a>",
"    , in addition to standard care, required prolonged observation or hospitalization compared with the control group (10 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/86\">",
"     86",
"    </a>",
"    ]. In contrast, a randomized trial of 117 children aged 5 to 15 years treated in the emergency department found no difference in the Modified Pulmonary Index Score (MPIS) between those treated with a single age-appropriate dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/87\">",
"     87",
"    </a>",
"    ]. A slightly lower rate in outpatient relapse was seen in patients from the adult study who were discharged on 20 mg of oral zafirlukast daily, in addition to standard care, compared with placebo (24 versus 29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/86\">",
"     86",
"    </a>",
"    ]. Intravenous montelukast was effective in improving FEV1 in two randomized trials of adults with acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/85,88\">",
"     85,88",
"    </a>",
"    ], but similar results were not seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefits were not seen with LTRAs as monotherapy in children discharged from the emergency department after treatment for acute asthma was successful. A five day course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    was not as effective as a similar course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    in a randomized trial of 130 children with mild to moderate acute asthma exacerbations who were stabilized with prednisolone in the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/90\">",
"     90",
"    </a>",
"    ]. Treatment failure occurred in 8 percent of children treated with prednisolone compared with 22 percent treated with montelukast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Leukotriene receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision regarding the need for hospitalization is a complex one that is based upon clinical and social factors. In general, a child who requires beta 2-agonist treatments every two to three hours needs to be admitted, as do children who require supplemental oxygen. Other factors used in making decisions regarding disposition include severity of previous exacerbations, adherence to medication regimen, access to care, and social support. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Hospitalization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Discharge to home",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have marked improvement in clinical parameters within the first one to two hours of therapy may be discharged home [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]. Marked improvement is manifest by diminished or absent wheezing and retracting and increased aeration that is sustained at least 60 minutes after the most recent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Discharge meds",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAEPP guidelines state that discharged patients should be treated with beta 2-agonists and oral systemic glucocorticoids for 3 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]. Corticosteroids that are administered for less than 10 days do not require a taper at discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether inhaled glucocorticoids should be added to inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    and oral glucocorticoids at the time of discharge from the ED for patients who are not already receiving glucocorticoids as controller therapy is a question that remains unanswered, as illustrated by the differing results in the studies described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, adult patients who were discharged from the ED after acute asthma exacerbation were discharged with standard medications, including oral glucocorticoids for five days and randomly assigned to receive inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33392?source=see_link\">",
"       flunisolide",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/92\">",
"       92",
"      </a>",
"      ]. At the 24-day follow-up, the addition of ICS did not result in a benefit in any of the outcomes assessed. However, the estimated adherence with the inhaled medication was low and many patients were lost to follow-up.",
"     </li>",
"     <li>",
"      In contrast, a similarly designed study noted a 48 percent decrease in relapse rates, a significant decrease in the frequency of beta 2-agonist use, and fewer asthma symptoms among adults treated with inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      following ED discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Discharge education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon discharge from the ED, it is recommended that patients and their parents receive education regarding [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of discharge medications, with respect to purpose, side effects, and proper technique for administration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H7#H7\">",
"       \"The use of inhaler devices in children\", section on 'Spacer devices'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H8#H8\">",
"       \"The use of inhaler devices in children\", section on 'Valved-holding chambers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A written asthma action plan should be reviewed or initiated (",
"      <a class=\"graphic graphic_form graphicRef71958 graphicRef55900 \" href=\"UTD.htm?43/41/44698\">",
"       form 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"       \"What do patients need to know about their asthma?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"       \"Risk factors for asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention of acute exacerbations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"       \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Continued treatment and observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with some, but incomplete improvement within the first two hours of therapy require continued observation. Incomplete response is manifest by modest, but insufficient benefits in degree of wheezing, retracting, and aeration.",
"   </p>",
"   <p>",
"    During continued observation, patients with partial improvement should continue to receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    nebulizations every 30 to 45 minutes (or continuously) for another one to two hours, after which a decision regarding hospitalization or discharge home is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who were moderately to severely ill on arrival and who have little improvement, and or continued need for supplemental oxygen after initial therapy with beta 2-agonists and systemic glucocorticoids require hospitalization. This includes patients who continue to have significant wheezing and retracting, poor aeration, or altered mental status, such as drowsiness or agitation.",
"   </p>",
"   <p>",
"    Additional factors that may influence the decision about hospitalization include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The medical regimen before the emergency department visit (especially if glucocorticoids have already been used or if beta-2 agonists have been overused)",
"     </li>",
"     <li>",
"      A history of poor adherence to the medical regimen",
"     </li>",
"     <li>",
"      Parental inability to provide careful medical care and supervision at home",
"     </li>",
"     <li>",
"      Inadequate transportation back to the hospital if deterioration occurs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most hospitalized children who do not require admission to an intensive care unit do not require the insertion of an intravenous catheter, unless they do not have adequate oral hydration.",
"   </p>",
"   <p>",
"    Inpatient therapy for acute asthma exacerbations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients discharged from the ED should have follow-up in one to four weeks with their primary care provider [",
"    <a class=\"abstract\" href=\"UTD.htm?32/16/33034/abstract/3\">",
"     3",
"    </a>",
"    ]. At the follow-up visit the primary care provider can review the child's asthma control and alter controller therapy as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/52/13122?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       \"Patient information: Asthma in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/4/33858?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical decision-making for the child with acute asthma exacerbation requires ability to assess the severity of the exacerbation and knowledge of the most effective pharmacologic agents. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings are used to assess the severity of an acute asthma exacerbation and to judge the response to therapy (",
"      <a class=\"graphic graphic_table graphicRef76344 \" href=\"UTD.htm?8/32/8718\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"       table 2",
"      </a>",
"      ). Clinical findings occasionally are supplemented by objective tests. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Assessment of severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consider chest x-ray in the presence of focal examination findings (eg, rales or decreased breath sounds), fever (&gt;39&ordm;C), or severe disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immediate goals of treatment of acute asthma exacerbation include rapid reversal of airflow obstruction and correction of severe hypercapnia or hypoxemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled short-acting beta 2-agonists are the mainstay of management of acute asthma exacerbation. Systemic glucocorticoids are added if the signs and symptoms of airway obstruction fail to improve after the first treatment with inhaled beta 2-agonists. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Mild attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the child with a mild asthma exacerbation (PIS &lt;7, (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    )) is as follows: (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Mild exacerbation'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend administration of short acting beta 2-agonist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Beta 2-agonists may be administered by nebulizer (0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 5 mg) or metered-dose inhaler with spacer (one-quarter to one-third",
"      <span class=\"nowrap\">",
"       puff/kg,",
"      </span>",
"      maximum 8 puffs). Short-acting beta 2-agonists are administered every 20 to 30 minutes for one to three doses. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Inhaled beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not improve after one inhalation therapy, we recommend the administration of systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Moderate attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to management of an asthma exacerbation of moderate severity (PIS 7 to 11, (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    )) is summarized in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef76087 \" href=\"UTD.htm?16/52/17230\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Moderate exacerbation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of supplemental oxygen is indicated if oxygen saturation is &le;92 percent in room air. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Oxygen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend inhalation therapy with a short acting beta 2-agonist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Inhaled beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children with asthma exacerbations of moderate severity also receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We administer ipratropium bromide with each of the first three beta 2-agonist nebulizer treatments or continuously; alternatively it may be administered with the second and third treatments. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ipratropium bromide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administration of systemic glucocorticoids soon after arrival in the emergency department or after the first inhalation therapy is initiated (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the administration of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for patients with moderate asthma exacerbations who have clinical deterioration despite treatment with beta 2-agonist,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      , and systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Magnesium sulfate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Severe attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to management of a severe asthma exacerbation (PIS &ge;12, (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    )) is summarized in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef52015 \" href=\"UTD.htm?4/12/4302\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Severe exacerbation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of supplemental oxygen is indicated if oxygen saturation is &le;92 percent in room air. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Oxygen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend nebulized therapy with a short acting beta 2-agonist for children with severe asthma exacerbations (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Subcutaneous or intramuscular administration is an alternative for children with poor inspiratory flow, those who are uncooperative with inhalation therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those who have suboptimal response to initial inhalation therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Inhaled beta agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Parenteral beta 2-agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children with severe asthma exacerbations also receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We administer ipratropium bromide with each of the first three beta 2-agonist nebulizer treatments or continuously; alternatively it may be administered with the second and third treatments. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ipratropium bromide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management after the first dose of short-acting beta 2-agonist depends on the response to initial therapy. Patients who improve after the initial inhalation treatment proceed with treatment as for patients with moderate exacerbations. (See",
"      <a class=\"local\" href=\"#H47\">",
"       'Moderate attack'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administration of systemic glucocorticoids after the first inhalation therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We administer systemic glucocorticoids intravenously since patients with severe exacerbations are likely to require additional intravenous medications. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a poor response to initial treatment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest administration of IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Magnesium sulfate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest administration of IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"       terbutaline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A bolus of 10",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      is administered over 10 minutes; this is followed by continuous infusion of 0.3 to 0.5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      per minute; the infusion may be increased by 0.5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      per minute every 30 minutes to a maximum of 5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      minute. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Parenteral beta 2-agonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Disposition decisions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The disposition of children with acute asthma exacerbation depends upon the response during the first one to two hours of therapy.",
"     </li>",
"     <li>",
"      Children who have marked improvement in clinical parameters may be discharged home. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Discharge to home'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with some, but incomplete improvement within the first two hours of therapy require continued observation and treatment. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Continued treatment and observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have little improvement, and or continued need for supplemental oxygen after initial therapy with beta 2-agonists and systemic glucocorticoids require hospitalization. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Hospitalization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link\">",
"       \"Acute asthma exacerbations in children: Inpatient management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients discharged from the ED should have follow-up in one to four weeks with their primary care provider. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/1\">",
"      Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/2\">",
"      Kerem E, Canny G, Tibshirani R, et al. Clinical-physiologic correlations in acute asthma of childhood. Pediatrics 1991; 87:481.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma.(NIH publication no. 08-4051). Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     Asthma team, Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for managing an acute exacerbation of asthma. Guideline 4. p.1. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm (Accessed on September 26, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/5\">",
"      Strunk RC. Identification of the fatality-prone subject with asthma. J Allergy Clin Immunol 1989; 83:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/6\">",
"      Wasserfallen JB, Schaller MD, Feihl F, Perret CH. Sudden asphyxic asthma: a distinct entity? Am Rev Respir Dis 1990; 142:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/7\">",
"      Roberts G, Patel N, Levi-Schaffer F, et al. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. J Allergy Clin Immunol 2003; 112:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/8\">",
"      Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/9\">",
"      Scarfone RJ, Loiselle JM, Wiley JF 2nd, et al. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med 1995; 26:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/10\">",
"      Scarfone RJ, Loiselle JM, Joffe MD, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med 2000; 36:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/11\">",
"      Hsu P, Lam LT, Browne G. The pulmonary index score as a clinical assessment tool for acute childhood asthma. Ann Allergy Asthma Immunol 2010; 105:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/12\">",
"      Gershel JC, Goldman HS, Stein RE, et al. The usefulness of chest radiographs in first asthma attacks. N Engl J Med 1983; 309:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/13\">",
"      Rushton AR. The role of the chest radiograph in the management of childhood asthma. Clin Pediatr (Phila) 1982; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/14\">",
"      Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003; 124:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/15\">",
"      Canny GJ, Reisman J, Healy R, et al. Acute asthma: observations regarding the management of a pediatric emergency room. Pediatrics 1989; 83:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/16\">",
"      Rudnitsky GS, Eberlein RS, Schoffstall JM, et al. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/17\">",
"      Lin RY, Sauter D, Newman T, et al. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/18\">",
"      Ben-Zvi Z, Lam C, Hoffman J, et al. An evaluation of the initial treatment of acute asthma. Pediatrics 1982; 70:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/19\">",
"      Rossing TH, Fanta CH, Goldstein DH, et al. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. Am Rev Respir Dis 1980; 122:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/20\">",
"      Rubilar L, Castro-Rodriguez JA, Girardi G. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatr Pulmonol 2000; 29:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/21\">",
"      Castro-Rodriguez JA, Rodrigo GJ. beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr 2004; 145:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/22\">",
"      Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; :CD000052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/23\">",
"      Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med 1996; 3:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/24\">",
"      Besbes-Ouanes L, Nouira S, Elatrous S, et al. Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial. Ann Emerg Med 2000; 36:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/25\">",
"      Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/26\">",
"      Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol 1994; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/27\">",
"      Johansson F, Rydberg I, Aberg G, Andersson RG. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/28\">",
"      Templeton AG, Chapman ID, Chilvers ER, et al. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/29\">",
"      Volcheck GW, Kelkar P, Bartemes KR, et al. Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005; 35:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/30\">",
"      Leff AR, Herrnreiter A, Naclerio RM, et al. Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/31\">",
"      Yamaguchi H, McCullough JR. S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol 1996; 14:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/32\">",
"      Mitra S, Ugur M, Ugur O, et al. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998; 53:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/33\">",
"      Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/34\">",
"      Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/35\">",
"      Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/36\">",
"      Ralston ME, Euwema MS, Knecht KR, et al. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005; 29:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/37\">",
"      Schuh S, Parkin P, Rajan A, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989; 83:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/38\">",
"      Clay MM, Pavia D, Newman SP, et al. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983; 2:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/39\">",
"      Wood JA, Wilson RS, Bray C. Changes in salbutamol concentration in the reservoir solution of a jet nebulizer. Br J Dis Chest 1986; 80:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/40\">",
"      Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983; 38:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/41\">",
"      Douglas JG, Leslie MJ, Crompton GK, Grant IW. Is the flow rate used to drive a jet nebuliser clinically important? Br Med J (Clin Res Ed) 1985; 290:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/42\">",
"      Ploin D, Chapuis FR, Stamm D, et al. High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial. Pediatrics 2000; 106:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/43\">",
"      Berg E. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med 1995; 8 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/44\">",
"      Tal A, Levy N, Bearman JE. Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatrics 1990; 86:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/45\">",
"      Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; :CD002178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/46\">",
"      Gordon S, Tompkins T, Dayan PS. Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with acute asthma. Pediatr Emerg Care 2007; 23:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/47\">",
"      Klig JE, Hodge D 3rd, Rutherford MW. Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone. J Asthma 1997; 34:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/48\">",
"      Gries DM, Moffitt DR, Pulos E, Carter ER. A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr 2000; 136:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/49\">",
"      Zemek R, Plint A, Osmond MH, et al. Triage nurse initiation of corticosteroids in pediatric asthma is associated with improved emergency department efficiency. Pediatrics 2012; 129:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/50\">",
"      Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr 2001; 139:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/51\">",
"      Altamimi S, Robertson G, Jastaniah W, et al. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care 2006; 22:786.",
"     </a>",
"    </li>",
"    <li>",
"     Schimmer BP, Parker KL. Adrenocortical steroids and their synthetic analogs. In: Goodman and Gilman's The pharmacological basis of therapeutics, 9th ed, Hardman JG, Limbird LE (Eds), McGraw-Hill, New York 1996. p.1459.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/53\">",
"      Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999; 88:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/54\">",
"      Manjra AI, Price J, Lenney W, et al. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med 2000; 94:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/55\">",
"      Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr 1999; 88:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/56\">",
"      Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998; 102:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/57\">",
"      Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006; 118:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/58\">",
"      Upham BD, Mollen CJ, Scarfone RJ, et al. Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial. Acad Emerg Med 2011; 18:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/59\">",
"      Jones CA, Madison JM, Tom-Moy M, Brown JK. Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle. Am J Physiol 1987; 253:C97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/60\">",
"      Zorc JJ, Pusic MV, Ogborn CJ, et al. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics 1999; 103:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/61\">",
"      Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/62\">",
"      Schuh S, Johnson DW, Callahan S, et al. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr 1995; 126:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/63\">",
"      Plotnick LH, Ducharme FM. Combined inhaled anticholinergic agents and beta-2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2000; :CD000060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/64\">",
"      Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/65\">",
"      Craven D, Kercsmar CM, Myers TR, et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr 2001; 138:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/66\">",
"      Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med 2001; 155:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/67\">",
"      Skobeloff EM, Spivey WH, McNamara RM, Greenspon L. Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA 1989; 262:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/68\">",
"      Bloch H, Silverman R, Mancherje N, et al. Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest 1995; 107:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/69\">",
"      Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/70\">",
"      Ciarallo L, Sauer AH, Shannon MW. Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial. J Pediatr 1996; 129:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/71\">",
"      Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. Arch Pediatr Adolesc Med 2000; 154:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/72\">",
"      Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000; :CD001490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/73\">",
"      Devi PR, Kumar L, Singhi SC, et al. Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy. Indian Pediatr 1997; 34:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/74\">",
"      G&uuml;rkan F, Haspolat K, Bonak M, et al. Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy. Eur J Emerg Med 1999; 6:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/75\">",
"      Cheuk DK, Chau TC, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005; 90:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/76\">",
"      Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/77\">",
"      Travers AH, Milan SJ, Jones AP, et al. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 2012; 12:CD010179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/78\">",
"      Bogie AL, Towne D, Luckett PM, et al. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatr Emerg Care 2007; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/79\">",
"      Kim IK, Phrampus E, Venkataraman S, et al. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics 2005; 116:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/80\">",
"      Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 2006; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/81\">",
"      Petrillo TM, Fortenberry JD, Linzer JF, Simon HK. Emergency department use of ketamine in pediatric status asthmaticus. J Asthma 2001; 38:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/82\">",
"      Allen JY, Macias CG. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med 2005; 46:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/83\">",
"      Jat KR, Chawla D. Ketamine for management of acute exacerbations of asthma in children. Cochrane Database Syst Rev 2012; 11:CD009293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/84\">",
"      Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev 2012; 5:CD006100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/85\">",
"      Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/86\">",
"      Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004; 126:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/87\">",
"      Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial. Arch Dis Child 2010; 95:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/88\">",
"      Camargo CA Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010; 125:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/89\">",
"      Morris CR, Becker AB, Pi&ntilde;ieiro A, et al. A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Ann Allergy Asthma Immunol 2010; 104:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/90\">",
"      Schuh S, Willan AR, Stephens D, et al. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. J Pediatr 2009; 155:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/91\">",
"      O'Driscoll BR, Kalra S, Wilson M, et al. Double-blind trial of steroid tapering in acute asthma. Lancet 1993; 341:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/92\">",
"      Brenner BE, Chavda KK, Camargo CA Jr. Randomized trial of inhaled flunisolide versus placebo among asthmatic patients discharged from the emergency department. Ann Emerg Med 2000; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/16/33034/abstract/93\">",
"      Rowe BH, Bota GW, Fabris L, et al. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA 1999; 281:2119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5740 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33034=[""].join("\n");
var outline_f32_16_33034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSMENT OF SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pulmonary index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peak flow rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arterial blood gas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mild exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Moderate exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Severe exacerbation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Inhaled beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Nebulizer versus MDI-S",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Continuous delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Levalbuterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ipratropium bromide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Parenteral beta 2-agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Subcutaneous or intramuscular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Intravenous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nonstandard therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Heliox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Ketamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Leukotriene receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Discharge to home",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Discharge meds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Discharge education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Continued treatment and observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Mild attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Moderate attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Severe attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Disposition decisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5740|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/52/17230\" title=\"algorithm 1\">",
"      Acute treatment of moderate asthma in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/12/4302\" title=\"algorithm 2\">",
"      Management of severe asthma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5740|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?38/15/39162\" title=\"form 1A\">",
"      Child asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"form 1B\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5740|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/4/27717\" title=\"picture 1\">",
"      Nebulizer and spacer use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/32/8718\" title=\"table 1\">",
"      Eval acute asthma attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/43/38587\" title=\"table 2\">",
"      Pulmonary index score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/21/44379\" title=\"table 3\">",
"      Medication doses for pediatric acute asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=related_link\">",
"      Acute severe asthma exacerbations in children: Intensive care unit management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20870?source=related_link\">",
"      Anticholinergic agents in the management of acute exacerbations of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/52/13122?source=related_link\">",
"      Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/4/33858?source=related_link\">",
"      Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=related_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_16_33035="Genetic test panel for PWS";
var content_f32_16_33035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic test panel for Prader-Willi syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Defect causing PWS",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent of PWS cases",
"      </td>",
"      <td class=\"subtitle1\">",
"       Molecular findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Risk of recurrence in future siblings, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Deletions of PWS-critical region on paternal 15q11-q13",
"      </td>",
"      <td rowspan=\"2\">",
"       70",
"      </td>",
"      <td>",
"       Methylation studies abnormal",
"      </td>",
"      <td rowspan=\"2\">",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FISH identifies deletion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Maternal uniparental disomy",
"      </td>",
"      <td rowspan=\"3\">",
"       28",
"      </td>",
"      <td>",
"       Methylation studies abnormal",
"      </td>",
"      <td rowspan=\"3\">",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FISH studies normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Microsatellite probes identify uniparental disomy (UPD) (requires testing parents and child)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Mutation or deletion in imprinting center",
"      </td>",
"      <td rowspan=\"3\">",
"       2",
"      </td>",
"      <td>",
"       Methylation studies abnormal",
"      </td>",
"      <td rowspan=\"3\">",
"       Up to 50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FISH studies normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Microsatellite probes find no uniparental disomy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Molecular defects associated with Prader-Willi syndrome and associated risk for recurrence in siblings of an affected child.",
"    <div class=\"footnotes\">",
"     PWS: Prader-Willi syndrome; FISH: fluorescent in-situ hybridization.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33035=[""].join("\n");
var outline_f32_16_33035=null;
var title_f32_16_33036="Pathology of ovarian tumors";
var content_f32_16_33036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathology of epithelial ovarian tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histologic type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cellular type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Serous",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"4\">",
"        Endosalpingeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Borderline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mucinous",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"4\">",
"        Endocervical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Borderline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endometrioid",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"5\">",
"        Endometrial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Borderline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Epithelial-stromal and stromal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Clear cell",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"4\">",
"        Mullerian",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Borderline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Transitional cell",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"5\">",
"        Transitional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign Brenner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Borderline Brenner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant Brenner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-Brenner transitional cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell tumors",
"       </td>",
"       <td>",
"        Squamous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mixed epithelial",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"4\">",
"        Mixed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Borderline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undifferentiated",
"       </td>",
"       <td>",
"        Anaplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unclassified",
"       </td>",
"       <td>",
"        Mesothelioma, etc",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Serov SF, Scully RE, Sobin IH.&nbsp;International Histological Classification of Tumors No. 9. Histological Typing of Ovarian Tumours. Geneva: World Health Organization, 1973.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33036=[""].join("\n");
var outline_f32_16_33036=null;
var title_f32_16_33037="Timing of onset of postoperative infection and fever";
var content_f32_16_33037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Timing of onset of postoperative infection and fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 502px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The timing of fever after surgery is one of the most important characteristics in ordering the differential diagnosis of fever in postoperative patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Garibaldi RA, Brodine S, Matsumiya S, Coloman M, Infect Control 1985; 6:273.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33037=[""].join("\n");
var outline_f32_16_33037=null;
var title_f32_16_33038="IMA versus vein graft patency after CABG";
var content_f32_16_33038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72584%7ECARD%2F69211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72584%7ECARD%2F69211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graft patency after CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patency of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery. The 10-year patency rate was significantly higher with the arterial grafts. There was a variable number of patients studied at each interval, accounting for the irregular shape of the curves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Loop FD, Lytle BW, Cosgrove DM, et al, N Engl J Med 1986; 314:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival advantage of arterial coronary bypass grafts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 254px; background-image: url(data:image/gif;base64,R0lGODlhRwH+AOYAAP///4CAgAAAAAAzmUBAQMDAwMDN5v8AAICZzKCz2SAgIP/AwDAwMEBmsyBNpv+AgKCgoPDw8FBzuXBwcNDQ0FBQUDBZrP8gIGCAvxBAn//g4P9AQP/w8JCQkPDz+f8QEODg4BAQELDA37CwsODm8/+goP9gYP9QUP9wcP8wMP+wsP/Q0P+QkGBgYNDZ7HCNxpCm07+MpoBZjB8shT9JfEBNZoCMpi8pfJ8TOd8GE89JXFBiqc9pfODW479NZjBJnK8PL78MJn85bFBTmYApXF8fXwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABHAf4AAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1LgFFIMREAEQEYMjAR0g1eTlshQBAgSDDOoCDIIT7yEh4+b3+KcEAuqCIwIVAFQQMCKCgBAAOgiYkK+hQ1AF+gFIF2CigAAR12UUVCCAR482EIg08LCkSUUbLVakuDFlx48BatCQQSTIhhMxEvQ4ybNkSoUM5XWg8A7Av4CHPArisIBFjB0DbgjR8aDEgp5YqVFQyKBABBACFBRQIGAc2REDISBSekgEBgcz/4oAOfBhAwoWCzRk3ZtsHz8BBQBAIKtALQAK7UIwXFtRkQsEFgYMifHAB44cBzaYeKBiBd/P+dgyIpGApAEJA37I4IFiw4UDKU5UvQq6NjTRktw6cIBBBIAFJR6cSHHggl28HGwrN4ab0uPIEkgOWqHigYkNBzJvzru8O6/mlkhLNwBD+iANTVt/gC1bBW3v8GGB12QAQ2QLGMofAv7AdfENDyAX34CnzNcJefYNgJ95hlAnHHZ13eUZgRR2YmAo5I0HgwuKoCfcBR/I9l6FJE5yYSn1OTBAAwiI4EGHJZjwGoALJFfijYyceIoHIiDQwAC8MXgIByqgQFwKKKhgI/+OTA6i4you6AeACKUl8OKQC/RXnAkl6NXkjU++IoKKA2SAgZCGZHnCBxecwMKEXw4YJiwJiEACArshQAIjK7BwAogixundnLTUl0EDaCKiQYwzPlCjoKARWosHpQligJWNEGkkbEkuCelDLxHQ2DGnDSABpplmid0FXHr5KT6hjooMpaideqUjarLpJpyvliOpL7Samugiff4ZoqO9VvMrMJQO68iiMmbmqKfJLrMsMZfuSYmmR3ZarTLXDlOqBQhwWAlTWrLa5bfFhFuMbrz5dkmubZZALbu7uHvMc8JmUixsLLiKby76JiMeANliwkEJa6bw5sC4FMzMuOVmooL/CWyiwCvE8snKE7y9WYzCBayqwHHHoPEbnb8jf2CCySevIjE1ByOMaiUasEDcCfbGXKDHypVq6yU5Y8ezwD5/MjM+wQ5tycInAIx00pos3VDTzj6yMMZIblwKeguEDQB6EzL1ntmaqLDBBl4jY/VDzXJyccZtg/JAdtkBcPcHgpiQtyAoZAezJRrA9kDhG9yiTTjeALB4N4m8zdOlm6zQ8sulLJCZIHcfYC/eg7x2gAkNniDb4Ro4qkIJALSmmWd+b1BCCcUdTksE7ewTgje5F8WYoAZY4AACt2JieQouKxmK5onrXZzDoguiwgEsrOepBh98oGXYdG1+wQMosAkA/3EXoBB4XXWzEhE8+xRwlEAE/Q7paWZqq0nOO/fcCfOcU08XC3/zmwb8xrpB3I11d+MeCgaxAPUc4DcHeIAgNlcL3L1DAS1QiQYB8JKPiKpXJMBABlbGiZxFbQMB2wT/nLcA4nAgby/MzGtSQIgEslBzEgTA9E6gAuJAMIcUvF0LQkAWBkSAIhvsoEc+mCwP4MkCWdsWw6RGNACm4CoJ1IBn8gbAzTxgPXDa4QKww70c3o0zr/nhBC/AnVkopCIDCcdCACAU+X2rUqGYW/nSt4jO5c2GE3ygCwF3gAUO4nzEKeNSyJdGHPbvAHxUBQTeUYB2QAAsYiGLPQwhue5QDv8UFyMZCkaECrz08AD3IsYEQhCWxgwmLIZJCtC+FbzhFa8TlgMR5lAhuhQMziGd9A79MGC/T6zgAcjjWSqTFUz4hHCEUcQE/g7As4E1Mz5OdAAUSbEw5KFgapC6JoHwWIoVYGwDvwznLKlmM1NwgAUks5062XmIWhLPFAuImglIiSNxlmiYxRRF6kimv36uk56CeCYJS1GCDbgsksWAQGCMMoJR+JNJ2dymKTQQPtk5g4kTWIcoLvolcrqzBN4EpzAi8hd+ICUUJJ1fAlBhTmqmUxgUIAARCUCACmBjpAdFaCLseUtRvDOey/SFRH8m1EkAFBUq0Cc/fRGBDnwklqD/iCkIRbjQr30xBQX1hV/4IVKYBrWpjMhoNDvRUJep9BaULMA1ILLEs6K1ESY9xQDrUsBdMMCumIjVXTfxyVN0U3tvjcUEFHBViwJ2sI0gaioW4Dce4mKsEjErZAkrgfqlggMPIBkLksoKCshVrj/V7GY3odC1diKqo4PoKSIQUgpUoKJAXW0n1KoKjn4ArKQ1xUAA04KXZvWxuo1EXlHR1m+6QgAdIEBHynrc5GJopqswJ19ZQRDp9tSx1gWFZFWxsHgm9hNDJKIAsKo05IZXEk9dBWWpOVVQRGAgiiGFVlfbWlYM9AKjJQUIAhMBr4D3vaPgLSvU9lBRMCAgEcDg/4ERTAo8FhYVvr0iKAAjiABQt70UTsV4U2EVUISgA4KogHFBHGIRd5aYy2jBOyw54Rajor/IiICM81tjG6NCwcWgQGohsbjGPK5xsvSxK5YbDJ5KggKsJIACBNE7eNhRya648C9GYGVIkCW17xsIbjnpXiyLV3j3/AVmP4wIoiiALAFBIhI5CBMPl9nM4n1xQHMRUp4SYDGLWF8l1yvni3CkzkzEMyxwvIsCO7oRRFkHRYBCR+heWdGvAPItJgkYBgB6EWdpRwEwOZayXBrTdHItKxTAALF42BGIOYhhXlmYyN0Z1abQciwAI92Q9hjXshgxLDD4Vx6rFti2iO8r/v/Bj3r8GtmzYHQr0CEO/d4a2jt6oqo/AY5qPxvbtagUlVQhj2YPmcXg5sWYHIBdUwDEfSFYsSf2m+5LJGA37R5FVzrMZgtdu96suDe7SRHSJYqKvZygN8AxIfB8ewKzZD32wn8hcHl5wrSnRa3EJ05xizPn3xwHE8hDTiKF56NHLXpEAhpgrlo04AWfEEEDWO4Mk5vDA5FpQGQQ4AgEDGDbp0CAwzNBAgXpaUWmKEALJuoJwfbK5zAHgAt884KZY4BDBkDAaSTAIZ/DAAMNkFcIG3B1ACSgRRLguiBEIIEGwEAQZ4c7zwEAg5m/wH492tPZX7RytwtC6GZHu9oJ4YL/tIuEBHcywLirTnYOYWBFCUgAkPRECqKo49yZcPqrJL+iigFgeC/IgAMA4HMWZSADpC/TjwaA+AyQ6/QA+JE2gTQlU71gADD/kSB0//gXQMY8kn+76AFw+xeg5u1Il31kRj8IEpzeRz83QJmQDvrhL/8Ftz9Uy0fREYRvwubmQEAGBkD+mRqg6uNPPUlun/WfE//nMBgABqBvAN0DIDIAQM2LLIB6++u+VlpHCB7gei4wADwneiKBdMk3AIKAf4PgczPlcwYgfVGHMOjHgNI3d0hnLSOnHFfiArcXdqYiAvgngepnghLoc/N3eP7HgC0YewwIgwDgAQkyAB73eI+3/yeTJxIztYC7F4N/534SmIFrN4L4R4QAsIGf0FJ/0W8J14G24SOl8XgJ2CIqknowIAKwh4I/V4AWIALn5wIvGH8tYir5Z3vplx/nNwBvNwgiQH4NIAiooXVx54My6IbC8iMTaIBBaIUYyIdJ6AAGsGeZ4GeG+Gno9in1R37DM4PLd4U+pyIO0HVC6H4kSH4WQAIvSHzjJwEv4gIqIgElOH4ZUIGDoCLYRYOkyHN2aH+DkH2RsYdzh3NAcoVI6HMDsH0fR08muAzlcYlFBQu25WeIOG9QeCO9qAxk8oW30A5N+G0khw/rJQAA0ALHaGvReBKAIRa+llvZWBKMJWMAAf+N30gOQnZfFYBk1VWODmFgpgB+7AgL+9ACY+aN8YgPEOCMCoBi9niP+JBTmQVpoyYIR4aN/ngP+dhs/AhprNQYVWaQB1kO81iPjeCMFRFm8ZNkEVkO7ggJAaAYhlZojaFEdraRygIC29BYjEAU4BCSLjmSiHaNJpkLvNZSTlgI6dBSchQUlqaRMxkNXoFxGscIA6Z0AtACIEBqmnRqP+kMHUCRjzBntOZ9HSaTTXkL+6AAE7BJG3eVzUABE+CMGdSPXukM2rAPN1k1VlmWs1Bu70aObFkMBMAAkGNtcekMc/WOa3mXr+BkesmXzMBlTAWYyrBmcEmYv9BnPFWM/ob/mHKyl46ZCor5Z4cZmbtgmGRpmcWgAFDZmJqJDAyQlpkAj59pCX3WDvKmCZpXmsAwVgqAeapZV6xpG6Q5m5AwAtJlQYzpmbbJCy0AD25Jld8Hmb3ZCR/UDiCgYpVZnH05AQYxZa+WmcxZC1xxlAKRmk84nbpgQfUAFgu5jtqJC482YOqYiOFZErV5nrKQnuqJMu2JnsT5nr7AnvLJCvRZn6pwn/g5CSBgVR3QOAXJlPupZn9hZQ8poAPaCwURYYCBkZ05EfGZoKWgSSJ5aDCRaBIqDJRWoXR2oRGaoaAgD2NJaXXkkyDqCwPBWBihlKZmoifKC0xYEVMJkS8aDfpZ/6PGiKPScKM6Opw9ehsf+qMyE6RCmgo8WqSWcKRISglKuqSS0KRO6pFEGqXLSaW6AKVWmiNTmqXmyaW9sJpe+qWyGabCgKVkSmZnGgxmmqZOsqVseglr+qZxyqZzmqZ1eqZ3SqZ5GqZ76qV9yqV/mqWBaqWDCqIB6qJvugoHiqiJigoOiqCNql8vaaEeJCp1dqmYmqmauqmc2qme+qmgGqqiOqqkWqqmeqqYynS3wKEkyVOoeqmu+qqIZqmyanC1eqG0Wquxeqselquyuqu3iqG2QKI9iabZyZtqmaPHuqzJiqy2wKJcSQiS00nTupbVqqw+6qy2MKOQOglyha2qqf+qzboJ36qtl1CuzNoubsqk62oi7fqk7xoJhWqm9BqvUtoLhYquuqCvucCv1iCu/xqpAjuwTnqouWBa0XoL6IAR1pBa/ck4tZCXBJmSwrCouABlhqYLk/RmGTsL6JBZY9VlwpgOZYWxUhYMj5oLFnmZBJESs+AXZbWgZAGwrACzg/Blw8ChqwqS9toIkxQCOgWbr+CyN9uisZASbgZnajqpCksQc9avIeCMwtkKRJsQczQLLkFJNPYLxPqdtJCTf9Gzi8BKh8EPtkC0IhqxEhFpG+QL0IoLRSljSKkLZNEBCjFltLAVlOQNKeoRNLsKetsV3hBqHAYM3HqlHXuxzujMU7WAWYERo7LguIeRGFNLsJZ7uZibuU1iWj81YEKruaUQEbsDAO0Duq0wEBMQEUgBATzFj6zbUxUFAhgxAmoRXX+WsKbrCCDASgrgbPIwAQOBYhUwAQGgSaKrDjJGvPuWuybCD/xIRB7RD7IrZYAREYsxEBXAsMxLCWYrCK3kEZcUtRAgY3KVsTrmjA+6vYvQvfCDEdugugXQPhHRGC3QAQVQouoLCeyrY6wUAhWxY6I2vx3Wv7uZvwZ8wAicwAq8wAzcwA78wBCsvoEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated survival rates for patients with angina who underwent internal mammary artery (IMA, n = 749) or saphenous vein (n = 4888) coronary bypass grafts. Patient survival was significantly prolonged with IMA grafts (64 versus 53 percent at 15 years), a difference that increased over time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cameron A, Davis KB, Green G, Schaff HV. N Engl J Med 1996; 334:216.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33038=[""].join("\n");
var outline_f32_16_33038=null;
var title_f32_16_33039="Parent questionnaire B";
var content_f32_16_33039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Questionnaire for parents (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 650px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_16_33039=[""].join("\n");
var outline_f32_16_33039=null;
